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Abstract 
 
 
The estrogen receptor (ER) is ligand-regulated nuclear hormone receptor and an 
important therapeutic target for breast cancer, hormone replacement therapy, contraception, and 
osteoporosis.  Novel organic cores have been identified and developed as possible estrogen 
pharmaceuticals.  The x-ray structures of both estrogen receptor subtypes bound to unique 
ligands provide a way to interpret, improve, and/or design estrogen ligands using computer 
modeling.   
Novel synthetic estrogen ligands were designed using computer modeling to occupy a 
solvent channel present in all of the ER crystal structures, although those ligands bound poorly to 
the estrogen receptor.  Also, single mutations of ER residues near the ligand binding pocket were 
evaluated using modeling to predict the size and shape of the mutated binding pocket that would 
not bind estradiol.  Ligands were designed, synthesized, and tested using a yeast two-hybrid 
assay to activate the mutated receptor to near wild type activity and create a novel gene switch. 
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Chapter 1 
Introduction and Background 
History of the Estrogen Receptor Mode of Action 
 In 1836, Ashley Cooper observed that breast cancer tumor growth increased and 
decreased during the menstrual cycle in premenopausal women.1  George T. Beaston, nearly 60 
years later, reported in 1896 that removal of the ovaries from a premenopausal woman with 
metastatic breast cancer for over five years reduced the size of the tumor based in part on Ashely 
Cooper’s observations.2  Beaston commented “I am satisfied that in the ovary of the female and 
the testicle of the male we have organs that send out influences more subtle it may be and more 
mysterious than those emanating from the nervous system, but possibly much more potent than 
the latter for good or ill as regards the nutrition of the body, and, undoubtedly, whatever cancer 
may be, it is very generally admitted that it is a disease of the nutrition of the part affected.”2 
In 1923, Allen and Doisy isolated the “mysterious influence” around the same time as 
Butenandt by extraction of the ovarian hormone with ethanol from the developed follicles of hog 
ovaries.  The isolated extract, identified as estrone, was injected into spayed animals and 
produced the same physiological effect as animals with functioning ovaries.3-5  Estrone action 
was mistakenly thought to be part of the metabolic pathway, where estrone reduction to 17-
estradiol was the prevailing hypothesis for the biological activity of estrogens throughout the 
1950’s  (Figure 1.1).6 
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Figure 1.1.  Transhydrogenation, the proposed metabolic action of estrogen in the cell
  
In 1960, Jensen injected 6,7-[3H]estradiol into immature rats and found reproductive 
tissues (the vagina and the uterus) retained the labeled hormone, while other tissues did not, 
indicating that estradiol selectively bound to target tissues to a possible estrogen receptor.7  
When the radioactive ligand bound to the uterus was identified as estradiol, Jensen prepared 17α-
[3H]estradiol and found no loss in radioactivity.  He showed 17-estradiol was not reduced to 
estrone in reproductive cells and essentially disproved the widely accepted theory of estrone as 
part of the metabolic pathway.8 
In the 1960s and 1970s, the estrogen receptor was identified as a regulator of various 
genes in target cells.9, 10  The simplified model of estrogen-mediated gene transcription is that 
17-estradiol (E2) diffuses through the cellular membrane and binds to unliganded estrogen 
receptor (ER) (Figure 1.2).11  Upon ligand binding, the receptor dimerizes and then binds to 
promoter region upstream of target genes on the DNA called the estrogen response elements 
(EREs).  The ER dimer can bind steroid receptor co-activators (SRC) that then recruit the 
cellular transcription machinery to transcribe mRNA with RNA Polymerase II, and the mRNA is 
translated into cellular proteins. 
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Figure 1.2.  A simplified model of estrogen dependant gene transcription. 
 
The Chambon lab in 1986 cloned and sequenced the estrogen receptor cDNA.12  The 
DNA sequence was compared to other sequenced proteins, and some homology was found 
between regions of the estrogen receptor and the glucocorticoid receptor.13  By comparing 
sequences and functions with other sequenced proteins, the estrogen receptor was identified as 
one member of a superfamily of nuclear receptor hormone receptors that includes, among others, 
the glucocorticoid receptor (GR), mineralocorticoid receptor (MR), progesterone receptor (PR), 
vitamin D3 receptor (VDR), thyroid hormone receptor (TR), and the androgen receptor (AR).14   
The amino acid sequence of all nuclear hormone receptors share a number of functional 
domains (Figure 1.3).15  Using the estrogen receptor as an example, the N-terminal receptor A/B 
domain contains activation function 1 (AF-1), allowing the receptor to have basal transcription 
activity in the absence of ligand.  The C domain is highly conserved and binds to the estrogen 
response element on the DNA with two zinc finger motifs.  The D domain is a small hinge 
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region between the DNA binding and E domains.  The E domain is the ligand-binding domain 
(LBD) and contains another activation domain (AF-2), which induces ligand-dependant 
transcription.  The role of the C-terminal F domain is not well understood.  The LBD  (E 
domain) of the estrogen receptor is used in our work, because the LBD is simpler to isolate 
compared to the full-length estrogen receptor and retains all of the ligand-binding character of 
the full estrogen receptor. 
Figure 1.3.  Estrogen Receptor Domains 
 
In 1997, the x-ray crystal structure of the estrogen receptor LBD bound to 17-estradiol 
and raloxifene was solved (Figure 1.4).16  17-estradiol activates ligand-induced transcription 
and is termed an estrogen receptor agonist.  Conversely, Raloxifene is termed an antagonist, 
because it inhibits ligand-induced transcription.  The x-ray structures of the agonist and 
antagonist provide a structural explanation of the role of the two types of ER ligands.  When 
agonist is bound, helix 12 of the LBD adopts a conformation enclosing the ligand in the receptor 
binding pocket and forms a binding site on the surface of the LBD for steroid receptor co-
activator proteins.  Antagonists like Raloxifene and Tamoxifen have a large substituent that 
N ‐ ‐C
AF‐1                    DNA            Ligand Binding Domain
Domains:            A/B                       C  D         E  F
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projects out of the ligand binding pocket to prevent helix 12 from forming the agonist 
conformation and prevents steroid co-activator proteins from binding to the estrogen receptor. 
 
 
17-Estradiol Raloxifene 
 
Figure 1.4.  X-Ray co-crystal structures of agonist estradiol (left) and antagonist 
Raloxifene (right) with the estrogen receptor ligand binding domain.  Helix 12 is 
highlighted in green. 
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Although the estrogen receptor was known to bind estradiol with a sub-nanomolar 
dissociation constant (Kd = 0.2 nM) since the early 1970s, the x-ray structure showed the 
interactions stabilizing the ligand-receptor complex in molecular detail (Figure 1.5).17  Ligand 
binding is expressed as a relative binding affinity (RBA) value that is compared to estradiol, 
where the RBA of estradiol is set to 100%, and ligand binding is expressed on a linear scale.  For 
example, a ligand with a Kd of 0.4 nM would have a RBA of 50%.  The ligand pocket 
surrounding estradiol is mostly hydrophobic and has extra space on the  and face of the 
steroid, allowing for a diverse set of compounds to act as estrogens.  Critical hydrogen bonds 
form between Glu 353 and Arg 394 residues of the LBD with the phenol at C3 of the steroid to 
stabilize the ligand-receptor complex.  Most estrogenic compounds contain a phenol or a 
bioisostere that forms the hydrogen bond with the receptor.  His 524 also forms an important, yet 
less energetically favorable, hydrogen bond with the 17-alcohol moiety of the steroid on the 
opposite side of the ligand binding pocket.  The rest of the interactions with the steroid and the 
receptor pocket are hydrophobic in nature. 
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Figure 1.5.  The ligand binding pocket of the ER bound to 17-estradiol 
 
In 1996, a second subtype of the estrogen receptor was identified and was named ER, 
with the receptor first cloned in 1986 being called ER.18  The ligand binding domain of ER 
shares a 59 percent sequence identity with ER, while the highly conserved DNA binding 
domain share a 97% sequence identity between the two estrogen receptor subtypes (Figure 1.6, 
top panel).  Even though the amino acid homology between the two receptors is fairly low, 
comparison of ER and ER ligand binding pockets when crystallized with ligand reveals little 
difference between the binding sites of the two receptors (Figure 1.6, bottom panel).16, 19  The 
ER binding pocket is approximately 100 Å3 smaller than the ER pocket, and only two amino 
acids are different when the two structures are overlaid. Subtype-selective ligands are useful to 
identify the specific role of each subtype in the cell.  Highly ER selective ligands have been 
prepared, but highly selective ER ligands have been difficult to identify.20, 21 
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Figure 1.6.  Comparison of the ER and ER sequences (top panel) and the differences in 
residues in the ligand binding pocket (bottom panel) 
 
Conclusions and Scope of Thesis 
The estrogen receptor is an important therapeutic target for breast cancer, hormone 
replacement therapy, contraception, and osteoporosis.  Novel organic cores have been identified 
and developed as possible estrogen pharmaceuticals.  The x-ray structures of both estrogen 
receptor subtypes bound to unique ligands provide a way to interpret, improve, and/or design 
estrogen ligands using computer modeling.  Novel synthetic estrogen ligands were designed 
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using computer modeling to occupy a solvent channel present in all of the ER crystal structures, 
although those ligands bound poorly to the estrogen receptor.  Also, single mutations of ER 
residues near the ligand binding pocket were evaluated using modeling to predict the size and 
shape of the mutated binding pocket that would not bind estradiol.  Ligands were designed, 
synthesized, and tested using a yeast two-hybrid assay to activate the mutated receptor to near 
wild type activity and create a novel gene switch. 
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Chapter 2 
Computer-Based Modeling of the Estrogen Receptor 
Introduction 
The published x-ray co-crystal structure of ligands bound to the estrogen receptor 
provides experimental data to explain the ligand binding orientation, shape of the ligand binding 
pocket and can be used to explain the activity of synthetic ligands.  Unfortunately, we do not 
have the capability to crystallize all prepared ligands with the estrogen receptor, so other 
methods must be used to help predict the size and shape of the ligand binding pocket and the 
ligand binding orientation. 
Computer-aided design is a useful method to rationalize our experimental results by 
examining our ligands in the context of published x-ray co-crystal structures.  Sybyl is a 
modeling program implementing a force field to calculate the minimum energy of the ligand-
receptor complex to predict the nature of the ligand orientation and the shape of the binding 
pocket.  Sybyl is initially used to prepare a model of the published crystal structure where 
unresolved portions of the crystal structure are added and the structure is minimized.  Using a 
model of the crystal structure, ligands can be modeled into the binding pocket to gain a better 
understanding of our experimental binding data and this information can be used to design new 
synthetic targets.  Since most published crystal structures of the estrogen receptor generally have 
the same relative secondary structure and mostly the same residues surrounding the ligand 
pocket, we start our analysis based on a solved crystal structures.  Using our binding and 
transcriptional data, we can approximate the binding orientations and potentially improve upon 
binding based on the predicted model of the scaffold. 
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Results and Discussion 
C4- and C3-Substituted Cyclofenil Ligands  
A series of fluorine-substituted cyclofenil derivatives (based on previous cylcofenil ER 
ligands1) were designed as potential agents imaging ER-positive breast tumors using positron 
emission tomography (PET).2  The most potent ligands with a fluorine-containing substitution on 
C3 and C4 of the cylcohexane ring were chosen for modeling to determine the most likely 
binding orientation of the cyclofenil ligand in the estrogen receptor binding pocket (Figure 2.1). 
 
Figure 2.1.  Relative binding affinities of cyclofenil derivatives for the 
estrogen receptors and 
 
To understand why the estrogen receptor differed so greatly in its tolerance of the bulk 
and polarity of substituents at the C4 and C3 positions of cyclofenil, we examined how these two 
ligands fit into the ligand binding pocket of ERα by computational modeling (Figure 2.2).  We 
based our modeling on the ER-estradiol co-crystal structure (1ERE in the RCSB), because the 
cyclofenil ligands are estrogen receptor agonists, like estradiol, so the 1ERE structure is a valid 
starting point for modeling purposes.  The initial docking orientation of substituted cyclofenil 
was based on models using unsubstituted cyclofenil (data not shown), where one phenol 
occupies a position equivalent to that of the A-ring of estradiol, the second projects in roughly a 
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“steroid 11β direction”, and the cyclohexyl ring occupies roughly the “steroid 7α subpocket” 
(Figure 2.2).  
To validate this ligand orientation, the cyclofenil analogues were initially modeled with 
one phenol as the steroid A-ring mimic, but intentionally “misorienting” the cyclohexyl ring in 
the “steroid 11β direction” of the binding pocket (opposite of what was predicted using 
cyclofenil), so that the other phenol occupied the “steroid 7α subpocket”. Despite this initial 
misorientation of the ligand, the FlexiDoc routine reoriented the cyclofenil core in a 
characteristic manner. In all cases, one of the phenol rings of cyclofenil remained in place of the 
A-ring of estradiol, where the hydroxyl group could engage in the canonical hydrogen bonds 
with the Glu and Arg residues (353 and 394 in ERα and 305 and 346 in ERβ, respectively).  In 
all but a few cases, the cyclofenil core was reoriented to place the other phenol in a roughly 
“steroid 11β direction”; in this orientation, the second hydroxyl is within 3 Å of a threonine 
residue (T347 in ERα and T299 in ERβ). Final optimization of the model utilized the three-step 
minimization process in the experimental section of this chapter. 
 
 
Figure 2.2.  Schematic picture of the interactions of the phenolic hydroxyls 
and the C3 and C4 cyclofenil substituents with residues in the ligand binding 
pocket. ER residue numbers precede ER residue numbers. 
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Modeling of the achiral C4-substituted cyclofenils was relatively straightforward; in 
these, the cyclohexane ring can adopt two chair conformations on each of which the substituent 
can be either axial or equatorial. Many of these cases were modeled to give stable structures. 
Docking always revealed one phenol as the steroidal A-ring mimic and typically placed the 
second pendent phenol in the “steroid 11β direction.” In most cases, the C4 substituents project 
toward a region of the ligand binding pocket that is somewhat flexible but essentially 
hydrophobic (I424 and L428 in ERα or I376 and L380 in ERβ) (see Figure 2.3, part A). This 
view is consistent with the binding behavior of other cyclofenil analogs having varying C3 alkyl 
groups with more polar groups being poorly tolerated in this region of the binding pocket. 
The chiral C3-substituted cyclofenils presented a greater challenge for modeling, because 
each enantiomer can adopt two chair conformations, each of which can have the substituent 
disposed in an axial or equatorial position. Modeling was done with some analogues in most of 
these orientations, from which a consistent pattern also emerged (see Figure 2.3 part B). By 
alternate choice of the phenols and chair conformation, each C3-substituted enantiomer can 
adopt an orientation in which the substituent can be extended toward His 524, the residue in ERα 
with which the 17β-hydroxyl group of estradiol forms a hydrogen bond. Thus, this model 
provides a satisfying rationale for the fact that at this site the ER can tolerate both bulky and 
electronegative groups. It is of note that substituents originating from the C4 carbon cannot 
access His 524. Attempts were not made to explain the modest ERα versus ERβ binding 
selectivities of the compounds in this series by modeling because they represent only small 
differences in free energy. 
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Figure 2.3.  Computational model of substituted cyclofenil interaction estrogen receptor, ERα.  
Panel A. Representative computational model of 4-fluorocyclofenil (1) in the ligand binding 
pocket of ERα. The hydrophobic residues near the C4 position are indicated. The surface shown 
is the ERα binding pocket displayed as dots mapped with the lipophilic potential. Residues 
identities are for ERα. Panel B. Representative computational model of 3-(2-
fluoropropyl)cyclofenil (2) in the ligand binding pocket of ERα. The surface is the same as Panel 
A. Residues identities are for ERα. 
 
The predicted estrogen receptor binding pocket tolerated much larger C3 substituted 
cylclofenil ligands compared to C4 substituted cylocfenils and agreed nicely with the binding 
data.  This general region of the receptor ligand binding pocket also contains one of two amino 
acid substitutions between ER and ER (Met421/Ile353).  Another small series of cyclofenil 
ligands was prepared based on the modeling results to expand the scope of the C3 substituted 
cyclofenil core ligands having a hydrophobic substituent based on the hydrophobic character of 
this region of the binding pocket based on the initial binding study.  Hyun Ju Sung prepared the 
small library of C3 substituted cyclofenils using McMurray coupling between 4,4’-
dihydroxybenzophenone and several commercially available 3-substituted cylclohexanones 
using previously reported methods (Table 2.1).1, 3, 4 
LP 
A 
HIS 524
ARG 394
GLU 353
LEU 428
ILE 424
MET 343THR 347
ALA 350
B
ARG 394
GLU 353
LEU 428 ILE 424
HIS 524
MET 343THR 347
ALA 350
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Table 2.1.  Relative binding Affinity (RBA) of Cyclofenil Derivatives for ER and ER 
 
 
 
#  Structure 
RBA 
(E2 = 100)   # Structure 
RBA 
(E2 = 100)  
ER  ER  ER  ER 
3 
 
435 ± 90  440 ± 76 1.0 7
 
374 ± 41  531 ± 146 1.4
4 
 
378 ± 51  339 ± 35 0.9 8
 
213 ± 3  75 ± 21  0.4
5 
 
237 ± 34  307 ± 35 1.3 9
 
222 ± 4  48 ± 13  0.2
6 
 
196 ± 31  141 ± 15 0.7 10
 
236 ± 42  168 ± 2  0.7
 
The binding affinity of each ligand was generally higher for both ER and ER 
compared to 2 since the substitutions were typically smaller than the fluoro-propyl group 
originally modeled.  Phenyl and phenol substitutions, 8 and 9, respectively, were well tolerated 
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in ER, yet ER showed decreased affinity likely due to the 100 Å3 smaller volume of the ER 
binding pocket compared to ER as discussed in the introduction chapter. 
 The most selective ligand for ERhad a (R)-methyl substitution at C3, 5, and was only 
two-fold selective for ERvs ER.  The individual enantiomers of 7 may show enhanced 
selectivity for ER since the racemic mixture of a C3 ethyl group, 7, was more ER selective 
than the racemic C3 methyl substitution, 3.  Unfortunately the (R) and (S) enantiomers of 3-ethyl 
cyclohexanone are not commercially available, and an asymmetric synthesis presumably via a 
conjugate addition of cylcohexenone using a chiral catalyst was not attempted.  The individual 
enantiomers of 7 would likely not show significant selectively for ERover ER useful in 
testing strictly ER function compared to existing ER selective ligands with >70-fold ER 
selectivity.5 
In general, designing ligands using modeling for subtype selective ligands has been 
difficult due to the similarity of the residues surrounding the ER and ER binding pocket.  
Although the selectivity of the C3-substituted cyclofenil ligands between ER and ER was not 
drastic enough for real sub-type selective ligands, the binding affinity was increased based on the 
model of the original ligands. 
 
Bridged Oxabicyclo[2.2.1]heptene Ligands  
 A series of oxabicyclo[2.2.1]heptene core compounds were prepared representing a new 
structural class of ER ligands.  We undertook a molecular modeling study of the highest affinity 
ligand, the sulfonate 11 (Figure 2.4), and hoped this investigation would point to how ligands in 
this class might be oriented in the ligand binding pockets of the receptors and why they behave 
as antagonists, rather than agonists.6 
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Figure 2.4.  Relative binding affinities of oxabicyclo[2.2.1]heptene 11. 
 
To build models, we selected the ERα-Ral (raloxifene) X-ray crystal structure (1ERR in 
the Protein Data Bank) for our ER model, because raloxifene, like ligand 11, is also an 
antagonist of ER action and has an ERα/ERβ selectivity similar to that of 11.7  Determining the 
orientation of 11 within the ligand binding pocket is challenging, because two pendant phenolic 
rings are attached to the bicyclic core, each of which could serve as the crucial “A ring” mimic 
of natural estrogens. Also, each phenolic moiety possesses two possible binding orientations of 
the bicyclic core within the receptor through a 180° rotation around the aryl-oxabicyclic core 
bond. Binding orientation determination is further complicated in that 11 was prepared as a 
racemic mixture of enantiomers.  
With eight possible orientations of the A-ring, four each of the two enantiomers of 11, we 
decided to use the FlexX routine for each enantiomer (Sybyl 7.0, Tripos Inc.) instead of 
individually prepositioning each of the eight possible binding modes as required for use of the 
FlexiDoc routine. FlexX uses an incremental construction algorithm to build a ligand into a 
binding pocket and calculate a docking score based on interactions with the binding pocket, and 
it can be used to run multiple ligands in one modeling experiment. We then selected the top-
ranked docking orientation and minimized the complex (Figure 2.5). Interestingly, only one 
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enantiomer, that possessing the 1R,2S,4R absolute configuration, shown in this figure, could be 
docked effectively into the ligand binding pocket, and a single binding orientation was predicted 
by the FlexX routine.  
Figure 2.5.  (Left) Model of oxabicyclo[2.2.1]heptene 11 in the ERα ligand binding pocket. The 
surface of the ligand is shown as the electrostatic potential while the ERα pocket is displayed as 
dots mapped with the electrostatic potential.  (Right) Comparison of 11 (element colors) overlaid 
with raloxifene (purple). 
 
The ligand binding pocket of the ER is largely hydrophobic and rather open, having polar 
residues only at the regions where the phenol and 17β-hydroxyl group of estradiol are 
accommodated; the phenol hydrogen bonds with glutamate and arginine residues and a 
structured water from the rather tight A-ring binding subpocket, while a histidine is the hydrogen 
bonding partner of the 17β-hydroxyl group.7  It was encouraging that FlexX predicted a phenol 
of the bicycle 11 as an “A ring” mimic, since the phenol moiety is estimated to provide 1.9 
kcal/mol of stabilization through its three hydrogen bonds.8  The second phenol of 11 was 
positioned in the 7α region of the ligand binding pocket, a position that is generally tolerant of 
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large substituents.8  Many ER ligands form a significantly weaker hydrogen bond with His524, 
which is estimated to provide 0.6 kcal/mol of stabilization energy.8  The second phenol of 11, 
however, is not oriented properly to hydrogen bond with His524, due to the rigidity of the 
oxabicyclic core, and it appears to have no hydrogen bonding partner in our model.  
The phenylsulfonate ester in our model is positioned into the 11β groove of the ligand 
binding pocket with the phenyl group extending outward. This could help to explain the 
antagonistic activity of the 11. Antagonists such as raloxifene appear to inhibit coactivator 
recruitment through displacement of helix 12 with a large substituent that protrudes through this 
same groove in the 11β-subpocket.7, 9  Analogous to known ER antagonists, the phenylsulfonate 
ester of 11 is positioned properly to prevent helix 12 from binding back over the ligand pocket, 
as it must to form the hydrophobic cleft into which the LXXLL motif of coactivators binds.9  A 
portion of the three-dimensional oxabicyclic core also occupies space in the 11β region of the 
binding pocket that is typically void of substituents with steroidal estrogens.  
Molecular modeling studies are not definitive and should be used as a guide in ligand 
design.  An X-ray crystallographic structure was later solved for another member of the 
oxabicyclo[2.2.1]heptene library, 12, having a drastically lower binding affinity for both 
subtypes of the estrogen receptor compared to 11 (Figure 2.6).6, 10   
 
Figure 2.6.  Relative binding affinities of oxabicyclo[2.2.1]heptene 12. 
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The oxabicyclo[2.2.1]heptene structure is unlike that of typical ER antagonists, and the 
crystal structure revealed a different binding orientation compared to the model generated based 
on compound 11 (Figure 2.7).  Compound 11 has a phenol positioned as an “A ring” mimic, but 
the other phenol was placed towards the 11 groove in the binding pocket.  The two ester ethyl 
esters were positioned towards His 524.  It is thought that the oxabicyclo[2.2.1]heptene library of 
compounds may antagonize estrogen action through distortion of helix 11.  Since we used the 
ERα-Ral X-ray crystal structure as a starting point, the orientation of the phenyl sulfonate moiety 
was predicted to fill the space provided by the 11 groove in the binding pocket.  A crystal 
structure of 11 with the ER would be useful to verify the orientation of the core and the 
substituents.  The bulkier phenylsulfonate would project towards HIS524 based on the 
orientation of 12 bound to the estrogen receptor, where the ERα-Ral structure could not 
accommodate this type of orientation. 
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Figure 2.7.  Rendering of X-Ray crystal structure of compound 12 (2HQ6 from RCSB).10 
 
Coactivator Binding Inhibitors 
 The classic method to block estrogen receptor action uses ligands that engender a 
conformation of the receptor that operates through an allosteric mechanism to block coactivator 
recruitment to ligand binding domain from the ligand binding pocket.  Drugs such as Tamoxifen 
and Raloxifene have a basic side chain that blocks helix 12 from the agonist conformation 
through an 11 groove the ligand binding pocket.7  Drugs like Tamoxifen are useful in hormone 
therapy to treat breast cancer through inhibition of estrogen receptor action in tumors, but tumors 
develop resistance to the Tamoxifen after extended use.   
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Another approach to block coactivator recruitment to the estrogen receptor ligand binding 
domain uses compounds termed coactivator binding inhibitors (CBIs) designed to fit directly into 
the coactivator binding groove on the surface of the ligand binding domain (Figure 2.8). Thus, 
this mode of inhibition is directly competitive with the coactivators, not allosteric.  CBIs could 
provide another drug for hormone therapy to treat estrogen receptor positive tumors and 
hopefully avoid some of the undesired affects. 
 
Figure 2.8. Electrostatic surface of the estrogen receptor 
interacting with the coactivator peptide (red tube) 
 
 A crystal structure of the ER ligand-binding domain complexed with diethylstilbestrol 
and a short peptide derived from the GRIP1 coactivator protein provides insight into the p160 
coactivator family’s ILXXLL sequence interaction with the estrogen receptor.9, 11  L690 and 
L694 of the GRIP1 peptide protrude deep into a hydrophobic pocket on the surface of the 
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receptor, while L693 and I689 fit into a shallow hydrophobic pocket on the ER surface (Figure 
7).  Also, E542 and K362 form a “charge-clamp” that is presumed to favorably interact with the 
inherent dipole of the GRIP1 peptide.  CBIs present some challenges using modeling, because 
there is not a well defined pocket in constrast to the estrogen receptor ligand binding pocket. 
One approach to design a CBI was to find a core that could mimic the critical residues in 
the GRIP1 peptide by overlaying possible scaffolds onto the GRIP1 peptide and ignoring the 
coactivator binding groove.  A hydrophobic core was found to mimic L690 and L694 residues of 
the GRIP1 peptide that extend deep into the CBI pocket.  Other important features were added to 
the core to mimic L693 and I689, and a carboxylate group was added to the designed ligand to 
take advantage of the “charge-clamp” on the surface of the estrogen receptor (Figure 2.8).  The 
bicyclo[2.2.2]octane core was designed by placing a boat cyclohexane ring (Figure 2.9, purple) 
between the two isopropyl groups of L690 and L694.  Two atoms from L694 isopropyl group 
make the 1,4-bridge of the bicyclo[2.2.2]octane core, while the L690 was mimicked by 
substitution of a gem-methyl group onto bicyclo[2.2.2]octane core.  A methyl substitution onto 
the core completed the L694 mimic, and two additional substitutions incorporated both L693 and 
I689 mimics and substitutions to properly interact with the “charge-clamp”.  These systems were 
shown to moderately block the recruitment of the coactivator peptide in a fluorescence 
anisotropy-based coactivator competition assay.12, 13 
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Figure 2.9. Cyclohexane connector (purple) creates a bicyclo[2.2.2]-octane CBI 
core from L690 and L694 of an SRC NR2 box peptide (green). 
  
Another approach to prepare a CBI used benzene exhibiting a substitution pattern 
alternating hydrophobic and hydrophilic groups.  These are termed amphipathic benzenes, 
because one face is hydrophobic in nature while the other face that is hydrophilic in nature.  
CBIs were designed to match the amphipathic nature of the GRIP1 peptide with hydrophobic 
groups that could interact with the hydrophobic groove on the estrogen receptor surface while the 
hydrophilic groups could interact with water surrounding the estrogen receptor.  The most potent 
amphipathic benzene CBI, 12, found using the fluorescence anisotropy-based coactivator 
competition assay, had three aminoethyl and three neohexyl substituents (Figure 2.10). 
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Figure 2.10.  Most potent amphipathic benzene CBI.  
 
Docking of 12 into the coactivator binding groove using the procedure for estrogen 
receptor ligands in the ligand binding pocket was not successful, because the neohexyl 
substituents of 12 occupy a larger volume than the GRIP1 peptide leucine and isoleucine 
residues.  Steric interactions prevented all three hydrophobic groups from docking into the 
hydrophobic groove.  The Flexi-Dock routine had to be modified to release both the backbone 
and all side-chains within 8 Å to reform the surface residues of the receptor around the bulky 
neohexyl groups of the amphipathic benzene.  The Flexi-Dock modification kept the charge 
clamp in place, but the deep and shallow potions of the hydrophobic groove changed in shape to 
accommodate the neohexyl groups (Figure 2.11).   
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Figure 2.11.  Amphipathic benzene 12 docked and minimized in the coactivator 
binding groove.  The lipophilic (panel A) and electrostatic (panel B) were mapped on  
the ER surface.  
 
 The model generated from CBI 12 accompanied with the biological inhibition data both 
suggest that the estrogen receptor can change the shape of the hydrophobic pockets on the 
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surface to accommodate bulkier hydrophobic leucine mimics of the GRIP1 peptide and still take 
advantage of the charge-clamp on the surface of the protein.  Future libraries of CBIs should 
utilize larger hydrophobic substituents to examine the size of the potential pocket on the surface 
of the estrogen receptor. 
E3 Ligase Substrates 
Another strategy used to inhibit the estrogen-mediated cell growth targeted the estrogen 
receptor to the cellular proteosome for degradation using the ubiquitination signaling pathway.  
One E3 ubiquitin ligase, pVHL, is an enzyme in the ubiquitination pathway that selectively binds 
a specific peptide sequence containing a key 4-hydroxylproline residue.  Once the peptide is 
bound to the pVHL, another portion of the enzyme complex catalyzes addition of ubiquitin to a 
nearby lysine residue.  After multiple ubiquitin proteins are added to the targeted protein, the 
protein degraded by the proteosome. 
 
Figure 2.12.  Reported PROTAC, 13, found to degrade the estrogen receptor. 
 
Ligands termed PROTACs (PROteolysis Targeting Chimeric molecules), such as 13, 
have estradiol tethered to the HIF-1 peptide; they are recognized by pVHL and have been 
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shown to induce ubiquitinylation of the estrogen receptor and ultimately its degradation by the 
26S proteosome (Figure 2.12).14  The post-transitionally modified 4-hydroxyproline residue is 
critical for substrate recognition by pVHL, while a proline substitution in the sequence binds 
poorly.  An X-ray crystal structure of pVHL bound to the peptide sequence containing 
hydroxyproline was solved, revealing a hydrophobic pocket on the surface of the pVHL enzyme 
(Figure 13, panel A).15  When the pocket of pVHL was mapped, a pocket was available if a 
substituent was placed on C3 of 4-hyroxyproline (Figure 2.13, red circle panel B).  If the affinity 
of the pVHL for a hydroxyproline analog could be increased, then a PROTAC containing only a 
4-hydroxyproline analog would avoid the draw-backs of peptide degradation of a PROTAC 
containing a peptide sequence. 
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Figure 2.13.  X-Ray Crystal structure of HIF-1a recognition peptide bound to pVHL 
with the electrostatic surface mapped, panel A.  A cross-section of the surface revealing 
a pocket for modification of hydroxyproline circled in red, panel B.  
 
 A reported method to prepare a hydroxyproline uses an asymmetric chelated Claisen 
rearrangement of crotyl ester 14, and the mixture was successfully resolved using (R)-
HYP 
B 
 
EP 
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phenethylamine to give a diastereomerically pure salt 15 (Figure 2.14).16, 17   Iodolactonization 
then alkylation of the amide nitrogen using a non-nucleophillic base form [2.2.1]bicyclolactone 
intermediate 16 that can be hydrolyzed to give an all cis substituted proline 17.  Since the 
naturally occurring configuration of proline requires the epimer of 17 at C2, the proline would 
need to be properly protected (18) and epimerized at C2 using strong base to give the lower 
energy R configuration at C2 on compound 19.  The synthesis of a library of 4-hydroxyproline 
analogs using the procedure in Figure 2.14 is cumbersome, because the 3-substitution must be 
installed at the beginning of the synthesis and the proper stereochemistry is set in the first step of 
the reactions.  Subsequent reactions were reported to give 80-90% dr, so a mixture of products 
would be synthesized.   
 
Figure 2.14.  Reported synthesis of 3-methyl-4-hydroxyproline. 
 
 An alternative and more useful synthetic route based on another reported synthesis may 
avoid these limitations.18, 19  The synthesis uses a TEMPO oxidation of a properly protected 
naturally abundant 4-hydroxyproline (20) to give the ketone 21 (Figure 2.15).  A Mannich-type 
reaction using Bredereck’s reagent gives the eneaminone 22.20  A 1,4-addition of a Grignard 
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reagent provides the enone 23 and also incorporates the variation at C3 from a potentially large 
number of commercially available alkyl halides much later in the synthesis.  The original report 
stated that sodium borohydride reduction gave the 1,4-reduction products.  This was not the 
desired reduction product targeted in the this report, but a 1,4-reduction should give the trans 
substitution at C3 relative to C2, 24, under thermodynamic control.  A subsequent 1,2-reduction 
of the ketone of 23 should give the desired stereochemistry due to the ability of the C3 
substituent to hinder attack from the re face of the carbonyl.   
 
Figure 2.15.  Modification of a synthesis of 3-substituted-4-hydroxyproline. 
 
 Unfortunately, our attempts to use the HIF-1 peptide sequence tethered to some of our 
more potent non-steroidal synthetic ligands did not provide the desired PROTAC; so, the 
synthetic routes proposed for improved binding of a 4-hydroxyproline analogs to pVHL were not 
investigated. 
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Conclusions 
Modeling is a useful tool to help visualize the orientation of ligands in a protein binding 
pocket.  Caution must be used when relying on a proposed model to explain binding affinity, 
because the model is simply a hypothesis.  The model must be tested experimentally to validate 
the modeling conclusions.  X-ray crystal structures provide experimental data to verify how a 
ligand binds to a protein, but proper crystals are difficult to prepare for our more potent ligands.  
Libraries of compounds should be prepared to provide some experimental evidence to validate 
our model. 
 
Experimental 
Published Crystal Structure Workup:  The protein structure used in docking simulations was 
based on the pdb of the desired X-ray crystallographic structure of the human estrogen receptor 
ligand binding domain bound to a ligand from the Protein Data Bank.  The crystal structure has 
at least one homodimer, but only one monomer (chain A) is chosen for modeling purposes. The 
crystal structure contains several residues with missing atoms, and the flexible loops helices H11 
and H12 and in some cases between H9 and H10. We used the molecular modeling program 
Sybyl 7.1 (Tripos Inc., St. Louis, MO) for all manipulations. Initially, we preformed a loop 
search of protein fragments from the Protein Data Bank to insert into the missing regions of the 
original X-ray structure. The optimal loop was selected based on a high RMS fit onto three 
resolved residues flanking the missing sequence and minimal van der Waals contacts with the 
rest of the protein. Finally, missing atoms were added to the ligand, protein, and water molecules 
within a 4 Å radius of the protein.  
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The ER-ligand complex later used for docking studies was minimized by a four-step 
procedure where each step used the Powell algorithm along with the MMFF94s molecular force 
field until convergence was reached (RMS < 0.05). First, the inserted loops were minimized, 
while the rest of the protein was fixed in space. Next, hydrogen atoms on the ligand, protein, and 
water molecules were allowed to reach a minimum energy. Third, the amino acid side chains 
were allowed to minimize, except for Glu353 and Arg394, which remained fixed along with the 
water molecules, the ligand, and the protein backbone. Finally, all atoms were released and 
allowed to reach a minimum energy. The minimized structure was overlaid with the original X-
ray structure and showed very little movement of residues to ensure our model was reasonable. 
 
Ligand Minimization:  The starting conformation of the ligand used for docking studies was 
generated using the Concord minimization in Sybyl 7.1 (Tripos, Inc.).  The ligand was 
minimized using the MMFF94s force field.  Charges of each atom were calculated using the 
MMFF94s force field for the ligand to be implemented in docking studies. 
 
Flexidock Ligand Docking:  The phenol moiety found in non-steroidal estrogens was 
prepositioned in the ER LBD crystal structure by aligning with the A-ring phenol of the 
original ligand in the crystal structure.  The original ligand was deleted and the prepositioned 
ligand was docked into the binding pocket using the Flexidock routine in Sybyl (Tripos, Inc.).  
All rotatable bonds in the ligand were allowed to rotate using the Flexidock routine.  Typically 
the top twenty results had the ligand in the same orientation, and the highest scoring docked 
ligand was used for further minimizations. 
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Flexidock CBI Docking:  The CBI was prepositioned in the ER LBD crystal structure by 
aligning the hydrophobic groups on the CBI with the leucine residues of the GRIP1 peptide.  The 
GRIP1 peptide was deleted and the prepositioned CBI was docked into coactivator binding 
groove using the Flexidock routine in Sybyl (Tripos, Inc.).  All rotatable bonds in the ligand 
were allowed to rotate using the Flexidock routine and all side-chains of the estrogen receptor 
within 8 Å of the CBI were allowed to move.  Typically the top twenty results had the CBI  in 
the same orientation, and the highest scoring CBI was used for further minimizations. 
 
 
Flex-X Ligand Docking:  The original ligand was deleted from the minimized receptor-ligand 
complex, and SiteID was used to identify the ligand binding site using a flood-fill solvation 
technique. FlexX was used incrementally to construct the new ligand in the binding pocket then 
identify and rank the most favored binding orientations in the estrogen receptor ligand binding 
pocket. The highest-ranked complex was minimized using the three-stage minimization 
procedure listed below. 
 
Three-Stage Ligand-Receptor Minimization:  The ligand underwent a three-step minimization 
process using the MMFF94s force field in each step and is based on previous report.21  First, the 
non-ring torsional bonds of the ligand were minimized while the receptor was kept fixed.  Next, 
the residues within side-chains of residues within 8 Å of the ligand were minimized while the 
ligand and the rest of the receptor remained fixed.  Finally, the entire complex was allowed to 
move freely to achieve a minimum global conformation. 
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Cyclofenil Modeling:  Briefly, 4 of 8 possible docking orientations of C4-substituted molecules 
were individually examined using the FlexiDoc routine in Sybyl 7.1 (Tripos Inc.) to account for 
both the axial/equatorial orientation of the ring substituent and the ring flips of the cyclohexane 
ring. Docking of the C3-substituted cyclofenils was further complicated because they were 
prepared as a mixture of enantiomers, so 8 of 16 orientations were examined. We eliminated half 
of the docking orientations by starting from an unfavorable orientation where one pendent 
phenol was overlaid with the A-ring of estradiol while the other phenol was placed away from a 
hydrogen-bonding partner (Thr347/299). The docking routine typically reoriented the cyclofenil 
core, placing the second phenol within hydrogen-bonding distance with the Thr347 residue. The 
top ranked docking orientation in the ER binding pocket was minimized using  
 
References 
1. Muthyala, R. S.; Sheng, S.; Carlson, K. E.; Katzenellenbogen, B. S.; Katzenellenbogen, J. 
A. Bridged Bicyclic Cores Containing a 1,1-Diarylethylene Motif Are High-Affinity Subtype-
Selective Ligands for the Estrogen Receptor. J. Med. Chem. 2003, 46, 1589-1602. 
2. Seo, J. W.; Comninos, J. S.; Chi, D. Y.; Kim, D. W.; Carlson, K. E.; Katzenellenbogen, J. 
A. Fluorine-Substituted Cyclofenil Derivatives as Estrogen Receptor Ligands:  Synthesis and 
Structure−Affinity Relationship Study of Potential Positron Emission Tomography Agents for 
Imaging Estrogen Receptors in Breast Cancer. J. Med. Chem. 2006, 49, 2496-2511. 
3. Coe, P. L.; Scriven, C. E. Crossed coupling of functionalised ketones by low valent 
titanium (the McMurry reaction): a new stereoselective synthesis of tamoxifen. J. Chem. Soc., 
Perkin Trans. 1 1986, 475-477. 
4. Detsi, A.; Koufaki, M.; Calogeropoulou, T. Synthesis of (Z)-4-Hydroxytamoxifen and 
(Z)-2-[4-[1-(p-Hydroxyphenyl)-2-phenyl]-1butenyl]phenoxyacetic Acid. The Journal of Organic 
Chemistry 2002, 67, 4608-4611. 
38 
 
5. De Angelis, M.; Stossi, F.; Carlson, K. A.; Katzenellenbogen, B. S.; Katzenellenbogen, J. 
A. Indazole Estrogens:  Highly Selective Ligands for the Estrogen Receptor β. J. Med. Chem. 
2005, 48, 1132-1144. 
6. Zhou, H.-B.; Comninos, J. S.; Stossi, F.; Katzenellenbogen, B. S.; Katzenellenbogen, J. 
A. Synthesis and Evaluation of Estrogen Receptor Ligands with Bridged Oxabicyclic Cores 
Containing a Diarylethylene Motif:  Estrogen Antagonists of Unusual Structure. J. Med. Chem. 
2005, 48, 7261-7274. 
7. Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; 
Ohman, L.; Greene, G. L.; Gustafsson, J.-A.; Carlquist, M. Molecular basis of agonism and 
antagonism in the oestrogen receptor. Nature 1997, 389, 753-758. 
8. Anstead, G. M.; Carlson, K. E.; Katzenellenbogen, J. A. The estradiol pharmacophore: 
Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor 
binding site. Steroids 1997, 62, 268-303. 
9. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, 
G. L. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of 
This Interaction by Tamoxifen. Cell 1998, 95, 927-937. 
10. Nettles, K. W.; Bruning, J. B.; Gil, G.; Nowak, J.; Sharma, S. K.; Hahm, J. B.; Kulp, K.; 
Hochberg, R. B.; Zhou, H.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S.; Kim, Y.; 
Joachimiak, A.; Greene, G. L. NF[kappa]B selectivity of estrogen receptor ligands revealed by 
comparative crystallographic analyses. Nat Chem Biol 2008, 4, 241-247. 
11. Heery, D. M.; Kalkhoven, E.; Hoare, S.; Parker, M. G. A signature motif in 
transcriptional co-activators mediates binding to nuclear receptors. Nature 1997, 387, 733-6. 
12. Zhou, H.-B.; Collins, M. L.; Gunther, J. R.; Comninos, J. S.; Katzenellenbogen, J. A. 
Bicyclo[2.2.2]octanes: Close structural mimics of the nuclear receptor-binding motif of steroid 
receptor coactivators. Bioorg. Med. Chem. Lett. 2007, 17, 4118-4122. 
39 
 
13. Rodriguez, A. L.; Tamrazi, A.; Collins, M. L.; Katzenellenbogen, J. A. Design, 
Synthesis, and in Vitro Biological Evaluation of Small Molecule Inhibitors of Estrogen Receptor 
α Coactivator Binding. J. Med. Chem. 2003, 47, 600-611. 
14. Sakamoto, K. M.; Kim, K. B.; Verma, R.; Ransick, A.; Stein, B.; Crews, C. M.; Deshaies, 
R. J. Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and 
Degradation. Molecular & Cellular Proteomics 2003, 2, 1350-1358. 
15. Min, J.-H.; Yang, H.; Ivan, M.; Gertler, F.; Kaelin, W. G.; Pavletich, N. P. Structure of an 
HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling. Sci 2002, 296, 1886-1889. 
16. Mues, H.; Kazmaier, U. The Asymmetric Chelate-Claisen Rearrangement as a Key Step 
in the Syntheses of Non-Proteinogenic Amino Acids. Synthesis 2001, 2001, 0487,0498. 
17. Kazmaier, U.; Mues, H.; Krebs, A. Asymmetric Chelated Claisen Rearrangements in the 
Presence of Chiral Ligands—Scope and Limitations. Chemistry – A European Journal 2002, 8, 
1850-1855. 
18. Barraclough, P.; Hudhomme, P.; Spray, C. A.; Young, D. W. Synthesis of kainoid 
analogues. Tetrahedron 1995, 51, 4195-4212. 
19. Chabaud, P.; Pèpe, G.; Courcambeck, J.; Camplo, M. Stereoselective synthesis of 
(3S,4S)-tert-butyl-N-Boc-3-ethyl-4-hydroxy-l-prolinate and (3S,4R)-tert-butyl-N-Boc-3-ethyl-4-
hydroxy-l-prolinate. Tetrahedron 2005, 61, 3725-3731. 
20. Bredereck, H.; Effenberger, F.; Hofmann, A. E. New Syntheses of 2,4-Disubstituted s-
Triazines. Angewandte Chemie International Edition in English 1962, 1, 331-331. 
21. Stauffer, S. R.; Coletta, C. J.; Tedesco, R.; Nishiguchi, G.; Carlson, K.; Sun, J.; 
Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Pyrazole Ligands:  Structure−Affinity/Activity 
Relationships and Estrogen Receptor-α-Selective Agonists. J. Med. Chem. 2000, 43, 4934-4947. 
 
 
40 
Chapter 3 
Synthesis of Ligands to Bind the Estrogen Receptor Solvent Channel 
Introduction 
The conformation of helix 12 in the estrogen receptor x-ray co-crystal structures of 17-
estradiol and 4-hydroxy-tamoxifen bound to ER both explain the structural mechanism of 
estrogen receptor agonism and antagonism, respectively.1  Steroid receptor coactivators bind to a 
groove comprised by helices 3, 4 and 12 when agonists ligands are bound, while the basic side 
chain of 4-hydroxytamoxifen prevents helix 12 from forming the binding groove (Figure 3.1).   
The x-ray co-crystal structures the estrogen receptor antagonists 4-hydroxytamoxifen and 
ICI 164,384 show the large side chain of both ligands prevents helix 12 from forming the agonist 
conformation of the estrogen receptor (Figure 1).2, 3  Although both antagonists block estrogen 
cell growth using the same mechanism, 4-hydroxytamoxifen is termed a Type I antiestrogen, 
because cell growth of certain  tissues and cell cultures is increased at low concentrations of 4-
hydroxy-tamoxifen and other Type I agonists.4  Conversely, pure anti-estrogens such as ICI 
164,384 are termed Type II antiestrogens, because no cell growth is observed at any 
concentration. 
 
4-hydroxytamoxifen ICI 164,384 
                 Figure 3.1.  Structure of a Type I (left) and a Type II (right) antiestrogen. 
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Since both ligands inhibit estrogen-dependant cell growth using the same mechanism, 
some postulate that a second binding site in the estrogen receptor can bind Type I antiestrogens 
and activate the estrogen receptor and not bind Type II antiestrogens.5  The 8S sedimentation 
peak of estrogen receptor in the MCF-7 human breast cancer cell cytosol bound twice as much 
tritiated 4-hydroxytamoxifen compared to tritiated estradiol after normalization of the data to 
allow for comparison.6  The data suggested that Type I antiestrogens bound to two sites in the 
full-length estrogen receptor whereas estradiol bound to only one site.   
 
Figure 3.2.  Structure of tetrahydrochrysene ketone (THCK) 
 
A series of tetrahydrochrysene (THC) ligands were agonists on ER, but either agonists 
or antagonists on ER depending on the substituents on the THC core.7, 8  The fluorescence of 
THC ketone (THCK, Figure 3.2) bound to the estrogen receptor under saturating concentrations 
of estradiol and suggested that THCK bound to a site other than the steroid binding pocket in 
both ER and ER.9  Even though some experimental evidence exists implicating a second 
ligand binding site in the estrogen receptor, a second ligand binding site is not obvious when 
examining the x-ray structure of the estrogen receptor ligand binding domain.   
A solvent channel present in all estrogen receptor x-ray crystal structures was identified as a 
possible second binding site once ordered water molecules were removed.10  Several scoring 
functions for ligand docking were evaluated to interpret the binding results of the THC library in 
the steroid binding pocket compared to the solvent channel (Figure 3.3).  The scoring functions 
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predicted all THC analogs should preferentially bind to the steroidal binding pocket in ERand 
ER.  When examining the docking scores on ER, the solvent channel became increasing 
favorable as a potential second binding site relative to the steroid binding pocket when the size of 
the substituent increased in the same manner that THC ligands switched from agonists to 
antagonists on ER. 
 Figure 3.3.  The solvent channel (left) and the steroid binding pocket (right) from the 1ERE 
 x-ray co-crystal structure. 
 
Although no estrogen receptor ligands exist occupying the solvent channel, other nuclear 
hormone receptors have ligands projecting into the regions of the receptor that correspond to the 
solvent channel in the estrogen receptor.  The vitamin D receptor is a nuclear hormone receptor 
that shares the overall tertiary structure with the estrogen receptor.  Several ligands from a library 
of vitamin D3 analogs with pendant groups at C2 were found to increase binding affinity relative 
to 1,25-dihydroxy vitamin D3 (Figure 3.4, top panel).11  X-ray co-crystal structures of the 
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ligands 1-5 bound to the vitamin D receptor verified the C2 substituent occupied the solvent 
channel and rationalized that the changes in binding affinity depended on the substituent, 
verifying analogs of natural steroid receptor ligands can occupy part of the solvent channel when 
proper substituents are added onto the core of the ligand (Figure 3.4, bottom panel).12  
Figure 3.4.  Relative binding affinity of 2-substituted 1,25-dihydroxy vitamin D3 analogs (top 
panel).  Rendering of x-ray co-crystal structure 2HBD with ligand 4 bound to the VD receptor 
(bottom panel). 
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 The glucocorticoid receptor (GR) is another nuclear hormone receptor sharing a similar 
tertiary structure with the estrogen receptor.  The x-ray crystal structure of cortisol bound to GR 
shows a related hydrogen bond motif that stabilizes the steroid ligand at C3 like the estrogen 
receptor.13  Both the ER and GR binding pockets have an arginine residue positioned to 
hydrogen bond with the C3 moiety of the ligand, but the GR has a glutamine residue acting as a 
hydrogen bond donor to the acceptor ketone of the glucocorticoid steroid, while the estrogen 
receptor has a glutamic acid as a hydrogen bond acceptor with the phenol moiety if estradiol.  
The x-ray crystal structure of deacylcortivzsol (DAC) bound to GR showed that the fused 
pyrazole nitrogen hydrogen bonded with the glutamine 570 residue, but the arginine 611 was 
rotated away from the ligand with the N-phenyl substituent occupying part of the solvent channel 
(Figure 3.5).14 
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Cortisol Deacylcortivazol (DAC) 
 
Figure 3.5.  Structures of two glucocorticoid receptor ligands (top panel).  Rendering of x-ray 
co-crystal structure 3BQD of DAC bound to the GR (bottom panel) 
 
Results and Discussion 
 A biphenyl ligand identified by a virtual screen of a commercial library initially was 
found to bind with low affinity to the estrogen receptor.  Although the ligand binding was found 
to be a false positive result, the initial modeling suggested that the decyl chain could fill up the 
solvent channel before searching the literature for ligands designed with this type of behavior 
(Figure 3.6).   
46 
 
Figure 3.6.  Model of biphenyl ligand 8b bound in the 1ERE ligand binding pocket. 
 
 Several biphenyl ligands were prepared using a Suzuki reaction between two 
commercially available methoxy-substituted phenyl boronic acids and 4-bromo-benzaldehyde to 
provide the biphenyl carboxaldehyde core in excellent yield (Scheme 3.1).  Next, the phenol was 
deprotected using molten pyridine hydrogen chloride instead of the common boron tribromide 
reagent to avoid elimination of the benzyl alcohol; this avoided formation of the dibromo-methyl 
group instead of the desired aldehyde.  Finally, an excess of nonyl-Grignard was added to 
prepare a small library of ligands based on the original biphenyl ligand.  Competitive binding 
assays showed that the biphenyl 8a and 8b bound poorly to the estrogen receptor (Scheme 3.1). 
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Scheme 3.1.  Synthesis of a biphenyl library. 
 
Since the biphenyl core used to occupy the steroidal binding site is not a high-binding 
ligand, the estrogen steroid scaffold was chosen to as a core ligand to project a substituent into 
the solvent channel.  An N-substituted 3-amino estradiol was modeled into the 1ERE crystal 
structure.  The aniline moiety could maintain the energetically favorable hydrogen bond with the 
Glu 353 and Arg 394 residues of the receptor, and an alkyl substituent could be added to the 
amino group to project into the solvent channel.  A polyethylene glycol chain was chosen based 
on the vitamin D3 analogs discussed earlier.  Modeling suggested a gauche conformation of the 
chain was needed properly orient into occupy the solvent channel.  Polyethylene glycol naturally 
adopts a gauche dihedral angle between the two oxygen atoms favorably instead of the anti 
conformation, which should engender the conformation needed to access the estrogen receptor 
solvent channel.15 
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The phenol of estrone was activated through formation of the triflate at C3.  
Benzophenone imine was used as an ammonia equavalent and was coupled to the 3-position of 
the steroid using a palladium-catalyzed cross coupling reaction (Scheme 3.2).16  3-Amino-
estrone was deprotected under acidic aqueous conditions and subsequently acylated using DCC 
with several poly-ethylene glycolic acids to generate an amide at C3.  The amide was reduced 
using borane to give the desired amine, which also give the 17 epimers of the corresponding 
estradiols.  Ligands 13a and 13b were isolated as the pure 17-hydroxy epimers, while 13c was 
only isolated as a mixture of 17and 17 hydroxyl epimers. 
 
Scheme 3.2.  Synthesis of a library of N-alkylated 3-amino estradiol ligands 
 
The relative binding affinity (RBA) values of both 12a-c and 13a-c were very low 
compared to estradiol.  The RBA of 3-amino-estradiol was expected to be around 30 based on 
the reported association constant, but our binding results found 3-amino-estradiol had a much 
lower RBA of 0.420 (Table 3.1).17  The estrone ligands 11 and 12a-c bound very poorly to the 
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estrogen receptor, while the 3-amino-estradiol ligands 13a-c showed some increased binding 
affinity.  The binding affinities were too low to expand upon the 3-amino estradiol scaffold. 
 
 RBA RBA  RBA RBA 
Ligand ER ER Ligand ER ER 
Estradiol 100.000  100.000 Estradiol 100.000 100.000 
11     0.013     0.026 3-Amino-estradiol     0.420     0.718 
12a   <0.002   <0.002 13a     0.078     0.057 
12b   <0.002   ~0.002 13b     0.090     0.099 
12c   <0.002   <0.002 13c     0.036     0.038 
 
Table 3.1.  Relative binding affinities of 3-amino-estrane ligands 
 
 A final attempt to prepare an estrogen receptor ligand to occupy the solvent channel used 
a pyrazole core fused to the A-ring of 17-estradiol to project a phenyl group into the solvent 
channel in a manner similar to how the  deacylcortivazol (DAC) glucocorticoid ligand, discussed 
in the introduction of this chapter, bound to the glucocorticoid receptor (Scheme 3.3, top panel).  
The N-phenyl substituted ligands 16 and 17 had a 1000-fold decrease in RBA, while the 
unsubstituted pyrazole 18 had only a 10-fold decrease in RBA.  The decrease in affinity for 16 
and 17 could be attributed to energetically disfavorable steric clashes of the N-phenyl group with 
the receptor pocket for ligands 17 and 18.  The unsubstituted pyrazole 18 could isomerize 
allowing the pyrazole core to form the critical hydrogen bond with Arg 394 and Glu 353.  A 
17-estradiol ligand with a fused N-phenyl pyrazolone to the steroid A-ring could provide 
hydrogen bond with Glu 353 and still have the N-phenyl group push Arg 394 away from the 
ligand binding pocket and occupy part of the solvent channel (Scheme 3.3, bottom right panel). 
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Scheme 3.3.  Relative binding affinity of a fused pyrazole on the steroid scaffold (top panel).  
Possible isomerization of ligand 18 (bottom left panel).  Proposed ligand that could retain 
hydrogen bond (bottom right panel) 
 
 
RBA: 0.013 0.026                 11.8 
    
  
 
  
 
Preparation of the pyrazolone ligand started with hydrolysis of the Birch-reduction 
product of 3-methoxy-estradiol to give 19-nor-testosterone 14 (Scheme 3.4).  A Claisen 
condensation of 14 with methyl formate added a hydroxymethylene group at C2 of 19-nor-
testosterone to provide 15.  Condensation of 15 with phenyl hydrazine provided the fused 
pyrazole ring 16 with the proper regioisomers, due to condensation of the terminal nitrogen of 
phenyl hydrazine with the more reactive enol moiety versus the -unsaturated ketone moiety.  
The A-ring of the steroid was aromatized with DDQ to provide 17 as a 92:8 mixture of desired 
product and some over-oxidized product.  Unfortunately, several attempts to oxidize the pyrazole 
ring of 17 to the pyrazolone were not successful.  The harshest conditions using bromine in 
potassium hydroxide preferentially brominated the N-phenyl ring over the desired bromination 
of the pyrazole ring. 
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Scheme 3.4.  Synthesis of fused pyrazolone to 17-estradiol 
 
Conclusions 
A library of estrogens designed to occupy the solvent channel of the estrogen receptor 
were made, but unlike deacylcortivazol binding to the glucocorticoid receptor did not prove to be 
high affinity ligands of the estrogen receptor.  Several synthetic routes were attempted to prepare 
a DAC-based ligand for the estrogen receptor, and these were unsuccessful.  Even though reports 
of ligands occupying the solvent channel of other steroid hormone receptors exist, an equivalent 
ligand occupying the solvent channel of the estrogen receptor has thus far not been found using 
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either an estrogen core or a biphenyl core.  It is possible that ligands using a different estrogen 
core could be designed to occupy the solvent channel of the estrogen receptor. 
 
Experimental 
All reagents were obtained from Sigma-Aldrich Chemical Company (Milwaukee, WI) 
and used without further purification unless otherwise noted.  Anhydrous solvents were obtained 
from a Solvent Dispensing System fabricated by J. C. Meyer based on a published design.18 
 NMR spectra were obtained in the Varian Oxford Instrument Center for Excellence in 
NMR Laboratory.  Funding for the instrumentation was provided in party by the W. M. Keck 
Foundation, the National Institutes of Health (Grant PHS 1 S10 RR104444-01) and the National 
Science Foundation (Grant NSF CHE 96-10502).  1H-NMR spectra were recorded on 400 or 500 
MHz spectrometers, and 13C-NMR were acquired at either 100 or 125 MHz using CDCl3, 
DMSO-d6, THF-d6 or acetone-d6 as the solvent.  Chemical shifts were reported as parts per 
million relative to the solvent. 
 Low and high resolution mass spectra were obtained in the Mass Spectrometry 
Laboratory, School of Chemical Sciences, University of Illinois.  Electron ionization (EI) data 
were collected using a Micromass 70-VSE mass spectrometer under electron impact conditions 
at 70 eV and purchased in part with a grant from the Division of Research Resources, National 
Institutes of Health (RR 04648), and electrospray ionization (ESI) data were collected from a 
Micromass Q-Tof Ultima spectrometer. 
 Melting points were obtained on a Thomas-Hoover Unitemp capillary apparatus and 
remain uncorrected. 
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4'-Methoxy-[1,1'-biphenyl]-4-carbaldehyde (6a):  4-Bromo-benzaldehyde (185 mg, 1.0 mmol) 
and palladium tetrakis triphenylphosphine (219 mg, 0.2 mmol) were dissolved in toluene (5 mL).  
A 2.0 M aqueous solution of Na2CO3 (2 mL, 4 mmol) then 4-methoxy-phenyl boronic acid (167 
mg, 1.1 mmol) were added, and the reaction heated to 95 °C for 12 h.  The reaction cooled to r.t. 
and was extracted with EtOAc (3 x 25 mL), washed with brine (2 x 25 mL), dried over MgSO4, 
and solvent was removed under reduced pressure.  The product 6a was isolated using flash 
column chromatography (4:1 hexanes:EtOAc) as a white powder (213 mg, 100 %).   1H-NMR 
(CDCl3, 500 MHz)   3.86 (s, 3H), 7.01 (AA’ of AA’XX’, J = 9.7 Hz, J = 2.1 Hz, 2H), 7.59 
(XX’ of AA’XX’, J = 8.8 Hz, J = 2.1 Hz, 2H), 7.71 (AA’ of AA’XX’, J= 8.2 Hz, J = 1.7 Hz, 
2H), 7.92 (XX’ of AA’XX’, J = 8.4 Hz, J = 1.7 Hz, 2H), 10.03 (s, 1H).  13C-NMR (CDCl3, 125 
MHz)   55.5, 114.6, 127.2, 128.6, 130.5, 132.2, 134.8, 146.9, 160.3, 192.1.  HRMS (EI, 70 eV):  
calcd for C14H12O2 (M)+·:  212.0837; found:  212.0838. 
 
3'-Methoxy-[1,1'-biphenyl]-4-carbaldehyde (6b): 4-Bromo-benzaldehyde (185 mg, 1.0 mmol) 
and palladium tetrakis triphenylphosphine (219 mg, 0.2 mmol) were dissolved in toluene (5 mL).  
A 2.0 M aqueous solution of Na2CO3 (2 mL, 4 mmol) then 3-methoxy-phenyl boronic acid (167 
mg, 1.1 mmo) were added and the reaction heated to 95 °C for 12 h.  The reaction cooled to r.t. 
and was extracted with EtOAc (3 x 25 mL), washed with brine (2 x 25 mL), dried over MgSO4, 
and solvent was removed under reduced pressure.  The product 6b was isolated using flash 
column chromatography (4:1 hexanes:EtOAc) as a white powder (214 mg, 100 %).  1H-NMR 
(Acetone-d6, 500 MHz)   3.87 (s, 3H), 7.00 (m, J = 8.2 Hz, J = 1.3 Hz, 1H), 7.28 (d, J = 8.4 Hz, 
1H), 7.40 (t, J = 7.9 Hz, 1H), 7.86 (AA’ of AA’XX’, J = 8.4 Hz, J = 1.7 Hz, 2H), 7.98 (XX’ or 
AA’XX’, J = 8.4 Hz, J = 1.7 Hz, 2H), 10.07 (s, 1H).  13C-NMR (Acetone-d6, 125 MHz)   56.1, 
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114.1, 115.3, 120.8, 128.9, 131.4, 137.1, 142.3, 147.9, 161.7, 193.0.  HRMS (EI, 70 eV):  calcd 
for C13H10O2 (M)+: 212.0837; found:  212.0840. 
 
4'-Hydroxy-[1,1'-biphenyl]-4-carbaldehyde (7a):  Aldehyde 6a (106 mg, 0.5 mmol) and 
pyridine hydrochloride (1.0 g) was heated to 200 °C for 2 h.  The reaction was cooled to room 
temperature, and 20 mL of 1M HCl and 20 mL of ethyl acetate were added, and the reaction 
mixture stirred until all components dissolved.  The organic layer was separated and the aqueous 
layer was washed with ethyl acetate (3x20 mL) and brine (2x20 mL), dried over Na2SO4, and the 
solvent was removed under reduced pressure.  The product 7a was isolated by flash column 
chromatography (4:1 hexanes:EtOAc) as a white solid (94 mg, 95%).  1H-NMR (Acetone-d6, 125 
MHz)  6.98 (AA’ of AA’XX’, J = 8.6 Hz, J = 2.1 Hz, 2H), 7.62 (AA’ of AA’XX’, J = 9.7 Hz, J 
= 2.1 Hz, 2H), 7.80 (XX’ of AA’XX’, J = 8.6 Hz, J = 2.1 Hz, 2H), 7.93 (XX’ of AA’XX’, J = 
8.4 Hz, J = 2.1 Hz, 2H), 8.82 (br. s, 1H),  10.03 (s, 1H).  13C-NMR (Acetone-d6, 125 MHz)  
116.8, 127.5, 129.3, 130.9, 131.5, 135.7, 147.2, 159.0, 192.4.  HRMS (EI, 70 eV):  calcd for 
C13H10O2 (M)+: 198.0681; found: 198.0688. 
 
3'-hydroxy-[1,1'-biphenyl]-4-carbaldehyde (7b):  Aldehyde 6b (93 mg, 0.43 mmol) and 
pyridine hydrochloride (1.0 g) was heated to 200 °C for 2 h.  The reaction cooled to room 
temperature, and 20 mL of 1M HCl and 20 mL of ethyl acetate were added and the reaction 
mixture stirred until all components dissolved.  The organic layer was separated, and the aqueous 
layer was washed with ethyl acetate (3x20 mL), brine (2x20 mL), dried over Na2SO4, and the 
solvent was removed under reduced pressure.  The product 7b was isolated by flash column 
chromatography (4:1 hexanes:EtOAc) as a white solid (43 mg, 50%).  1H-NMR (Acetone-d6, 500 
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MHz)  6.92 (m, J = 8.2 Hz, J = 1.5 Hz, 1H), 7.21 (m, J = 7.5 Hz, J = 0.9 Hz, 1H), 7.34 (t, J = 
8.2 Hz, 1H), 7.85 (AA’ of AA’XX’, J = 8.4 Hz, J = 1.7 Hz, 2H), 8.00 (XX’ of AA’XX’, J = 8.6 
Hz, J = 1.7 Hz, 2H), 10.09 (s, 1H).  13C-NMR (Acetone-d6, 125 MHz)  115.4, 116.8, 119.8, 
128.9, 131.4, 131.5, 137.1, 142.4, 160.1, 193.0).  HRMS (EI, 70 eV):  calcd for C13H10O2 (M)+: 
198.0681; found: 198.0685. 
 
4'-(1-Hydroxydecyl)-[1,1'-biphenyl]-4-ol (8a):  Biphenyl carboxaldehyde 7b (50 mg, 0.25 
mmol) was dissolved in diethyl ether (0.5 mL) then cooled to 0 °C.  A 1.0 M nonylmagnesium 
bromide solution in diethyl ether (1.5 mL, 1.5 mmol) was added drop-wise over 10 min and 
continued for 15 min at 0 °C, then stirred for 3.5 h at r.t.  The reaction was quenched by slow 
addition of 4.0 M HCl (1.0 mL), solvent was removed under reduced pressure, extracted using 
EtOAc (20 mL), washed with brine (2 x 20 mL), dried over Na2SO4, and solvent was removed 
under reduced pressure.  Flash column chromatography (4:1 hexanes:EtOAc) provided 8a as a 
tan solid (59 mg, 72%).  1H-NMR (Acetone-d6, 500 MHz)  0.85 (t, J = 7.9 Hz, 3H), 1.19-1.39 
(m, 14H), 4.66 (dd, J = 7.3 Hz, J = 4.7 Hz, 1H), 6.91 (AA’ of AA’XX’, J = 8.6 Hz, J = 2.1 Hz, 
2H), 7.40 (AA’ of AA’XX’, J = 8.2 Hz, J -= 1.9 Hz, 2H), 7.50 (XX’ of AA’XX’, J = 8.6 Hz, J = 
1.9 Hz, 2H), 7.53 (XX’of AA’XX’x, J = 8.2 Hz, 2H, J = 1.7 HRMS (EI, 70 eV):  calcd for 
C22H30O2 (M)+: 326.2246; found: 326.2243 
 
4'-(1-Hydroxydecyl)-[1,1'-biphenyl]-3-ol (8b):  Biphenyl carboxaldehyde 7b (25 mg, 0.13 
mmol) was dissolved in diethyl ether (0.25 mL) then cooled to 0 °C.  A 1.0 M nonylmagnesium 
bromide solution in diethyl ether (0.25 mL, 0.8 mmol) was added drop-wise over 10 min and 
56 
 
continued for 15 min at 0 °C, the stirred for 3.5 h at r.t.  The reaction was quenched by slow 
addition of 4.0 M HCl (1.0 mL), solvent was removed under reduced pressure, extracted using 
EtOAc (20 mL), washed with brine (2 x 20 mL), dried over Na2SO4, and solvent was removed 
under reduced pressure.  Flash column chromatography (4:1 hexanes:EtOAc) provided 8b as a 
white solid (35 mg, 83%).  1H-NMR (Acetone-d6, 500 MHz)  0.85 (t, J = 7.9 Hz, 3H), 1.19-1.39 
(m, 14H), 4.66 (dd, J = 7.3 Hz, J = 4.7 Hz, 1H), 6.92 (m, J = 8.2 Hz, J = 1.5 Hz, 1H), 7.21 (m, J 
= 7.5 Hz, J = 0.9 Hz, 1H), 7.34 (t, J = 8.2 Hz, 1H), 7.85 (AA’ of AA’XX’, J = 8.4 Hz, J = 1.7 Hz, 
2H), 8.00 (XX’ of AA’XX’, J = 8.6 Hz, J = 1.7 Hz, 2H), 8.21 (br. s, 1H).  HRMS (EI, 70 eV):  
calcd for C22H30O2 (M)+: 326.2246; found: 326.2249. 
 
3-Trifluoromethanesulfonyloxy-estra-1,3,5(10)-triene-17-one (9):  Estrone (2.70 g, 10 mmol), 
p-nitrophenol triflate (2.98 g, 11 mmol), and K2CO3 (2.62 g, 20 mmol) were dissolved in DMF 
(50 mL) and stirred at r.t. for 5 h.  Water (25 mL) and EtOAc (25 mL) were added, and the 
reaction was washed with 1.0 M HCl (1 x 25 mL), water (1 x 25 mL), 1.0 M NaOH (4 x 25 mL), 
brine (2 x 25 mL), dried over Na2SO4, and the solvent was removed under reduced pressure.  
Flash column chromatography (1:1 hexanes:EtOAc) provided the protected estrone 9 as an off-
white solid (1.86 g, 92 %).  1H-NMR (CDCl3, 500 MHz)  0.91 (s, 3H), 1.41-1.71 (m, 6H), 1.97 
(m, J = 9.8 Hz, J = 2.9 Hz, 2H), 2.01-2.10 (m, 2H), 2.15 (m, J = 9.0 Hz, 1H), 2.29 (m, J = 7.6 Hz, 
J = 3.4 Hz, 1H), 2.36-2.43 (m, 1H), 2.51 (dd, J = 18.9 Hz, J = 8.7 Hz, 1H), 2.94 (dd, J = 8.6 Hz, J 
= 3.9 Hz, 2H), 6.99 (d, J = 2.4 Hz, 1H), 7.03 (dd, J = 8.7 Hz, J = 2.6 Hz, 1H), 7.34 (d,  J = 8.8 
Hz, 1H).  13C-NMR (CDCl3, 125 MHz)  13.7, 13.7, 21.5, 25.6, 26.0, 29.3, 31.4, 35.8, 37.7, 
44.0, 47.8, 50.3, 118.2, 118.7 (q, J = 320 Hz), 121.2, 127.2, 139.2, 140.2, 147.5, 220.0.  HRMS 
(ESI) m/z calcd for C19H21F3O4S 402.1113, found 402.1117. 
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3-((Diphenylmethylene)amino)estra-1,3,5(10)-triene-17-one (10):  Triflate 9 (2.299 g, 5.7 
mmol), benzophenone imine (1.24g, 6.8 mmol), palladium(II)acetate (38 mg, 0.17 mmol), 
BINAP (191 mg, 0.26 mmol), and cesium carbonate (2.63 g, 8 mmol) were dissolved in THF (40 
mL) and heated to 70 °C for 72 h under a N2 atmosphere.  The reaction cooled, was filtered 
through Celite, and the filtrate was concentrated under reduced pressure.  Flash column 
chromatography (3:1 hexanes:EtOAc) provided 10 as a yellow solid (2.28 g, 92%).  1H-NMR 
(CDCl3, 500 MHz)  0.90 (s, 3H), 1.32-1.72 (m, J = 12.2 Hz, 6H), 1.86-2.08 (m, 3H), 2.13 (m, J 
= 9.7 Hz, J = 8.6 Hz, 2H), 2.20 (t, J = 8.4 Hz, 1H), 2.30 (m, J = 6.2 Hz, 1H), 2.49 (m, J = 19.1 
Hz, J = 8.8 Hz, 1H), 2.75 (d, J = 13.1 Hz, 2H), 6.46 (d, J = 8.4 Hz, 1H), 6.53 (s, 1H), 7.02 (d, J = 
8.4 Hz, 1H), 7.14 (d, J = 6.2 Hz, 2H), 7.27 (m, J = 6.0 Hz, 3H), 7.44 (m, J = 9.9 Hz, J = 8.6 Hz, J 
= 7.5 Hz, 3H), 7.72 (d, J = 7.7 Hz, 2H).  13C-NMR (CDCl3, 125 MHz)  13.9, 20.6, 21.6, 25.7, 
26.5, 29.3, 31.5, 35.8, 38.1, 41.3, 44.1, 48.0, 50.5, 99.8, 109.7, 118.4, 121.7, 125.2, 127.9, 128.1, 
128.2, 128.4, 129.2, 129.5, 130.0, 130.5, 132.4, 134.6, 136.4, 136.5, 139.9, 148.6, 164.0, 167.6, 
184.7, 212.3.  HRMS (ESI) m/z calcd for C31H32NO 434.2484, found 434.2484. 
 
3-Amino-estra-1,3,5(10)-triene-17-one (11):  Benzophenone-protected amino estrone (2.02 g, 
4.7 mmol) was dissolved in THF (40 mL) and HCl (2.0 M, 10 mL) and stirred for 3 h.  The 
reaction was cooled to 0 °C, and NaOH (840 mg, 21 mmol) was slowly added.  Solvent was 
removed under reduced pressure, and EtOAc (50 mL) was added then washed with 1.0 M NaOH 
(3 x 25 mL), water (2 x 25 mL), brine (2 x 25 mL), and dried over Na2SO4.  Solvent was 
removed under reduced pressure, and 11 was isolated by flash column chromatography (2:1 
hexanes:EtOAc) as a tan solid (931 mg, 74%).  1H-NMR (CDCl3, 500 MHz)  0.91 (s, 3H), 1.36-
1.67 (m, 6H), 1.89-2.09 (m, 3H), 2.14 (m, J = 10.1 Hz, J = 8.8 Hz, 1H), 2.19-2.26 (m, 1H), 2.33-
58 
 
2.41 (m, 1H), 2.50 (dd, J = 19.1, J = 8.8 Hz, 1H), 2.83 (d, J = 5.2 Hz, 2H), 3.54 (br. s, 2H), 6.46 
(s, 1H), 6.52 (dd, J = 8.4 Hz, J = 2.1 Hz, 1H), 7.09 (d, J = 8.2 Hz, 1H).  13C-NMR (CDCl3, 125 
MHz)  13.8, 21.5, 25.9, 26.5, 29.4, 31.5, 35.8, 38.4, 43.9, 48.0, 50.3, 113.0, 115.3, 126.1, 129.9, 
137.3, 144.2, 184.9, 211.3.  HRMS (ESI) m/z calcd for C18H24NO 270.1858, found 270.1856. 
 
3-(2-Methoxyacetyl)amino-estra-1,3,5(10)-triene-17-one (12a):  3-Amino-estrone (58 mg, 0.2 
mmol), 2-methoxyacetic acid (18 mg, 0.2 mmol), and DMAP (5 mg, cat) were dissolved in 
methylene chloride (10 mL) and cooled to 0 °C.  DCC (50 mg, 0.24 mmol) was added, and the 
reaction was warmed to r.t. for 12 h.  The urea precipitate was filtered from the reaction, and the 
filtrate was concentrated under reduced pressure.  Amide 12a (60 mg, 88 %) was isolated as an 
off-white solid using flash column chromatography (19:1 DCM:HOAc).  1H-NMR (CDCl3, 500 
MHz)  0.91 (s, 3H), 1.38-1.74 (m, 6H), 1.90-2.10 (m, 3H), 2.15 (m, J = 9.2 Hz, 1H), 2.23-2.33 
(m, 1H), 2.37-2.45 (m, 1H), 2.51 (dd, J = 19.0 Hz, J = 8.7 Hz, 1H), 2.91 (dd, J = 8.9 Hz, J = 4.0 
Hz, 2H), 3.50 (s, 3H), 4.00 (s, 2H), 7.26 (m, 1H), 7.38 (s, 1H), 8.15 (s, 1H).  13C-NMR (CDCl3, 
125 MHz)  13.8, 28.5, 43.9, 49.1, 99.9, 109.8, 114.3, 122.3, 184.7, 212.3.  HRMS (ESI) m/z 
calcd for C21H28O4NO3 342.2069, found 342.2066. 
 
3-(2-Ethoxyacetyl)amino-estra-1,3,5(10)-triene-17-one (12b):  3-Amino-estrone (58 mg, 0.2 
mmol), 2-ethoxyacetic acid (21 mg, 0.2 mmol), and DMAP (5 mg, cat) were dissolved in 
methylene chloride (10 mL) and cooled to 0 °C.  DCC (50 mg, 0.24 mmol) was added and the 
reaction warmed to r.t. for 12 h.  The urea precipitate was filtered from the reaction, and the 
filtrate was concentrated under reduced pressure.  Amide 12b (76 mg, 99 %) was isolated as an 
off-white solid using flash column chromatography (19:1 DCM:HOAc).  1H-NMR (CDCl3, 500 
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MHz)  0.91 (s, 3H), 1.02-1.20 (m, 3H), 1.30 (t, J = 7.1 Hz, 3H), 1.32-1.73 (m, 12H), 1.89-2.09 
(m, 5H), 2.15 (m, J = 8.6 Hz, 1H), 2.24-2.32 (m, 1H), 2.36-2.45 (m, 1H), 2.51 (dd, J = 18.9 Hz, J 
= 8.6 Hz, 1H), 2.92 (dd, J = 8.9 Hz, J = 4.0 Hz, 2H), 3.43-3.52 (m, 1H), 3.65 (q, J = 7.0 Hz, 2H), 
4.04 (s, 3H), 7.21-7.31 (m, 1H), 7.38 (s, 1H), 8.21 (s, 1H).  13C-NMR (CDCl3, 125 MHz)  13.8, 
15.1, 21.6, 25.0, 25.8, 26.4, 29.4, 31.5, 34.0, 35.7, 38.1, 44.2, 50.4, 67.3, 70.0, 117.4, 120.1, 
123.1, 126.0, 126.5, 129.8, 167.8.  HRMS (ESI) m/z calcd for C22H30NO3 356.2226, found 
356.2224. 
 
3-(2-(2-Methoxyethoxy)acetyl)amino-estra-1,3,5(10)-triene-17-one (12c):  3-Amino-estrone 
(58 mg, 0.2 mmol), 2-(2-methoxyethoxy)acetic acid (27 mg, 0.2 mmol), and DMAP (5 mg, cat) 
were dissolved in methylene chloride (10 mL) and cooled to 0 °C.  DCC (50 mg, 0.24 mmol) 
was added and the reaction warmed to r.t. for 12 h.  The urea precipitate was filtered from the 
reaction, and the filtrate was concentrated under reduced pressure.  Amide 12c (51 mg, 66 %) 
was isolated as an off-white solid using flash column chromatography (19:1 methylene 
chloride:HOAc).  1H-NMR (CDCl3, 500 MHz)  0.91 (s, 3H), 1.39-1.69 (m, 6H), 1.90-2.10 (m, 
3H), 2.14 (m, J = 10.3 Hz, J = 8.8 Hz, 1H), 2.23-2.33 (m, 1H), 2.41 (m, J = 2.4 Hz, 2H), 2.51 
(dd, J = 19.0 Hz, J = 8.7 Hz, 1H), 2.92 (dd, J = 8.6 Hz, J = 3.4 Hz, 2H), 3.47 (s, 3H), 3.62 (m, J 
=2.1 Hz, 2H), 4.09 (s, 2H), 7.21-7.33 (m, 1H), 7.42 (s, 1H), 8.77 (s., 1H).  13C-NMR (CDCl3, 
125 MHz)  13.8, 21.6, 25.8, 26.4, 29.5, 31.5, 35.9, 38.2, 44.2, 48.0, 50.4, 59.1, 70.5, 71.2, 71.4, 
117.3, 120.1, 125.8, 168.1, 212.4.  HRMS (ESI) m/z calcd for C23H32NO4 386.2331, found 
386.2331. 
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3-(2-Methoxyethyl)amino-estra-1,3,5(10)-triene-17-(S)ol (13a):  Amide 12a (58 mg, 0.17 
mmol) was dissolved in THF (2 mL) and 1.0 M BH3.THF (1.0 mL, 1.0 mmol) was added slowly 
to the reaction then heated to 66 °C for 12 h.  1.0 M HCl (2 mL) was slowly added and the 
solvent was removed under reduced pressure.  Methylene chloride (20 mL) was added and 
washed with sat’d NaHCO3 (2 x 10 mL) and brine (2 x 10 mL), then dried over Na2SO4.  The 
reduction product 13a was isolated by flash column chromatography (1:9 acetone:methylene 
chloride) as the 17-hydroxy epimer as a white solid (28 mg, 50%).  1H-NMR (CDCl3, 500 
MHz)  0.78 (s, 3H), 1.19 (m, J = 11.6 Hz, J = 7.3 Hz, 1H), 1.31 (m, J= 5.8 Hz, 3H), 1.39-1.54 
(m, 3H), 1.69 (m, J = 3.9 Hz, J = 2.6 Hz, 1H), 1.82-1.90 (m, 1H), 1.93 (m, J = 12.5 Hz, J = 3.2 
Hz), 2.13 (m, J = 4.3 Hz, 2H), 2.29 (m, J = 13.3 Hz, J = 2.8 Hz, 1H), 2.72-2.89 (m, 2H), 3.27 (t, J 
= 5.3 Hz, 2H), 3.39 (s, 3H), 3.60 (t, J = 5.3 Hz, 2H), 6.39 (d, J = 2.4 Hz, 1H), 6.48 (dd, J = 8.4 
Hz, J = 2.6 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H).  13C-NMR (CDCl3, 125 MHz)  11.0, 23.1, 27.3, 
29.8, 30.5, 36.7, 39.0, 43.2, 43.6, 43.9, 49.9, 58.6, 71.1, 81.9, 111.1, 113.2, 126.1, 129.7, 137.4, 
146.0.  HRMS (ESI) m/z calcd for C21H32NO2 330.2433, found 330.2430. 
 
3-(2-Ethoxyethyl)amino-estra-1,3,5(10)-triene-17-(S)ol (13b):  Amide 12b (58 mg, 0.17 
mmol) was dissolved in THF (2 mL) and 1.0 M BH3.THF (1.0 mL, 1.0 mmol) was added slowly 
to the reaction then heated to 66 °C for 12 h.  1.0 M HCl (2 mL) was slowly added and the 
solvent was removed under reduced pressure.  Methylene chloride (20 mL) was added and 
washed with sat’d NaHCO3 (2 x 10 mL) and brine (2 x 10 mL), then dried over Na2SO4.  The 
reduction product 13b was isolated by flash column chromatography (1:9 acetone:methylene 
chloride) as the 17-hydroxy epimer as a white solid (32 mg, 47%).  1H-NMR (CDCl3, 500 
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MHz)  0.77 (s, 3H), 1.22 (t, J = 7.0 Hz, 3H), 1.25-1.57 (m, 6H), 1.62-1.78 (m, 1H), 1.79-1.90 
(m, 1H), 1.90-1.99 (m, 1H), 2.04-2.23 (m, 2H), 2.23-2.36 (m, 1H), 2.68-2.95 (m, 2H), 3.20-3.35 
(m, 2H), 3.53 (q, J = 6.9 Hz, 2H), 3.64 (t, J = 5.3 Hz, 2H), 3.72 (t, J = 8.6 Hz, 2H), 6.32-6.45 (m, 
1H), 6.48 (dd, J = 8.4 Hz, J = 2.1 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H).  13C-NMR (CDCl3, 125 
MHz)  11.3, 15.4, 23.3, 26.5, 27.6, 30.0, 30.1, 36.9, 39.2, 43.5, 44.0, 44.1, 50.2, 66.6, 69.2, 
82.1, 111.4, 113.5, 116.5, 126.3, 126.6, 129.9, 137.7, 146.3.  HRMS (ESI) m/z calcd for 
C22H34NO2 344.2590, found 344.2590. 
 
3-(2-(2-Methoxyethoxy)ethyl)amino-estra-1,3,5(10)-triene-17-(S)ol (13c):  Amide 12c (58 
mg, 0.12 mmol) was dissolved in THF (2 mL) and 1.0 M BH3.THF (0.7 mL, 0.7 mmol) was 
added slowly to the reaction then heated to 66 °C for 12 h.  1.0 M HCl (2 mL) was slowly added, 
and the solvent was removed under reduced pressure.  Methylene chloride (20 mL) was added 
and washed with sat’d NaHCO3 (2 x 10 mL) and brine (2 x 10 mL), then dried over Na2SO4.  
The reduction 13c was isolated by flash column chromatography (1:9 acetone:methylene 
chloride) as a clear waxy solid (41 mg, 92%).  1H-NMR (CDCl3, 500 MHz)  0.77 (s, 3H), 1.18 
(m, J = 7.5 Hz, J = 4.5 Hz, 1H), 1.30 (m, J = 6.0 Hz, 4H), 1.38-1.53 (m, 3H), 1.63-1.74 (m, 1H), 
1.93 (dt, J = 12.4 Hz, J = 3.1 Hz, 1H), 2.04-2.20 (m, 2H), 2.25-2.33 (m, 1H), 2.72-2.88 (m, 2H), 
3.29 (t, J = 5.4 Hz, 2H), 3.40 (s, 3H), 3.56 (dd, J = 6.2 Hz, J = 5.2 Hz, 2H), 3.63 (m, 2H), 3.67-
3.75 (m, 2H), 6.38 (d, J = 2.1 Hz, 1H), 6.47 (dd, J = 8.4 Hz, J = 2.4 Hz, 1H), 7.10 (s, J = 8.4 Hz, 
1H).  13C-NMR (CDCl3, 125 MHz)  11.0, 23.0, 26.2, 27.3, 29.8, 30.5, 36.7, 38.9, 43.2, 43.9, 
49.9, 59.1, 69.7, 70.1, 71.8, 81.8, 111.1, 113.2, 126.0, 129.6, 137.4, 146.0, 163.9, 212.3.  HRMS 
(ESI) m/z calcd for C23H36NO3 374.2695, found 374.2693. 
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19-Nor-testosterone (14):  Methanol (100 mL) and water (60 mL) were heated to 60 °C and the 
Birch reduction product of 3-methyl-estradiol (2.88g, 10 mmol) was added and stirred for 30 min 
then cooled to r.t.  Solvent was removed under reduced pressure, and the residue was dissolved 
in diethyl ether, washed with brine (2 x 25 mL) and dried over MgSO4.  The solvent was 
removed under reduced pressure, and 19-nor-testosterone 14 (2.14 g, 78%) was isolated as a 
granular solid using flash column chromatography (1:1 hexanes:EtOAc).  1H-NMR (CDCl3, 500 
MHz)  0.69-0.89 (m, 1H), 0.78 (s, 3H), 0.90-1.14 (m, 3H), 1.20-1.37 (m, 3H), 1.42-1.65 (m, 
3H), 1.67-1.91 (m, 4H), 1.96-2.14 (m, 2H), 2.17-2.33 (m, 3H), 3.64 (t, J = 8.6 Hz, 1H), 5.81 (s, 
1H).  13C-NMR (CDCl3, 125 MHz)  11.0, 23.1, 26.1, 26.5, 26.8, 26.9, 30.3, 30.6, 35.4, 36.3, 
36.5, 40.4, 42.5, 42.9, 49.5, 49.7, 81.6, 124.5, 166.7, 200.0.  HRMS (EI, 70 eV):  calcd for 
C18H26O2 (M)+: 274.1933; found: 274.1930. 
 
2-((Z)-(2-Hydroxy)vinyl)-19-nor-testosterone (15):  19-Nor-testosterone, 14, (823 mg, 3 
mmol) was dissolved in pyridine (5 mL) and 60% NaH in mineral oil (480 mg, 12 mmol) was 
added and stirred until hydrogen evolution ceased.  The reaction was cooled to 0 °C and methyl 
formate (1.80 g, 30 mmol) was added, the reaction warmed to r.t. and stirred for 20 h.  Water (5 
mL) was slowly added to the reaction and solvent was removed under reduced pressure.  EtOAc 
(25 mL) was added and washed with 1.0 M HCl (3 x 10 mL), water (2 x 20 mL), brine (2 x 20 
mL), dried over Na2SO4, and solvent was removed under reduced pressure.  The product, 15, 
(433 mg, 48 %) was isolated by flash column chromatography (9:1 methylene chloride:MeOH) 
as a yellow oil.  1H-NMR (CDCl3, 500 MHz)  0.77 (s, 3H), 0.84-0.95 (m, 1H), 0.96-1.16 (m, 
3H), 1.27-1.40 (m, 3H), 1.40-1.68 (m, 3H), 1.77-1.90 (m, 3H), 2.05-2.20 (m, 3H), 2.26 (td, J = 
13.7 Hz, J = 5.4 Hz, 1H), 2.53 (dd, J = 15.0 Hz, J = 2.6 Hz, 1H), 2.58-2.68 (m, 1H), 3.66 (t, J = 
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8.6 Hz, 1H), 5.88 (s, 1H), 7.33 (s, 1H).  13C-NMR (CDCl3, 125 MHz)  11.3, 14.4, 23.5, 26.7, 
28.3, 30.7, 35.4, 36.7, 40.1, 42.9, 43.3, 50.0, 81.9, 107.1, 124.0, 132.6, 158.4, 162.3, 163.9, 
170.4, 187.4.  HRMS (EI, 70 eV):  calcd for C19H26O3 (M)+: 302.1882; found: 302.1880. 
 
N-phenyl-pyrazolo[4,5-b]estra-4-ene-17(S)-ol (16):  Steroid, 15, (151 mg, 0.5 mmol) was 
dissolved in EtOH (2 mL), and freshly distilled phenyl hydrazine (65 mg, 0.6 mmol) was added 
along with 4.0 M HCl (1 drop, cat) and heated to 60 °C for 2 h.  The reaction was cooled and 
solvent was removed under reduced pressure.  EtOAc (20 mL) was added and washed with water 
(2 x 20 mL), brine (2 x 20 mL), dried over Na2SO4, and solvent was removed under reduced 
pressure.  The product, 16, (100 mg, 53 %) was isolated by flash column chromatography (9:1 
methylene chloride:acetone) as a yellow solid.  1H-NMR (CDCl3, 500 MHz)  0.79 (s, 3H), 0.93-
1.06 (m, 3H), 1.13 (dd, J = 12.8 Hz, J = 4.0 Hz, 1H), 1.20-1.34 (m, 3H), 1.44 (d, J = 13.5 Hz, 
1H), 1.56-1.65 (m, 1H), 1.75 (dt, J = 12.6 Hz, J = 2.4 Hz, 1H), 1.84 (dt, J = 12.3 Hz, J = 3.3 Hz, 
1H), 1.92 (dd, J = 13.3 Hz, J = 3.0 Hz, 1H), 2.00-2.10 (m, 1H), 2.17-2.35 (m, 2H), 2.39-2.48 (m, 
2H), 3.08 (dd, J = 15.4 Hz, J = 8.8 Hz, 1H), 3.65 (t, J = 8.6 Hz, 1H), 6.20-6.23 (m, 1H), 7.30-
7.34 (m, 1H), 7.42-7.49 (m, 4H).  13C-NMR (CDCl3, 125 MHz)  11.1, 23.3, 24.9, 26.5, 29.3, 
30.5, 30.7, 35.1, 36.7, 41.2, 42.6, 43.2, 50.0, 50.9, 81.8, 109.9, 114.4, 121.6, 123.7, 124.9, 126.9, 
129.1, 137.4, 145.3.  HRMS (EI, 70 eV):  calcd for C25H30N2O (M)+: 374.2358; found: 
374.2358. 
 
N-phenyl-pyrazolo[4,5-b]estra-4,1(10)-diene-17(S)-ol (17):  Steroid, 16, (85 mg, 0.23 mmol) 
was dissolved in THF (5 mL) and cooled to 0 °C under an inert atmosphere.  A solution of DDQ 
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(56 mg, 0.23 mmol) in THF (1 mL) was added slowly over 10 min, then stirred at 0 °C for 2 h.  
The reaction was quenched with a sat’d solution of Na2SO3 (1 mL) and stirred for 30 min..  A 
yellow precipitate was removed by filtration, and washed with methylene chloride (2 x 10 mL).  
Solvent was removed under reduced pressure, methylene chloride (20 mL) was added, then 
washed with brine (2 x 20 mL), dried over Na2SO4, and solvent was removed under reduced 
pressure.  The product, 17, (63 mg, 75 %) was isolated by flash column chromatography (9:1 
methylene chloride:MeOH) as a yellow solid.  1H-NMR (CDCl3, 500 MHz)  0.81 (s, 3H), 1.20-
1.30 (m, 2H), 1.31-1.58 (m, 7H), 1.62-1.78 (m, 2H), 1.88-1.97 (m, 1H), 2.02 (dt, J = 12.3 Hz, J = 
3.5 Hz, 1H), 2.08-2.20 (m, 1H), 7.50-7.56 (m, 2H), 7.70 (s, 1H), 7.71-7.75 (m, 2H), 8.11 (s, 1H), 
7.31-7.37 (m, 1H), 7.48 (s, 1H), 7.50-7.56 (m, 2H), 7.70 (s, 1H), 7.71-7.75 (m, 2H), 8.11 (s, 1H).  
13C-NMR (CDCl3, 125 MHz)  11.0, 23.2, 26.3, 27.2, 30.3, 36.6, 38.7, 43.2, 44.1, 50.4, 81.8, 
109.2, 116.8, 122.3, 122.3, 124.1, 126.2, 129.4, 135.2, 135.4, 137.5, 137.6, 140.4, 153.9.  HRMS 
(EI, 70 eV):  calcd for C25H30N2O (M)+: 372.2202; found: 372.2199. 
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Chapter 4 
Preparation of a Gene Switch Using the Estrogen Receptor 
 
Introduction 
A gene switch is a powerful tool used in molecular cellular, and organismic biology to 
examine the role of a specific gene throughout the life cycle through external control of gene 
expression.1, 2  Fortunately, gene switches exist in nature and provide a standard for comparison 
when designing a new gene switch.  The nuclear hormone super-family of receptors is a well-
documented class of naturally occurring gene switches controlling cellular function through gene 
regulation.  Notable examples of nuclear hormone receptors are the estrogen and androgen 
receptor due to their prominent role in the development and regulation of the female and male 
reproductive systems, respectively.   
The estrogen receptor is an ideal gene switch used by nature to regulate cellular function 
for numerous reasons.1  The estrogen receptor is highly active in the presence of estradiol and 
operates in a reversible and dose-dependent manner; conversely the estrogen receptor has low 
basal activity in the absence or removal of estradiol.  Other naturally occurring ligands sharing 
the same steroidal core structure do not bind to or activate the estrogen receptor.  For example, 
testosterone differs from estradiol only in the A-ring of the steroid, were the testosterone A-ring 
is an -unsaturated ketone with a C19 angular methyl group, while estradiol has a phenolic A-
ring.  Despite the differences in hormone structure, testosterone is more than 10,000-fold less 
potent than estradiol in activating the estrogen receptor.3, 4  Conversely, the estradiol is 
minimally 175-fold less active on the androgen receptor than is testosterone, verifying that the 
estrogen receptor and the androgen ligand receptor pairs are essentially completely orthogonal to 
each other. In fact, nearly all nuclear hormone ligand receptor pairs are orthogonal or nearly 
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orthogonal. It is notable that this orthogonal specificity of natural nuclear receptors for their 
cognate ligands is a detailed function of their precise sequence and structure, with single natural 
or synthetic mutations leading to a major decrease in specificity,5-7 which can, in fact, underlie 
endocrine disorders (in the mineralocorticoid series)5 or resistance to endocrine therapies in 
prostate cancer (LNCaP mutation).7   
Since the estrogen receptor (ER) ligand binding domain (LBD) acts as a transcriptional 
activator independently from its DNA binding domain, the estrogen receptor LBD fused to the 
DNA binding domain of any transcription factor would create a unique transcription factor 
capable of regulating gene transcription in vivo in a graded response depending on the 
concentration of estradiol.8  An orthogonal gene switch based on an engineered mutant form of 
the estrogen receptor that no longer responded to endogenous estrogens but responded instead to 
a matched ligand that itself did not activate wild type ER or any other nuclear receptors, should 
retain all the advantageous properties of the estrogen receptor as a gene switch and should not 
risk an immune response from the host.  This modular system would be an ideal tool for studying 
the role of gene transcription throughout the cell cycle and potentially to regulate transgenes in 
gene therapy. 
We are interested in the development of just such an engineered estrogen receptor that is 
selectively activated by an unnatural ligand.  Our goal was first to identify mutations of the 
estrogen receptor that diminish affinity for estradiol, then design new ligands to restore the 
mutant receptor to wild-type activity based on modeling of new ligands in the x-ray crystal 
structure of estradiol bound to the estrogen receptor ligand binding domain.9  Finally, we planned 
to synthesize and evaluate our compounds to verify their effectiveness and specificity. 
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When creating a new ligand-receptor pair through reengineering the specificity of a 
known ligand-receptor combination, it is useful to follow a general scheme and use a clear the 
terminology to describe the four possible ligand-receptor combinations (Figure 4.1).10  The 
endogenous receptor-ligand combination is termed ‘match’, as in the estrogen receptor-estradiol 
pair, while the mutated estrogen receptor with a modified ligand is termed ‘rematch’.  An ideal 
rematch would be one in which the modified ligand had the same potency and activity on the 
mutated receptor as do the natural ligand and the wild type receptor in the match.  The two 
possible ‘mismatch’ combinations are termed either ‘ligand mismatch’ or ‘receptor mismatch’, 
depending on whether a manipulation has been made to the ligand or to the receptor, 
respectively.  In order for the rematch to be orthogonal, both mismatches should be poor gene 
switches with very low potency and activity.  Identifying a mutated estrogen receptor that 
inactive in the presence of the natural endogenous ligand, estradiol, is the critical first step in 
creating a receptor orthogonal to the estrogen receptor.   
  
Wild Type Estrogen Receptor 
 
Mutated Estrogen Receptor 
 
Estradiol 
 
 
Match 
 
Receptor Mismatch 
 
Modified Ligand  Ligand Mismatch 
 
Rematch 
Figure 4.1.  Four possible ligand-receptor interactions when creating a gene switch through 
nuclear receptor mutagenesis. 
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Two simultaneous reports described efforts to create a gene switch from the estrogen 
receptor through rational design of a mutated estrogen receptor in which the key polar 
interactions between the A-ring phenol of estradiol and the receptor were “reversed”.10, 11 E353 
in estradiol receptor α is crucial for high affinity ligand binding, since the carboxylate acts as an 
acceptor in the formation of a critical hydrogen bond with the phenolic moiety of estradiol.  
(Notably, in receptors for 3-keto steroids, Glu at this position is replaced by Gln, so the receptor 
can donate a hydrogen bond to the ketone oxygen.) A mutation of the glutamic acid residue at 
position 353 of the estrogen receptor was proposed to significantly decrease the affinity of 
estradiol for the estrogen receptor (Figure 4.2).  The strategy of reversing the hydrogen bonding 
profile of the protein from an acceptor to a donor via a glutamic acid-to-serine mutation (E535S), 
in combination with the synthesis of a steroid ligand bearing a carboxylate acceptor on the A-
ring, was proposed to form an ideal orthogonal ligand-receptor pair.  Unfortunately the receptor 
mismatch was nearly as active in vivo as the rematch example in these studies.10, 11  Because 
estradiol significantly activated the E353S mutant receptor, a different mutant receptor, one that 
was essentially inactive to estradiol, was needed to overcome this drawback in the rational 
design strategy. 
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Figure 4.2.  Previous design strategy for creation of an orthogonal ligand-receptor pair and 
                 transactivation response.  
 
Before the x-ray structure of estradiol bound to the estrogen recptor was reported, an 
alanine scan of residues encompassing part of helix 11 and the loop region before helix 12 
(residues 519-535) identified important amino acids that stabilized binding and activity of the 
estrogen receptor-estradiol complex.12, 13  Leucine 525 was one of several residues indentified to 
be important for both ligand binding and receptor activation, because it was not activated by 
estradiol (Figure 4.3).  Independent titrations of L525A with estradiol and several non-steroidal 
estrogen receptor ligands indicated that L525 was the only residue essential for both binding and 
activity in all cases.  It is important to note that the L525A only reduced ligand binding and 
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ligand potency, and it did not affect the global conformation of the receptor, because high 
concentrations of estrogen ligands returned the activity of the L525A mutant to nearly the level 
of that of the matched case.12, 13  It is also of note that the L525A mutation appears to destabilize 
ER, so that in the absence of any ligand, its cellular levels are lower; ligand binding, however, 
restores normal levels.12  Such behavior could well lead to a better orthogonal gene switch, 
because it would ensure that in the absence of an effective ligand, the L525A ER would have 
very low basal activity. Therefore, a leucine-to-alanine mutation at position 525 (L525A) of the 
estrogen receptor, found by alanine scanning, appears to be a more promising receptor mismatch 
than the E353S approach of polar residue exchange proposed by rational and structure-guided 
design.   
Figure 4.3. Relative transactivation profile of residues 515-535 from alanine scan. 
 
The challenges, at this point, were to identify why a conservative mutation like leucine to 
alanine would drastically change the binding affinity and activity of estradiol for the estrogen 
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receptor and then to develop a ligand that could overcome this deficiency and activate the L525A 
mutant with high potency without activating wild type ER. Molecular modeling was used to 
determine the size and shape of the binding pocket of the mutated estrogen receptor, and ligands 
were designed based upon those findings. 
An alternate and more efficient approach identifying potential mutant receptors serving 
as a gene switch focused on directed evolution of the estrogen receptor ligand binding    
domain.4, 14  (This approach has also been used to develop gene switches for other nuclear 
receptors.11, 15, 16)  Unlike structure-guided design, directed evolution does not limit the search for 
potential mutants to just one mutation at one position in the ligand binding pocket.  It can 
efficiently generate all amino acid substitutions at any site of the estrogen receptor using site 
saturation mutagenesis of a yeast plasmid containing the estrogen receptor ligand binding 
domain sequence.  Alternatively, it can be supplemented by using random mutation of the 
estrogen receptor ligand binding domain using error-prone PCR on that same plasmid used for 
the saturation mutagenesis.  Screening of the mutant library, generated in this fashion, used a 
growth-based yeast two-hybrid assay to identify yeast colonies containing active mutants of a 
rematch case compared to the receptor mismatch. 
The yeast two-hybrid system utilized two constructs to evaluate the activity of a ligand 
(Figure 4.4).  One gene expresses the estrogen receptor ligand binding domain fused to GAL4 
DNA binding domain, while the other gene expresses the coactivator protein, SRC-1, fused to 
the GAL4 activation domain (GAL4 AD).  A GAL4 regulatory site is introduced stably in the 
promoter region of the HIS3 gene.14 When the mutated estrogen receptor binds a ligand, the 
ligand binding domain adopts a conformation in which the C-terminal helix, helix 12, adopts an 
active conformation. This enables SRC-1 to be recruited to the complex, thereby bringing the 
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GAL4 AD portion of the construct to the DNA-tethered estrogen receptor and activating the 
HIS3 gene.  Transcription of the HIS3 gene allows the yeast to produce histidine, which is 
needed for survival.  Yeast cultures with an active ligand-receptor combination can grow in 
media lacking histidine, while little yeast growth is observed if the ligand receptor pair is not 
active and no histidine is produced. 
 
Figure 4.4.  Yeast two hybrid growth-based assay 
 
This assay can be used to query the receptor mismatch and the ligand rematch. A library 
of mutants can be incubated with a concentration of estradiol that will activate the wild-type 
receptor, and a synthetic ligand concentration can be used that does not activate the wild-type 
receptor.  With a particular mutant estrogen receptor, if the yeast cells do not grow in the 
presence of estradiol (indicates a potential receptor mismatch) and significant growth occurs with 
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an unnatural ligand (indicates a potential rematch), then the colony can be visually identified as a 
potential mutant of interest.  Titration with the unnatural ligand is used to verify the level of 
selectivity that the unnatural ligand has over estradiol for the mutant.  Isolation of the plasmid 
and DNA sequencing is then used to identify the actual mutant that was created. 
A combination of rational ligand design using molecular modeling based on the location 
of the receptor mutation with site saturation directed evolution is a more robust approach to 
identify potential gene switches.  These two methods can evaluate all 20 amino acids substituted 
a position 525 of the estrogen receptor and increase the chances of discovering a new gene 
switch. 
Results and Discussion 
Molecular Modeling 
 Molecular modeling was used to predict the size, shape, and electrostatic potential of the 
L525A binding pocket bound with estradiol, as well as with tetra-substituted pyrazole ligands.  
Modeling of the L525A mutant was based upon the ERα 17β-estradiol X-ray crystal structure 
from the PDB (reference code: 1ERE).9  After the muti-step minimization process of the L525A 
ER-estradiol complex, a surface was created around the binding pocket of both the mutated 
receptor and the original wild-type receptor for comparison (Figure 4.5).  One noticeable 
difference between the wild-type receptor and the L525A mutant is the larger overall size of the 
binding pocket of the L525A mutant.  A large cavity appeared to open in the binding pocket of 
the L525A estrogen receptor as a result of the loss of an isopropyl moiety from the leucine 
residue at position 525 when it was mutated to an alanine residue (yellow surface Figure 4.5).  
This indicated that ligands specifically designed to be too bulky for accommodation in the 
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smaller ligand binding pocket of the wild-type estrogen receptor may prove to be excellent 
candidates for good binding and activation of the L525A mutant.  
 
Figure 4.5.  Overlay of ligand pockets of the wild-type estrogen receptor (green surface) and 
the L525A mutant (yellow dot surface). 
 
 In an effort to rationally design new ligands for the L525A ER, the mutant binding pocket 
was further explored by mapping both electrostatic and lipophilic potentials on the surface 
(Figure 4.6).  The large unoccupied region of the L525A receptor binding was found to be 
mostly hydrophobic, although there is a small region that is positively-charged.  When the 
electrostatic potential was mapped onto the binding pocket surface, the electrostatic potential 
Glu 353 
Arg 394 
Leu 525/Ala 
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was not as strong as the lipophilic mapping suggested.  Therefore, ligands containing mostly 
hydrophobic groups were selected, based on the mapping of the binding pocket 
 
 
Figure 4.6.  Electrostatic (top) and lipophilic potential (bottom) surfaces of the L525A  
estrogen receptor with estradiol docked into the binding pocket. 
  
 These surface maps can also be used not just for ligand design but also to rationalize the 
poor stability of the L525A-estradiol complex.  Although leucine cannot form stabilizing 
electrostatic interactions with estradiol, the L525A-estradiol complex is hypothesized to be 
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78 
 
energetically disfavored due to loss of hydrophobic interactions with hydrophobic regions of the 
ligand when the leucine residue is replaced with and alanine; this will be addressed later. 
 Previous molecular modeling studies suggested that large hydrophobic substituents on the 
core nitrogen of a tetra-substituted pyrazole might be properly orientated to fill the free space 
created by the L525A mutation.  A modeling study was performed using the minimized L525A-
E2 complex, and several pyrazole ligands were docked and minimized in the L525A structure.   
 We chose not to use an N-phenyl pyrazole a potential target, because it was known to be 
a potent ligand for the wild-type estrogen receptor.17  An obvious extension of the aryl group are 
the N-naphthyl pyrazoles, which are considerably bulkier than the previously prepared pyrazole 
ligands. An illustrative example of this modeling study utilizing a non-steroidal pyrazole target is 
displayed below (Figure 4.7).  The model showed that the β-naphthyl-substituent projected 
nicely into the expanded binding pocket of the mutant estrogen receptor.  Also, the large 
naphthyl group could not be docked into the wild-type receptor, presumably because of 
unfavorable steric clashes with the smaller wild-type estrogen receptor binding pocket.  The 
electrostatics and lipophilicity of the larger pocket indicated that the N-napthyl pyrazole is a 
viable target for the L525A mutant and does not have any disfavored interactions with the 
mutated receptor. 
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Figure 4.7. Electrostatic (top) and lipophilic potential (bottom) 
surfaces of the L525A estrogen receptor with a N-naphthylpyrazole 
docked into the binding pocket. 
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Pyrazole Library Synthesis 
A series of pyrazole compounds were prepared by the condensation of a 1,3-diketone 
with various substituted hydrazines.  Synthesis of the 1,3-dikentone (Scheme 4.1) started with 
the preparation of ketone 1 by Fridel-Crafts acylation of anisole with valeryl chloride.  Acylation 
of p-nitrophenol with anisoyl chloride gave the activated ester 2 used in the crossed-Claisen 
condensation with ketone 1 to form the 1,3-diketone intermediate 3.17 
 
Scheme 4.1.  Tri-substituted 1,3-diketone synthesis. 
 
 
Variation of the pyrazole core was introduced by substitutions of either aryl or alkyl 
groups on the hydrazine component of the pyrazole.  Several different routes were used for 
hydrazine preparation, depending on the desired substituted hydrazine.  For naphthyl hydrazines, 
a Hartwig procedure using palladium-catalyzed cross-coupling of benzophenone hydrazone with 
two commercially available naphthyl-bromides was successful in producing the protected N-
naphthyl hydrazine, 4a-b. These were then condensed with 1,3-diketone 3 under acid catalyst to 
form the protected pyrazole (Scheme 4.2).18 
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Scheme 4.2.  N-naphthyl pyrazole synthesis. 
 
 
 
To prepare alkyl substituted pyrazoles, hydrazine itself was first condensed with the 1,3-
diketone 3 in Scheme 4.3.  The intermediate pyrazole 6 has one reactive nitrogen atom towards 
alkylation avoiding the preparation of alkyl-hydrazines through alkyation of hydrazine where 
multiple alkylations would make purification cumbersome.  Deprotonation of the pyrazole using 
hydride and alkylation using several commercially available alky halides cleanly afforded the 
desired protected pyrazoles 5c-h. 
Scheme 4.3.  N-alkyl pyrazole synthesis. 
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The alkylation in Scheme 4.3 conveniently prepared pyrazoles with simple N-substituted 
alkyl groups from common alkyl halides, but the reaction conditions would not work for 
sterically hindered alkyl halides such as adamantyl bromide.  Adamantyl hydrazine had to be 
prepared using a different method than was used for the aryl hydrazines (Scheme 4.4).  t-Butyl 
carbazate was condensed with adamantanone  to form the protected imine.19  Reduction of the 
imine and subsequent deprotection of the Boc moiety provided the desired hydrazine, which was 
condensed on to the 1,3-diketone 3.  
Scheme 4.4.  Branched alykyl pyrazole synthesis. 
 
 
Molten pyridinium chloride was typically used to deprotect the phenol moiety.  In cases 
where the R group was not a linear alkane, such as the adamantyl and naphthyl analogs, loss of 
the alkyl group under the molten salt conditions required the milder deprotection conditions 
(Lewis acid, boron tribromide dimethylsulfide complex, at room temperature) to remove the 
methyl group (Scheme 4.5). 
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Scheme 4.5.  Demethylation of protected pyrazole. 
 
 
L525X Mutant Screening 
Once the library of pyrazole ligands was prepared, site-saturation mutagenesis was used 
to substitute all possible amino acid substitutions at position 525 of the estrogen receptor ligand 
binding domain, and all of the L525 mutants were assayed for selective activation by members of 
the pyrazole library, relative to estradiol, using the yeast two-hybrid assay, discussed in the 
Introduction. 
Titration of the wild-type human estrogen receptor ligand binding domain using several 
concentrations of the pyrazole library and estradiol was necessary to identify the proper 
concentration required to screen for a mutant ER that could be activated selectively (Figure 4.8).  
The highest pyrazole concentration that did not activate the wild-type estrogen receptor was 
chosen for screening; for example, 10-6 M was used in screening 9b instead of 10-7 M.  
Conversely, the lowest concentration of estradiol that can activate the wild-type receptor was 
chosen to monitor wild-type activity, while allowing for the possibility that one of the mutated 
receptors generated in the library would show lower activity.   
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    Figure 4.8.  Titration of wtER with pyrazole ligands. 
 
A parent library of 95 L525X mutants was generated along with the wild-type estrogen 
receptor, which was used as a standard.  The yeast library was grown on 96 well plates, using 
cell culture media with histidine to allow maximum yeast growth.  The yeast mutant library was 
transferred to a series of individual 96 well plates containing the appropriate ligand 
concentration, as discussed above, and each plate was diluted with media lacking histidine to 
promote ligand-dependant yeast growth.  After incubation at 30 ºC for 24 hours, or when the 
wild type receptor well had reached growth saturation in the presence of estradiol, the plates 
were visually screened to identify wells containing yeast bearing ER mutants that showed growth 
in the presence of pyrazole ligand, but little to no growth in the presence of estradiol. 
Unfortunately, none of the mutants at position 525 showed any significant selectivity 
towards any of the pyrazole ligands compared to estradiol.  Several yeast colonies showed 
significant growth in the presence of both the pyrazole and estradiol.  Their plasmid DNA was 
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isolated and sequenced.  The sequence revealed that most of the mutants identified were the 
wild-type estrogen receptor.  Since the pyrazole ligand concentration did activate the wild-type 
estrogen receptor, a lower concentration of the pyrazole was used, and the assay was repeated.  
Again, no estrogen receptor mutants showing any significant preference for a pyrazole ligand 
over estradiol were found. 
The L525A mutant was identified as a potential site for engineering selectivity based on 
an alanine scan of helix 11, but this identification relied solely on the poor activation of L525A 
by estradiol.  Modeling revealed that this mutation resulted in an enlarged binding pocket in a 
position where it appeared that it could be filled by members of a pyrazole library having larger 
substituents on the nitrogen. The experimental results of assaying the L525X mutant library, 
however, did not identify any member of the pyrazole ligand library that could activate any 
member of the receptor mutant library sufficiently to allow for yeast growth.   
It is not clear why this structure-based ligand design-L525 saturation mutagenesis 
approach failed. Based on the crystal structure, one might speculate that L525 residue on helix 
11 has energetically important hydrophobic interactions not only with the ligand, but also with 
residues L540 and L544 of helix 12, the latter of which help to stabilize helix 12 in the agonist 
confirmation (Figure 4.9).  Although the pyrazole ligands in our library were intentionally 
designed to have alkyl groups properly positioned to replace the missing hydrophobic component 
that would be present in some of the L525X mutants, they were, apparently, unable to provide 
sufficient overall stabilization to activate the receptor.  Thus, despite the structural attractiveness 
of the N-substituted pyrazole L525X mutant approach, it failed.   
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Figure 4.9.  L525 interaction with helix 12 leucine residues. 
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L521X and L518X Mutant Screening 
Since position 525 was not a viable site to obtain ER mutants having selectivity towards 
members of the pyrazole library, other residues near position 525 were chosen for site-saturation 
mutagenesis using the directed evolution method, because the pyrazole ligands were designed to 
fit into the general region of the estrogen receptor binding pocket occupied by the D-ring of 
estradiol.  Positions G521 and S518 were individually selected for saturation mutagenesis, 
because those residues occupy the same region of the steroid binding pocket. In addition, the 
Zhao and Gambhir groups had reported that mutants at these sites altered the selectivity of 
estrogen receptor ligands, lowering the potency of estradiol compared to that of several synthetic 
ligands.20, 21  G521 is much closer to the ligand binding pocket of the estrogen receptor, while 
S518 is much further away, although Figure 4.10 does not depict this clearly. 
Figure 4.10.  Location of G521 and S518 of the estrogen receptor ligand binding domain. 
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The pyrazole ligands were screened in the same way as described for the L525X mutant 
library, but this time using a library with S518X and another library containing G521X mutants.  
These screening efforts revealed several mutants having selective activity towards some of the 
pyrazole compounds, but only for position 521.  Saturation mutagenesis at position 518 revealed 
no mutant receptors that were selective for any member of the pyrazole library relative to 
estradiol, as was the case with the L525X library.   
Identification of the specific mutant at position 521 required isolation of the plasmid from 
the yeast cells, and transformation of the plasmid into E. coli DH5 cells.  E. coli can only 
accept one plasmid, whereas yeast can theoretically accept multiple plasmids containing multiple 
mutated estrogen receptors.  Isolation of the plasmid from E. coli served to ensure that the 
original selectivity detected was based on only one mutant of the estrogen receptor from one 
plasmid.  E. coli was transfected with the isolated yeast plasmid and grown in proper media.  The 
plasmid was re-isolated from the bacteria, and used for DNA sequencing, since bacteria produce 
a significant quantity of plasmid compared to yeast.  DNA sequencing revealed two mutants of 
the estrogen receptor, G521T and G521V, responsible for the selectivity observed for several 
pyrazole compounds.   
To verify this hit, plasmids containing the known mutant DNA sequences were 
transformed back into yeast cells, and the cells were grown to saturation in cell culture 
containing histidine to promote ligand independent growth.  Dilution of the stock yeast culture 
and titration with the entire pyrzole library was used to reexamine the selectivity, even though 
only three pyrazole compounds showed selectivity. This was done to ensure that no false 
negative results were obtained from the inactive pyrazoles used in the screen. 
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Figure 4.11.  Titration of G521T (top) and G521V (bottom panel) with N-substituted β-naphthyl 
pyrazole 9b.  EC50 values are in parenthesis for each curve. 
 
Yeast growth was plotted using the OD 600 reading as a function of the pyrazole 
concentration on a log scale to determine the EC50 value of the ligand.  Out of the 11 ligands 
initially used in the screen, one pyrazole containing an N-substituted β-naphthyl ring, compound 
9b, was the only ligand found to provide good gene activation on both the G521V and the 
G521T estrogen receptor mutants. 
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The β-naphthyl pyrazole, 9b, and the G521V mutant was the best gene switch found in 
the first round of mutations.  The rematch case (red curve Figure 4.11), however, is nearly two 
orders of magnitude less potent than the natural estradiol-estrogen receptor pair (green curve 
Figure 4.11).  Although the new gene switch is less potent than the match case, the ligand 
mismatch is inactive at any concentrations used in the assay (Figure 11, blue curve), and the 
receptor mismatch was not active at the concentrations of estradiol normally found in cells 
(Figure 4.11, purple curve). 
Molecular modeling was useful in explaining some of these experimental results.  The 
poor response of the wild type estrogen receptor to the β-naphthyl pyrazole, 9b, can be attributed 
to the ligand design discussed in the modeling section.  Briefly, a tetra-substituted pyrazole 
containing an N-substituent bulkier than a phenol moiety should not fit in wild-type estrogen 
receptor ligand binding pocket and thereby creates a steric clash that greatly reduces potency 
(effective ligand mismatch). 
Estradiol also had diminished activity on both mutants G521T and G21V relative to the 
match case (purple and green curves Figure 4.11 respectively).  The G521V receptor mismatch is 
10-fold less active than G521T receptor mismatch, making G521V a more viable mutant as a 
gene switch.  G521T and G521V mutants were previously identified, along with a G521R 
mutant, as having significantly decreased activity to estradiol; these mutants also showed 
increased activity to synthetic ligands such as raloxifene.  Therefore, the yeast two-hybrid 
screening method that we have used here, independently identified the G521V and G521T 
estrogen receptor mutants as promising receptor mismatches for the pyrazole library as well.   
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Modeling using the x-ray structure of the estrogen receptor ligand binding domain can 
help explain the decreased activity of the G521 mutants to estradiol.  Space-filling models of the 
estrogen receptor binding pocket surrounding estradiol shows that G521 is in close proximity 
with carbons 15 and 16, looming above the edge of the D-ring of the steroidal core of estradiol 
(Figure 4.12). Using this structure, we modeled a valine residue at position 521 and minimized 
the complex.  It is evident that the larger residue clashes sterically with both the D-ring atoms 
and the angular methyl group of estradiol, which is consistent with the reduced potency of 
estradiol on G521V ER.  Modeling did not reveal an obvious explanation for why estradiol was 
10-times more active on G521T compared to G521V. 
 
Figure 4.12.  Space-fill model of G521 and G521V with 17-estradiol. 
 
Computer-aided docking studies were done to see how the β-naphthyl pyrazole 9b might 
be accommodated into the G521V mutant receptor. However, binding of the pyrazole into the 
mutant binding pocket could not be achieved without extreme distortion of the planar naphthyl 
ring when it was aligned with either phenol moiety as the estradiol A-ring mimic.  It is perhaps 
not surprising that a mutation that increases the size of a binding pocket residue, which would 
Gly 521 G521V
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make the pocket smaller, would make it difficult to accommodate a larger ligand, although—
apparently—this occurs experimentally! This suggests that there are alterations to the size and/or 
shape of the ligand binding pocket that take place upon binding of β-naphthyl pyrazole 9b to the 
G521V mutant receptor that cannot be accessed with simple molecular mechanics-based 
computational modeling.  More advanced docking and minimization methods that incorporate 
molecular dynamics components that allow for repositioning of major tertiary structural elements 
(e.g., helix backbones) will probably be required. 
Since Raloxifene is known to be a potent ligand for G521V and G521T, we modeled the 
non-steroidal anti-estrogen into the G521T mutant binding pocket (Figure 4.13).  We predicted 
that the pendant phenol could rotate to minimize the steric clash with the bulkier threonine side-
chain, while estradiol cannot twist due to the rigid steroidal core.  By extrapolation, the pyrazole 
may become accommodated within the smaller binding pocket of G521T ER, at least in part, by 
rotation of either the phenol or the naphthyl substituent to avoid contact with the threonine side-
chain. 
 
Figure 4.13.  Orientation of Raloxifene in the WT (left) and G521T mutant (right) receptor. 
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The first round of mutagenesis found a ligand-complex that is a viable gene switch, but 
we wanted to improve upon the EC50 of the rematch case while improving on the selectivity 
compared to both mismatch cases by introducing a second mutation at a site near the naphthyl 
moiety.  A second round of mutagenesis was attempted on the G521V and G521T receptors by 
site-saturation of positions H524 and L525, the latter revisiting the original target site.  These 
sites were chosen because they are in close spatial proximity to the naphthyl moiety of the N-
substituted pyrazole.  We also used the propyl and the adamantyl ligands (9d and 9i 
respectively), because they activated the G521V mutant with greater potency than the rest of the 
pyrazole library members (data not shown).  The second round of screening did not produce any 
double mutant receptors having better selectivity than the first round of mutants. 
Since the second round of mutagenesis did not produce a better mutant and the modeling 
studies did not provide a useful model, another round of mutations was not attempted.  Although 
it would be desirable to improve the potency of the rematch case by introducing more mutations, 
the first round mutation gave a rematch case that was still had an EC50 value of 46 nM.  While 
the wild type estrogen receptor-estradiol complex has an EC50 of 0.7 nM, the rematch is still a 
potent, and, more notably, the potency of the rematch is far greater than either of the two 
mismatches. 
Dihydroxy Benzil Modification 
 Dihydroxy benzyl (DHB) was the original ligand used in the yeast two-hybrid screening 
assay to identify estrogen receptor mutants to create a gene switch.  In the original report, five 
rounds of mutagenesis were required to find a mutated estrogen receptor that had significant 
selectivity for DHB over estradiol.  After the original report, two additional mutants were 
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identified that enhanced the selectivity of DHB over estradiol.  The fourth (4S) and seventh (7S) 
round mutants were introduced into a mouse model to examine the gene switch in a live animal. 
The original report showed DHB-4S mutant was an excellent gene switch.  
Unfortunately, initial studies on mice revealed that DHB, applied topically (the best route), did 
not readily penetrate through the skin of the mouse due in part to lack of solubility in the delivery 
vehicle (DMSO-water or oil).  DHB is a highly crystalline compound.  One approach to avoid 
solubility problems is to create a pro-drug.  To do this, the two phenols of DHB were protected 
using various acid chlorides to make a series of more lipophilic and less crystalling DHB esters 
pro-drug to circumvent the solubility problem (Scheme 4.6).  The DHB esters should increase 
the solubility of the pro-drug in the delivery vehicle and perhaps even facilitate both dermal 
transport and entry into cells.  At some point, cellular or extracellular esterases would cleave the 
ester to reveal DHB. 
 
 
Scheme 4.6.   Preparation of DHB as a pro-drug. 
 
 
 Another method that often improves the pharmacokinetics and potency of a drug is to 
introduce a halogen substituent onto the core of the drug. This can have varying effects: raising 
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lipophilicity, altering the pKA of ionizable groups, block sites of metabolic inactivation, etc.  To 
investigate this approach, DHB analogs incorporating various degrees of halogenations on the 
aryl rings were prepared.  DHB symmetrically substituted with either bromine or chlorine on 
each aryl ring was prepared using the benzoin condensation of the 3-halo anisaldehyde to give 
the benzoin intermediates 12a-b in low yields (Scheme 4.7).  Oxidation of the benzyl alcohol 
provided the methoxy-protected DHB compounds 13a-b.  3-Fluoro and 2-fluoro anisaldehydes, 
however, would not form significant quantities of the benzoin product under these standard 
conditions; so, an alternate route for their preparation was implemented and will be discussed 
later. 
Scheme 4.7.  Benzoin Condensation to prepare di-halogenated anisil. 
 
 
 For mono-halogenated DHB compounds, a more selective synthetic route was chosen 
over the benzoin condensation to avoid isomer formation and achieve better yields.  Triphenyl 
phosphine was alkylated with 4-(chloromethyl)anisole to form the ylide, 14, which was used in 
the Wittig reaction with various halogen-substituted anisaldehydes to form a mixture of the cis 
and trans-stilbenes 15a-d having only one halogen substituent.  Both stillbene isomers were 
oxidized using permanganate to form the desired anisil product, but an acyl-protected anisoin 
side-product could not be separated from the desired anisil product.  Hydrolysis of the anisoin 
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side-product using weak base and subsequent oxidation using the same ammonium 
nitrate/copper(II) reagent allowed for simple purification of the protected anisil products 13c-f  
(Scheme 4.8). 
Scheme 4.8.  Preparation of mono-halogenated anisil. 
 
 
 
 Preparation of the symmetrically substituted difluoro anisil analogs was accomplished 
with the McMurray coupling reaction, because the benzoin condensation did not give any of the 
desired products mentioned earlier.  The McMurray coupling was chosen over the Wittig 
reaction to prepare 15i-j, because the stillbene intermediate could be prepared in one step, 
avoiding the preparation of the ylide over multiple steps starting from the fluorinated aldehyde 
(Scheme 4.9).  Once the stillbene was prepared, the same permanganate oxidation, hydrolysis, 
and oxidation sequence used in Scheme 4.7 gave the protected fluoro anisil products 13i-j. 
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Scheme 4.9.  Synthesis of difluoro anisil. 
 
 
Deprotection of the phenol on the halogenated anisil compounds, 16a-j, all used molten 
pyridine hydrogen chloride to cleanly remove both methyl groups without the formation of side 
products (Scheme 4.10). 
 
 
 
Scheme 4.10.  Deprotection of Halogenated DHB Ligands. 
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Titration of 7S and 4S Mutants using Halogenated DHB Ligands 
 The fourth round estrogen receptor mutant (4S) was determined the most selective mutant 
in the five rounds of mutagenesis in the original report, while the seventh round mutant 7S 
(prepared after three more rounds of mutagenesis following the original report) had a higher 
affinity and better selectivity for DHB over estradiol.21 The 7S and 4S mutated estrogen 
receptors engineered using DHB were titrated with the library of halogenated DHB analogs 16a-
h.  The titration curves of both mutants with DHB match the previous data within experimental 
error (Figure 4.14 top panels) and the individual EC50 values of 16a-h with both mutant receptors 
are listed in Table 4.1. 
All of the halogenated DHB analog EC50 values are within 10-fold activity relative to 
DHB for both mutants (rematch cases, red curves Figure 4.14) while some halogenated DHB 
analogs showed improved activity on the mutated receptors and others had diminished activity.  
Also, most halogenated DHB analogs displayed much lower activity on the wild-type estrogen 
receptor (ligand mistmatch, blue curves Figure 4.14) creating a better ligand mismatch with the 
exception two DHB analogs fluorinated alpha to the carbonyl (16h and 16f).  
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Figure 4.14.  Titration of the 7S (left panels) and 4S (right panels) with DHB (top panels)  
and 16a-h (bottom panels). 
 
  7S 4S WT 
Ligand Description EC50 (nM) EC50 (nM)  EC50 (nM)  
Estradiol Estradiol >104 >103 0.7 
DHB DHB 2.2 15.3 992 
16d Monochloro 0.9 6.5 >103 
16b Dichloro 1.2 5.1 >103 
16g Difluoro ( to OH) 1.2 14.0 >103 
16e Monofluoro ( to OH) 1.4 8.9 >103 
16h Difluoro  ( to C=O) 2.2 30.6 145 
16f Monofluoro ( to C=O) 4.0 15.3 454 
16c Monobromo 4.1 15.0 >104 
16a Dibromo 6.2 28.1 >104 
 
Table 4.1. EC50 values of 16a-h with 7S, 4S, and wild-type estrogen 
receptor. 
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Modeling was used to understand the nature of increased DHB activity and decreased 
estradiol activity of the 7S mutant receptor.  The model is based on the 1ERE X-ray crystal 
structure of ER bound to estradiol.9  All mutations were introduced at once, and the entire 
ligand-receptor complex was minimized.  Four of the mutated residues are near the ligand 
binding pocket of the estrogen receptor, while three mutants are much further away from the 
ligand (Figure 4.15, left panel).   
The mutations close to the ligand in the binding pocket occupy more space compared to 
the wild-type receptor appear to constrict the volume the ligand binding pocket.  The steric 
clashes of the smaller binding pocket with estradiol likely significantly reduce the binding 
affinity.  The effect of the mutations further away from the ligand on EC50 values is not obvious 
from the model.  The model also does not explain the increased activity of the 7S mutant to 
DHB.  Since seven mutations were required to engineer the estrogen receptor, it is possible that 
the overall tertiary structure was changed, and modeling would not likely find that conformation.  
The only way to identify the roles of all the mutants is to obtain an X-ray crystal structure of the 
mutated receptor bound to DHB. 
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Figure 4.15.  Location of 7S mutants (left).  (Right) Modeling of the WT estrogen receptor 
binding pocket surface (green) and the 7s mutant (yellow). 
 
DHB analog was 16b having one chlorine substitution created an ideal orthogonal ligand-
receptor pair as potent as the wild-type estradiol-estrogen receptor pair.  DHB analog 16b only 
activated the estrogen receptor at concentrations greater than 1 mM (Figure 4.16).  
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Figure 4.16.  Comparison of EC50 values of DHB (left) versus 16d (right). 
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Conclusions 
The assay developed in the Zhao laboratory is a powerful tool to generate a large number 
of mutated receptors and quickly screen for receptors activated by modified ligands where 
rational design was not a necessity.    Rational design was used to create an orthogonal ligand-
receptor pair in the pyrazole series of ligands only needing one mutation.  Also, synthetic 
chemistry can provide a larger variety of potential ligands for reengineering.   A simple series of 
ligands containing conservative halogen substitutions on the DHB core provided a ligand that 
was more potent on the 7S mutant and less potent on the estrogen receptor. 
 
Experimental 
 
All reagents were obtained from Sigma-Aldrich Chemical Company (Milwaukee, WI) 
and used without further purification unless otherwise noted.  Anhydrous solvents were obtained 
from a Solvent Dispensing System fabricated by J. C. Meyer based on a published design.22 
 NMR spectra were obtained in the Varian Oxford Instrument Center for Excellence in 
NMR Laboratory.  Funding for the instrumentation was provided in party by the W. M. Keck 
Foundation, the National Institutes of Health (Grant PHS 1 S10 RR104444-01) and the National 
Science Foundation (Grant NSF CHE 96-10502).  1H-NMR spectra were recorded on 400 or 500 
MHz spectrometers, and 13C-NMR were acquired at either 100 or 125 MHz using CDCl3, 
DMSO-d6, THF-d6 or acetone-d6 as the solvent.  Chemical shifts were reported as parts per 
million relative to the solvent. 
 Low and high resolution mass spectra were obtained in the Mass Spectrometry 
Laboratory, School of Chemical Sciences, University of Illinois.  Electron ionization (EI) data 
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were collected using a Micromass 70-VSE mass spectrometer under electron impact conditions 
at 70 eV and purchased in part with a grant from the Division of Research Resources, National 
Institutes of Health (RR 04648), and electrospray ionization (ESI) data were collected from a 
Micromass Q-Tof Ultima spectrometer. 
 Melting points were obtained on a Thomas-Hoover Unitemp capillary apparatus and 
remain uncorrected. 
 
1-(4-Methoxy-phenyl)-pentan-1-one (1):  A solution of AlCl3 (7.9 g, 59.0 mmol) and 
methylene chloride (15 mL) were allowed to stir at 0 ºC for 10 min, after which valeryl chloride 
(7.0 g, 58.1 mmol) was added drop wise over 15 min.  The reaction mixture stirred for an 
additional 15 min, and a solution of anisole (6.1 g, 56.1 mmol) in methylene chloride (30 mL) 
was added over 20 min.  The reaction was warmed to room temperature and stirred for 3 h.  The 
reaction was quenched by pouring over crushed ice.  The product was extracted with methylene 
chloride, washed with water then brine, and dried over Na2SO4.  Solvent was removed under 
reduced pressure, and the product distilled at 0.05 mm Hg at 125 ºC to yield the aryl ketone 1 as 
clear oil (7.6 g; 77%).  1H-NMR (CDCl3, 400 MHz)  0.94 (t, J = 7.4 Hz, 3H), 1.40 (m, J = 7.5 
Hz, 2H), 1.69 (m, 2H), 2.90 (t, J = 7.5 Hz, 2H), 6.93 (d, J = 6.7 Hz, 2H); 13C-NMR (CDCl3, 100 
MHz) 14.2, 22.7, 26.9, 38.2, 55.6, 113.8, 130.3, 130.5, 163.4, 199.5.  HRMS (EI, 70 eV):  
calcd for C12H16O2 (M)+·:  192.1150; found:  192.1148. 
 
4-Methoxy-benzoic acid 4-nitro-phenyl ester (2):  A solution of p-nitro-phenol (13.9g, 100 
mmol), triethyl amine (14.0 mL, 100 mmol), and anhydrous THF (100 mL) was cooled to 0 ºC 
under N2.  A solution of p-anisoyl-chloride (8.5 g, 50 mmol) in THF (10 mL) was syringed in 
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over 15 min and stirred for 1 h.  The yellow precipitate was collected by filtration and 
recrystallized in methylene chloride to produce the white needle-like crystals of the ester 2 (11.2 
g, 50%): m.p. 164-165 °C; 1H-NMR (CDCl3, 400 MHz)  3.91 (s, 3H), 7.00 (AA’ of XX’, J = 
9.0 Hz, J = 3.2 Hz, 2H), 7.41 (AA’ of AA’XX’, J = 9.3Hz, J = 3.0 Hz, 2H), 8.16 (XX’ of 
AA’XX’, J = 9.0 Hz, J = 2.9 Hz, 2H), 8.32 (XX’ of AA’XX’, J = 9.3 Hz, J = 3.1 Hz, 2H); 13C-
NMR (CDCl3, 100 MHz)  55.8, 114.2, 122.9, 125.4, 127.7, 132.7, 156.1, 164.1, 164.6.   HRMS 
(EI, 70 eV):  calcd for C14H11NO5 (M)+·:  273.0637; found:  273.0632. 
 
1,3-Bis-(4-methoxy-phenyl)-2-propyl-propane-1,3-dione (3):  Ketone 3 (4.0 g, 16.1 mmol) 
and activated ester 2 (3.1 g, 14.6 mmol) were dissolved in THF (10 mL) and stirred at 0 ºC under 
N2.  A LHMDS (7.58 g; 45.3 mmol) solution in THF was syringed into the reaction over 20 min, 
which was then was allowed to slowly warm to room temperature and continued to stir for 3 h.  
The reaction was quenched by addition of ice water (50 mL), extracted with diethyl ether, then 
washed with brine, and dried over anhydrous Na2SO4.  Solvent was removed under reduced 
pressure, and the crude material was purified by flash column chromatography (7:3 
hexanes:EtOAc) to yield brown viscous oil 3 (3.71 g, 63%).  1H-NMR (CDCl3, 400 MHz) 0.95 
(t, J=7.3 Hz, 3H), 1.36-1.47 (m, 2H), 2.05-2.11 (m, 2H), 3.83 (s, 6H), 5.05 (t, J=6.7 Hz, 1H), 
7.96 (AA’ of AA’XX’, J =  9.0 Hz, J = 2.9 Hz, 2H), 6.90 (XX’ of AA’XX’, J = 9.0 Hz, J = 3.0 
Hz, 2H); 13C-NMR (CDCl3, 100 MHz) 14.3, 21.7, 31.9, 55.6, 57.4, 114.1, 129.4, 131.1, 163.8, 
195.0.  HRMS (EI, 70 eV):  calcd for C20H22O4 (M)+·:  326.1518; found:  326.1512. 
 
N-Benzhydrylidene-N'-naphthalen-1-yl-hydrazine (4a):  Pd(OAc)2 (11.2 mg, 0.05 mmol), 
dppf (41.6 mg, 0.075 mmol), benzophenone hydrazone (1.18 g, 6.0 mmol) and sodium t-
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butoxide (721 mg, 7.5 mmol) were placed in a dry flask then purged with dry Ar for 10 min.  1-
bromonaphthalene (1.04 g, 5.0 mmol) was dissolved in anhydrous toluene (4 mL), and the 
solution was cannulated into the reaction over 10 minutes, then heated to 90 °C for 11 h.  The 
reaction was allowed to cool slowly to r.t., ethyl acetate (5 ml) was added, the mixture was 
filtered under vacuum, and the remaining residue was washed ethyl acetate.  The solvent was 
removed from the filtrate under reduced pressure.  Purification by flash column chromatography 
(19:1 hexanes:EtOAc) N-aryl benzophenone hydrazone 4a as an orange wax (1.18g, 72%).  1H-
NMR (CDCl3, 500 MHz)  7.24-7.51 (m, 9H), 7.58-7.81 (m, 8H), 8.21 (s, 1H); 13C-NMR 
(CDCl3, 120 MHz) 108.2, 109.9, 119.1, 120.7, 122.0, 125.2, 128.8, 126.9, 128.5, 128.9, 129.2, 
129.7, 130.0, 133.0, 134.4, 138.4, 139.4, 146.5. HRMS (EI, 70 eV):  calcd for C23H18N2 (M)+·:  
322.14670; found:  322.14623. 
 
N-Benzhydrylidene-N'-naphthalen-2-yl-hydrazine (4b):  Pd(OAc)2 (11.2 mg, 0.05 mmol), 
dppf (41.6 mg, 0.075 mmol), benzophenone hydrazone (1.18 g, 6.0 mmol) and sodium t-
butoxide (721 mg, 7.5 mmol) were placed in a dry flask then purged with dry Ar for 10 min 
while the contents stirred in the vial.  1-Bromonaphthalene (1.04 g, 5.0 mmol) was dissolved in 
anhydrous toluene (4 mL), and the solution was cannulated into the reaction over 10 minutes 
then heated to 90 °C for 11 h.  The reaction was allowed to cool slowly to r.t., ethyl acetate (5 
ml) was added, the mixture was filtered under vacuum, and the remaining residue was washed 
ethyl acetate.  The solvent was removed from the filtrate under reduced pressure.  Purification by 
flash column chromatography (19:1 hexanes:EtOAc) gave N-aryl benzophenone hydrazone 4b 
as an brown waxy residue (865 mg, 54%).  1H-NMR (CDCl3, 400 MHz) 7.26-7.44 (m, 8H), 
7.48 (d, J = 2.2 Hz, 1H), 7.55-7.75 (m, 9H); 13C-NMR (CDCl3, 100 MHz)  107.2, 115.8, 123.1, 
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126.6, 126.7, 126.8, 127.9, 128.3, 128.4, 129.1, 129.3, 129.4, 129.5, 129.9, 132.9, 134.9, 138.5, 
142.4, 144.9.  HRMS (EI, 70 eV):  calcd for C23H18N2 (M)+·:  322.1467; found:  322.14637. 
 
3,5-Bis(4-methoxyphenyl)-1-(naphthalen-1-yl)-4-propyl-1H-pyrazole (5a): Diketone 3 (124 
mg, 0.38 mmol) and aryl-hydrazone 4a (150 mg, 0.46 mmol) were dissolved in n-propanol (2 
mL), and conc. HCl (0.02 mL, 0.6 mmol) was added dropwise.  The reaction was heated to 
reflux for 12 h and then quenched by addition of sat’d NaHCO3 (3.0 mL).  Water was added, and 
the product extracted with ethyl acetate and washed with brine, and dried over Na2SO4.  The 
solvent was removed under reduced pressure, and the crude material purified flash column 
chromatography (17:1 hexanes:EtOAc) gave the protected pyrazole 5a (143 mg, 77%) as a 
viscous brown oil.  1H-NMR (CDCl3, 500 MHz) 0.85 (t, J = 7.3 Hz, 3H), 1.52 (m, J = 7.6 Hz, 
2H), 2.69 (t, J = 8.0 Hz, 2H), 3.71 (s, 3H), 3.86 (s, 3H), 6.69 (AA’ of AA’XX’, J = 9.0 Hz, J = 
3.0 Hz, 2H), 7.06 (AA’ of AA’XX’, J = 9.0 Hz, J = 2.7 Hz, 2H), 7.30 (dd, J = 7.3 Hz, J = 1.2 Hz, 
1H), 7.35 (t, J = 7.8 Hz, 1H), 7.46 – 7.49 (m, 2H), 7.67 – 7.69 (m, 1H), 7.75 (XX’ of AA’XX’, J 
=  9.0 Hz, J = 2.8 Hz, 2H), 7.80 (d, J = 8.1 Hz, 1H), 7.83 – 7.85 (m, 1H); 13C-NMR (CDCl3, 120 
MHz)  14.4, 24.3, 26.5, 29.9, 55.3, 55.5, 113.8, 114.1, 123.1, 123.9, 125.1, 126.1, 126.6, 127.2, 
127.3, 128.1, 128.9, 129.4, 131.1, 131.3, 134.4, 137.0, 150.9, 159.4, 159.4.  HRMS (EI, 70 eV):  
calcd for C30H28N2O2 (M)+·:  448.2151; found:  448.2152. 
 
3,5-Bis-(4-methoxy-phenyl)-1-naphthalen-2-yl-4-propyl-1H-pyrazole (5b):  Diketone 3 (124 
mg, 0.38 mmol) and aryl-hydrazone 4a (150 mg, 0.46 mmol) were dissolved in n-propanol (2 
mL), and conc. HCl (0.02 mL, 0.6 mmol) was added dropwise.  The reaction was heated to 
reflux for 12 h and quenched by addition of sat’d NaHCO3 (3.0 mL).  Water was added, and the 
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product was extracted with ethyl acetate and washed with brine, and dried over Na2SO4.  The 
solvent was removed under reduced pressure, and the crude material purified flash column 
chromatography (17:1 hexanes:EtOAc) gave the protected pyrazole 5b as a dark brown oil (140 
mg, 82%).  1H-NMR (CDCl3, 500 MHz)  0.85 (t, J = 7.3 Hz, 3H), 1.53 (m, J = 7.6 Hz, 2H), 
2.70 (t, J = 7.93 Hz, 2H), 3.70 (s, 3H), 3.86 (s, 3H), 6.70 (AA’ of AA’XX’, J = 9.3 Hz, J = 2.4 
Hz, 2H), 7.00 (AA’ of AA’XX’, J = 9.4 Hz, J = 2.5 Hz, 2H), 7.07 (XX’ of AA’XX’, J = 9.2 Hz, 
J = 2.5 Hz, 2H), 7.30 (dd, J = 7.2 Hz, J = 1.2 Hz, 1H), 7.36 (tx, J = 7.7 Hz, 1H), 7.48 (m, 1H), 
7.69 (m, 2H), 7.76 (XX’ of AA’XX’, J = 9.4 Hz, J = 2.5 Hz, 2H), 7.80 (d, J = 8.2 Hz, 1H), 7.84 
(m, 1H); 13C-NMR (CDCl3, 125 MHz)  14.4, 24.2, 26.4, 55.2, 55.4, 113.8, 114.0, 117.6, 123.1, 
123.9, 125.0, 126.0, 126.5, 127.2, 127.2, 128.1, 128.9, 129.3, 131.0, 131.2, 134.4, 137.0, 144.0, 
150.8, 159.3, 159.3.  HRMS (EI, 70 eV):  calcd for C30H28N2O2 (M)+·:  448.2151; found:  
448.2153. 
 
3,5-Bis(4-methoxyphenyl)-4-propyl-1H-pyrazole (5c):  Diketone 3 (1.63g, 5.0 mmol) was 
dissolved in ethanol and hydrazine hydrate (320 mg, 10 mmol) was syringed into the reaction.  
One drop of conc HCl was added, and the reaction heated to reflux for 12 h.  The reaction was 
cooled, and solvents were removed under reduced pressure.  The crude product was isolated by 
recrystallization from a saturated EtOH and water solution.  The product was collected by 
filtration and kept under reduced pressure until all solvent was removed.  The product 7 was 
isolated a white crystalline solid (1.32g, 82%). 1H-NMR (CDCl3, 500 MHz) 0.81 (t, J = 7.4 Hz, 
3H), 1.44 (t, J = 7.5 Hz, 2H), 2.64 (t, J = 7.7 Hz, 2H), 3.85 (s, 6H), 6.93 (AA’ of AA’XX’, J = 
9.7 Hz, J = 2.8 Hz, 4H), 7.46 (br. s, 4H), 10.92 (br. s, 1H).  13C-NMR (CDCl3, 125 MHz) 13.8, 
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23.7, 25.5, 55.0, 113.7, 115.0, 128.8, 153.6, 159.0, 184.2.  HRMS (ESI) m/z calcd for 
C20H23N2O2 323.1760, found 323.1757. 
 
General Procedure for Pyrazole Alkylation:  10 mL anhydrous DMF was added to a mixture 
of pyrazole 5c (0.3 mmol, 1.0 eq) and NaH (60 % dispersion in mineral oil, 0.36 mmol, 1.2 eq) 
and was stirred under N2 for 15 min or until H2 evolution stopped.  The alkyl halide (0.6 mmol, 
2.0 eq) was syringed into the reaction mixture and stirred at r.t. for 4-12 h, depending when TLC 
analysis indicated that all of the starting material 6 had been consumed.  The reaction was diluted 
with 25 mL EtOAc, and washed with water, then brine, and dried over Na2SO4.  The solvent was 
removed under reduced pressure, and the crude product was isolated by flash column 
chromatography (2:1 hexanes:EtOAc) unless otherwise noted. 
 
 
1-Isopropyl-3,5-bis(4-methoxyphenyl)-4-propyl-1H-pyrazole (5d):  Pyrazole 5d was prepared 
using the general procedure for pyrazole alkylation and was isolated as a white solid (75 mg, 
69%).  1H-NMR (CDCl3, 500 MHz)  0.75 (t, J = 7.4 Hz, 3H), 1.36 (m, J = 7.5 Hz, 2H), 1.45 (d, 
J = 6.9 Hz, 6H), 2.44 (t, J = 7.9 Hz, 2H), 3.85 (s, 3H), 3.88 (s, 3H), 4.31 (q, J = 6.6 Hz, 2H), 6.97 
(AA’ of AA’XX’, J = 8.8 Hz, J = 1.9 Hz, 2H), 7.02 (AA’ of AA’XX’, J = 8.8 Hz, J = 1.9 Hz, 
2H), 7.26 (XX’ of AA’XX’, J = 8.6 Hz, J = 2.8 Hz, 2H), 7.65 (XX’ of AA’XX’, H = 8.8 Hz, J = 
2.8 Hz, 2H).  13C-NMR (CDCl3, 125 MHz)  14.1, 22.8, 24.1, 26.0, 49.8, 55.2, 55.2, 113.7, 
114.0, 116.5, 123.5, 127.8, 128.9, 131.3, 141.0, 148.4, 158.7, 159.2.  HRMS (ESI) m/z calcd for 
C23H29N2O2 365.2229, found 365.2226. 
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3,5-Bis(4-methoxyphenyl)-1,4-dipropyl-1H-pyrazole (5e):  Pyrazole 5e was prepared using the 
general procedure for pyrazole alkylation and was isolated as a clear wax-like substance (86 mg, 
75%).  1H-NMR (CDCl3, 500 MHz)  0.73 (t, J = 7.3 Hz, 3H), 0.80 (t, J = 7.4 Hz, 3H), 1.34 (m, 
J = 7.7 Hz, 2H), 1.77 (t, J = 7.5 Hz, 2H), 2.45 (t, J = 7.7 Hz, 2H), 3.84 (s, 3H), 3.87 (s, 3H), 3.92 
(t, J = 7.3 Hz, 2H), 6.96 (AA’ of AA’XX’, J = 8.8 Hz, J = 2.1 Hz, 2H), 7.01 (AA’ of AA’XX’, J 
= 8.8 Hz, J = 2.1 Hz, 2H), 7.25 (XX’ of AA’XX’, J = 8.8 Hz, J = 2.1 Hz, 2H), 7.62 (XX’ of 
AA’XX’, J = 8.8 Hz, J = 2.1 Hz, 2H).  13C-NMR (CDCl3, 125 MHz)  11.1, 14.0, 23.9, 24.0, 
26.0, 50.9, 55.2, 55.2, 113.7, 113.9, 116.7, 123.2, 127.4, 128.8, 131.2, 141.8, 148.7, 158.7, 159.5.  
HRMS (ESI) m/z calcd for C23H29N2O2 365.2229, found 365.2230. 
 
3,5-Bis(4-methoxyphenyl)-1-pentyl-4-propyl-1H-pyrazole (5f):  Pyrazole 5f was prepared 
using the general procedure for pyrazole alkylation and was isolated as a yellow oil (88 mg, 
75%).  1H-NMR (CDCl3, 500 MHz)  0.73 (t, J = 7.3 Hz, 3H), 0.82 (t, J = 7.1 Hz, 3H), 1.10-1.28 
(m, 4H), 1.34 (t, J = 7.7 Hz, 2H), 1.76 (t, J = 7.7 Hz, 2H), 2.45 (t, J = 7.9 Hz, 2H), 3.84 (s, 3H), 
3.86 (s, 3H), 3.95 (t, J = 7.5 Hz, 2H), 6.96 (AA’ of AA’XX’, J = 9.0 Hz, J = 2.1 Hz, 2H), 7.01 
(AA’ of AA’XX’, J = 8.8 Hz, J = 2.1 Hz, 2H), 7.26 (XX’ of AA’XX’, J = 8.8 Hz, J = 2.1 Hz, 
2H), 7.62 (XX’ of AA’XX’, J = 9.0 Hz, J = 2.0 Hz, 2H).  13C-NMR (CDCl3, 125 MHz)  13.9, 
14.0, 22.1, 24.0, 26.0, 28.7, 30.3, 49.3, 55.2, 113.7, 113.9, 116.7, 123.3, 127.4, 128.8, 131.2, 
141.7, 148.6, 158.7, 159.5.  HRMS (ESI) m/z calcd for C25H33N2O2 393.2542, found 393.2533. 
 
1-Hexyl-3,5-bis(4-methoxyphenyl)-4-propyl-1H-pyrazole (5g):  Pyrazole 5g was prepared 
using the general procedure for pyrazole alkylation and was isolated as a tan oil (94 mg, 77%).  
1H-NMR (CDCl3, 500 MHz)  0.73 (t, 7.4 Hz, 3H), 0.82 (t, J = 7.1 Hz, 3H), 1.1-1.3 (m, 6H), 
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1.34 (m, J = 7.5 Hz, 2H), 1.75 (t, J = 7.7 Hz, 2H), 2.45 (t, J = 7.7 Hz, 2H), 3.84 (s, 3H), 3.87 (s, 
3H), 3.95 (t, J = 7.5 Hz, 3H), 6.96 (AA’ of AA’XX’, J = 8.8 Hz, J = 2.1 Hz, 2H), 7.01 (AA’ of 
AA’XX’, J = 8.8 Hz, J = 2.1 Hz, 2H), 7.26 (XX’ of AA’XX’, J = 8.8 Hz, J = 2.8 Hz, 2H), 7.62 
(XX’ of AA’XX’, J = 8.8 Hz, J = 2.8 Hz, 2H).  13C-NMR (CDCl3, 125 MHz)  13.9, 14.0, 22.4, 
24.0, 26.0, 26.2, 30.1, 31.2, 49.3, 55.2, 55.2, 113.7, 113.9, 116.7, 123.3, 127.4, 128.8, 131.2, 
141.7, 148.6, 158.7, 159.5.  HRMS (ESI) m/z calcd for C26H35N2O2 407.2699, found 407.2692. 
 
3,5-Bis(4-methoxyphenyl)-1-nonyl-4-propyl-1H-pyrazole (5h):  Pyrazole 5h was prepared 
using the general procedure for pyrazole alkylation and was isolated as a yellow oil (94 mg, 
75%).  1H-NMR (CDCl3, 500 MHz)  0.73 (t, J = 7.4 Hz, 3H), 0.87 (t, J = 7.2 Hz, 3H), 1.12-1.23 
(m, 11H), 1.23-1.30 (m, 3H), 1.34 (m, J = 7.5 Hz, 2H), 1.75 (t, J = 6.9 Hz, 2H), 2.45 (t, J = 7.2 
Hz, 2H), 3.84 (s, 3H), 3.87 (s, 3H), 3.95 (t, J = 7.3 Hz, 2H), 6.96 (AA’ of AA’XX’, J = 8.8 Hz, J 
= 3.0 Hz, 2H), 7.01 (AA’ of AA’XX’, J = 8.8 Hz, J = 2.8 Hz, 2H), 7.25 (XX’ of AA’XX’, J = 
8.8 Hz, J = 2.8 Hz, 2H), 7.62 (XX’ of AA’XX’, J = 8.8 Hz, J = 3.0 Hz, 2H).  13C-NMR (CDCl3, 
125 MHz)  14.0, 14.0, 22.6, 24.0, 26.0, 26.5, 29.1, 29.3, 30.1, 31.8, 49.3, 55.1, 55.2, 113.7, 
113.9, 116.7, 123.3, 127.4, 128.8, 131.2, 141.7, 148.6, 158.7, 159.5.  HRMS (ESI) m/z calcd for 
C29H41N2O2 449.3168, found 449.3163. 
 
3,5-Bis(4-methoxyphenyl)-4-propyl-1-tetradecyl-1H-pyrazole (5i):  Pyrazole 5i was prepared 
using the general procedure for pyrazole alkylation except (9:1 hexanes:EtOAc) was used for 
flash column chromatography purification. Product was isolated as a clear oil (122 mg, 78%).  
1H-NMR (CDCl3, 500 MHz) 0.73 (t, J = 7.4 Hz, 3H), 0.88 (t, J = 6.9 Hz, 3H), 1.30 (m, J = 7.5 
Hz, 25H), 2.44 (t, J = 7.9 Hz, 2H), 3.85 (s, 3H), 3.88 (s, 3H), 3.94 (t, J = 7.5 Hz, 2H), 6.95 (AA’ 
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of AA’XX’, J = 9.4 Hz, J = 2.8 Hz, 2H), 7.00 (AA’ of AA’XX’, J = 9.4 Hz, J = 2.8 Hz, 2H), 7.25 
(XX’ of AA’XX’, J = 8.4 Hz, J = 2.1 Hz, 2H), 7.61 (XX’ of AA’XX’, J = 9.4 Hz, J = 2.8 Hz, 
2H).  13C-NMR (CDCl3, 125 MHz) 14.1, 14.1, 24.0, 26.0, 26.6, 29.1, 29.4, 29.5, 29.6, 29.6, 
29.7, 30.6, 31.9, 49.4, 55.2, 55.3, 113.8, 114.0, 116.8, 128.9, 131.3, 148.7, 158.8, 159.6.  HRMS 
(ESI) m/z calcd for C34H51N2O2 519.3951, found 359.3954. 
 
1-(Adamantan-2-yl)-3,5-bis(4-methoxyphenyl)-4-propyl-1H-pyrazole (5j):  Diketone 3 (98 
mg, 0.3 mmol) and adamantlyhydrazine 8 (75 mg, 0.45 mmol) were dissolved in n-propanol (3 
mL), and conc. HCl (0.02 mL, 0.6 mmol) was added dropwise.  The reaction was heated to 
reflux for 18 h and then quenched by addition of sat’d NaHCO3 (3.0 mL).  Water was added, and 
the product extracted with ethyl acetate and washed with brine, and dried over Na2SO4.  The 
solvent was removed under reduced pressure, and the crude material purified flash column 
chromatography (2:1 hexanes:EtOAc) gave the protected pyrazole 5i (62 mg, 45%) as a viscous 
yellow oil.  1H-NMR (CDCl3, 500 MHz)  0.76 (t, J = 7.4 Hz, 3H), 1.38 (m,  J = 15.4 Hz, J = 7.7 
Hz, 2H), 1.56 (d, J = 12.4 Hz, 2H), 1.62 (d, J = 11.8 Hz, 2H), 1.74 (br. s, 2H), 1.81 (d, J = 12.4 
Hz, 3H), 1.96 (br. s, 1H), 2.09 (br. s, 1H) 2.44 (t, J = 7.7 Hz, 2H), 2.85 (d, J = 11.4 Hz, 2H), 3.86 
(s, 3H), 3.88 (s, 3H), 4.25 (s, 1H), 6.96 (AA’ of AA’XX’, J = 8.8 Hz, J = 2.1 Hz, 2H), 6.99 (AA’ 
of AA’XX’, J = 9.4 Hz, J = 1.9 Hz, 2H), 7.21 (XX’ of AA’XX’, J = 9.4 HZ, J = 2.6 Hz, 2H), 
7.71 (XX’ of AA’XX’, J = 9.7 Hz, J = 1.9 Hz, 2H).  13C-NMR (CDCl3, 125 MHz) 14.2, 24.1, 
26.2, 27.5, 27.7, 31.7, 33.6, 38.1, 38.6, 39.3, 55.2, 62.1, 113.7, 113.9, 116.5, 124.2, 128.2, 128.5, 
131.2, 141.9, 146.8, 158.5, 159.4, 184.5.  HRMS (ESI) m/z calcd for C30H37N2O2 457.2855, 
found 457.2853. 
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tert-Butyl 2-(adamantan-2-ylidene)hydrazinecarboxylate (7):  Adamantanone (601 mg, 4.0 
mmol) was dissolved in hexanes (5 mL) and t-butyl carbazate (529 mg, 4.0 mmol) was added to 
the reaction mixture.  The reaction was heated to reflux for 1 h, and the product crystallized from 
the solution upon cooling.  Isolation by filtration then recrystalization from hexanes and drying 
under reduced pressure afforded 7 as a white solid (931 mg, 94%).  1H-NMR (CDCl3, 500 MHz) 
 0.86 (t, J = 6.8 Hz, 2H), 1.28 (m, J = 3.4 Hz, 4H), 1.43-1.50 (br. s, 11H), 2.26 (td, J = 7.6 Hz, 
5.7 Hz, 2H), 7.13 (s, 1H), 7.76 (s, 1H).  13C-NMR (CDCl3, 100 MHz)  28.1, 28.3, 32.3, 36.8, 
37.7, 150.4, 159.9.  HRMS (EI, 70 eV):  calcd for C30H28N2O2 (M)+·:  264.1838, found:  
264.1841. 
 
Adamantan-2-ylhydrazine (8):  Adamantyl-hydrazone 7 (931 mg, 3.5 mmol) was dissolved in 
3.5 mL dry THF.  1.0 M BH3.THF complex in THF (1.0 ml, 3.5 mmol) was syringed into the 
reaction under a N2 atmosphere and stirred at r.t. for 30 min. A 6M HCl solution (1.75 mL) was 
slowly syringed into the reaction while stirring until CO and isobutylene evolution ceased.  The 
reaction was heated to reflux for 20 min.  The reaction cooled to r.t. and 5mL of 4M NaOH was 
added then extracted twice with ethyl acetate, washed with brine, and dried over Na2SO4.  
Removal of the solvent under reduced pressure gave 8 as a white powder (506 mg, 87%) and 
further purification was not necessary.  The product was not soluble in common NMR solvents at 
r.t and spectral data have been published elsewhere.23, 24 
 
4,4'-(1-(Naphthalen-1-yl)-4-propyl-1H-pyrazole-3,5-diyl)diphenol (9a):  Methylene chloride 
(1.5 mL) was added to pyrazole 5a (27.3 mg, 0.06 mmol) and cooled to -78 ºC while under N2 
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atmosphere.  BF3.SMe2 (0.028 mL, 0.27 mmol) was syringed into the reaction over 5 min.  The 
reaction warmed slowly to 25°C for 12 h.  The reaction was quenched by adding sat’d NaHCO3 
(1.0 mL), and the mixture was extracted with ethyl acetate and washed with brine.  Solvent was 
removed under reduced pressure, and the crude solid was purified using flash column 
chromatography (7:3 hexanes:EtOAc) The deprotected pyrazole 9a (14 mg, 55%) was isolated as 
a yellow solid.  1H-NMR (acetone-d6, 500 MHz)  0.85 (t, J = 7.3 Hz, 3H), 1.53 (m, 7.6 Hz, 2H), 
2.70 (t, J = 7.93 Hz, 2H), , 6.58 (AA’ of AA’XX’, J = 9.3 Hz, J = 2.4 Hz, 2H), 7.00 (AA’ of 
AA’XX’, J = 9.4 Hz, J = 2.5 Hz, 2H), 7.07 (XX’ of AA’XX’, J = 9.2 Hz, J = 2.5 Hz, 2H), 7.30 
(ddx, J = 7.2 Hz, J = 1.2 Hz, 2H), 7.36 (t, J = 7.7 Hz, 1H), 7.48 (m, 1H), 7.69 (m, 2H), 7.76 (XX’ 
of AA’XX’, J = 9.4 Hz, J = 2.5 Hz, 2H), 7.80 (d, J = 8.2 Hz, 1H), 7.84 (m, 1H); 13C-NMR 
(CDCl3, 125 MHz)  14.4, 24.2, 26.4, 113.8, 114.0, 117.6, 123.1, 123.9, 125.0, 126.0, 126.5, 
127.2, 127.2, 128.1, 128.9, 129.3, 131.0, 131.2, 134.4, 137.0, 144.0, 150.8, 159.3, 159.3.  HRMS 
(EI, 70 eV):  calcd for C28H26N2O2 (M)+·:  420.5024; found:  420.5021. 
 
4,4'-(1-(Naphthalen-2-yl)-4-propyl-1H-pyrazole-3,5-diyl)diphenol (9b):  Methylene chloride 
(1.5 mL) was added to pyrazole 5b (30 mg, 0.08 mmol) and cooled to -78 ºC while under N2 
atmosphere.  BF3.SMe2 (0.035 mL, 0.34 mmol) was syringed into the reaction over 5 min.  The 
reaction warmed slowly to 25 °C for 12 h.  The reaction was quenched by adding sat’d NaHCO3 
(1.0 mL), and the mixture was extracted with ethyl acetate and washed with brine.  Solvent was 
removed under reduced pressure, and the crude solid was purified using flash column 
chromatography (7:3 hexanes:EtOAc) The deprotected pyrazole 9b (14 mg, 55%) was isolated 
as a yellow solid,  1H-NMR (acetone-d6; 400 MHz)  0.85 (t, J = 7.3 Hz, 3H), 1.52 (m, J = 7.6 
Hz, 2H), 2.69 (t, J = 8.0 Hz, 2H), 6.71 (AA’ of AA’XX’, J = 9.0 Hz, J = 3.0 Hz, 2H), 7.06 (AA’ 
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of AA’XX’, J = 9.0 Hz, J = 2.7 Hz, 2H), 7.30 (dd, J = 7.3 Hz, J = 1.2 Hz, 1H), 7.35 (t, J = 7.8 
Hz, 1H), 7.46 – 7.49 (m, 2H), 7.67 – 7.69 (m, 1H), 7.75 (XX’ of AA’XX’, J = 9.0 Hz, J = 2.8 
Hz, 2H), 7.80 (d, J = 8.1 Hz, 1H), 7.83 – 7.85 (m, 1H); 13C-NMR (CDCl3, 125 MHz)  14.4, 
24.3, 26.5, 29.9, 113.8, 114.1, 123.1, 123.9, 125.1, 126.1, 126.6, 127.2, 127.3, 128.1, 128.9, 
129.4, 131.1, 131.3, 134.4, 137.0, 150.9, 159.4, 159.4.  HRMS (EI, 70 eV):  calcd for 
C28H26N2O2 (M)+·:  420.5024; found:  420.5028. 
 
General Procedure for Demethylation using Pyridine Hydrochloride:  In a flame dried flask 
was placed methoxy protected ligand.  Approximately 100mg of pyridine hydrochloride was 
added in a dry nitrogen-filled glove bag for every 1 mg of protected ligand.  The reaction was 
sealed with a septum, placed on a nitrogen bubbler, and was heated to 200 °C for 2 h.  The 
reaction was allowed to cool to room temperature, and 20 mL of 1M HCl and 20 mL of ethyl 
acetate were added and the flask stirred until all components dissolved.  The organic layer was 
separated and the aqueous layer was washed with 3x20 mL ethyl acetate.  The organic layers 
were combined, washed with 2x20 mL brine, dried over Na2SO4, the solvent was removed under 
reduced pressure, and the product was isolated by flash chromatography. 
 
4,4'-(4-Propyl-1H-pyrazole-3,5-diyl)diphenol (9c):  Pyrazole 9c was prepared using the 
general procedure for demethylation using pyridine hydrochloride from 5c (120 mg, 0.37 mmol) 
and 9c was isolated as a white solid (98 mg, 90%) using flash column chromatography (1:1 
hexanes:EtOAc).  1H-NMR (acetone-d6; 500 MHz)  0.81 (t, J = 7.3 Hz, 3H), 1.47 (m, J = 7.5 
Hz, 2H), 2.69 (m, J = 7.8 Hz, 2H), 6.92 (AA’ of AA’XX’, J = 8.3 Hz, J = 2.0 Hz, 4H), 7.48 (XX’ 
of AA’XX’, J = 8.6 Hz, J = 2.0 Hz, 4H), 8.30-8.91 (br. s, 2H).  13C-NMR (acetone-d6; 125 MHz) 
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 14.8, 25.3, 27.0, 115.2, 116.7, 130.3, 158.4, 173.6.  HRMS (EI, 70 eV):  calcd for C18H18N2O2 
(M)+·:  294.1368; found:  294.1376. 
 
4,4'-(1-Isopropyl-4-propyl-1H-pyrazole-3,5-diyl)diphenol (9d):  Pyrazole 9d was prepared 
using the general procedure for demethylation using pyridine hydrochloride from 5d (63 mg, 
0.17 mmol) and 9c was isolated as a white solid (55 mg, 96%) using flash column 
chromatography (1:1 hexanes:EtOAc).  1H-NMR (acetone-d6; 500 MHz)  0.71 (t, J = 6.8 Hz, 
3H), 1.34 (m, J = 6.8 Hz, 2H), 1.38 (d, J = 6.6 Hz, 6H), 2.45 (t, J = 7.8 Hz, 2H), 4.30 (m, J = 6.6 
Hz, 1H), 6.89 (d, J = 8.3 Hz, 2H), 6.99 ( d, J = 8.1 Hz, 2H), 7.20 (d, J = 8.3 Hz, 2H), 7.57 (d, J = 
8.6 Hz, 2H), 8.36 (br. s, 1H), 8.71 (br. s, 1H).  13C-NMR (Acetone-d6, 125 MHz)  14.8, 23.5, 
25.2, 27.3, 50.8, 116.3, 116.9, 117.0, 129.9, 132.7, 142.6, 149.3, 157.8, 159.0.  HRMS (EI, 70 
eV):  calcd for C21H24N2O2 (M)+·:  336.1838; found:  338.1832. 
 
 
4,4'-(1-Propyl-4-propyl-1H-pyrazole-3,5-diyl)diphenol (9e):  Pyrazole 9e was prepared using 
the general procedure for demethylation using pyridine hydrochloride from 5e (75 mg, 0.20 
mmol) and 9d was isolated as a clear oil (54 mg, 77%) using flash column chromatography (1:1 
hexanes:EtOAc).   0.72 (t, J = 7.3 Hz, 3H), 0.76 (t, J = 7.5 Hz, 3H), 1.35 (m, 7.5 Hz, 2H), 1.72 
(m, J = 7.1 Hz, 2H), 2.47 (t, J = 7.8 Hz, 2H), 3.88 (t, J = 7.1 Hz, 2H), 6.88 (d, J = 8.3 Hz, 2H), 
6.98 (d, J = 8.3 Hz, 2H), 7.20 (d, J = 8.6 Hz, 2H), 7.54 (d, J = 8.6 Hz, 2H), 8.42 (br. s, 1H), 8.76 
(br. s, 1H).  13C-NMR (Acetone-d6, 125 MHz)  11.8, 14.6, 24.7, 25.0, 27.2, 51.6, 110.9, 116.3, 
116.8, 117.2, 123.2, 127.9, 129.9, 132.6, 143.4, 149.4, 157.8, 158.9, 173.5.  HRMS (EI, 70 eV):  
calcd for C21H24N2O2 (M)+·:  336.1838; found:  336.1846. 
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4,4'-(1-Pentyl-4-propyl-1H-pyrazole-3,5-diyl)diphenol (9f):  Pyrazole 9f was prepared using 
the general procedure for demethylation using pyridine hydrochloride from 5f (42 mg, 0.11 
mmol) and 9e was isolated as a clear oil (30 mg, 75%) using flash column chromatography (1:1 
hexanes:EtOAc).  1H-NMR (Acetone-d6, 500 MHz)  0.71 (t, J = 7.1 Hz, 3H), 0.83 (t, J = 6.8 
Hz, 3H), 1.19 (m, J = 5.1 Hz, 4H), 1.35 (m, J = 7.6 Hz, 2H), 1.72 (m, J = 7.1 Hz, 2H), 2.47 (t, J = 
7.6 Hz, 2H), 3.92 (t, J = 7.6 Hz, 2H), 6.88 (m, J = 8.3 Hz, 2H), 6.99 (m, J = 8.1 Hz, 2H), 7.20 (m, 
J = 8.3 Hz, 2H), 7.54 (m, J = 8.8 Hz, 2H), 8.41 (br. s, 1H), 8.74 (br. s, 1H).  13C-NMR (Acetone-
d6, 125 MHz)  14.8, 23.3, 25.2, 27.4, 31.2, 50.2, 116.4, 116.8, 130.0, 132.8, 141.5.  HRMS (EI, 
70 eV):  calcd for C23H28N2O2 (M)+·:  364.2151; found:  364.2160. 
 
4,4'-(1-Hexyl-4-propyl-1H-pyrazole-3,5-diyl)diphenol (9g):  Pyrazole 9g was prepared using 
the general procedure for demethylation using pyridine hydrochloride from 5g (60 mg, 0.15 
mmol) and 9e was isolated as a clear oil (45 mg, 75%) using flash column chromatography (1:1 
hexanes:EtOAc).  1H-NMR (Acetone-d6, 500 MHz)  0.72 (t, J = 7.3 Hz, 3H), 0.82 (t, J = 7.1 
Hz, 3H), 1.20 (m, J = 7.6 Hz, J = 3.7 Hz, 6H), 1.35 (m, J = 7.3 Hz, 2H), 1.71 (m, J = 7.8 Hz, 2H), 
3.93 (t, J = 7.1 Hz, 2H), 6.89 (AA’ of AA’XX’, J = 8.8 Hz, J = 2.2  Hz, 2H), 7.00 (AA’ of 
AA’XX’, J = 8.6 Hz, J = 2.0 Hz, 2H), 7.22 (XX’ of AA’XX’, J = 8.8 Hz, J = 2.2 Hz, 2H), 7.56 
(XX’ of AA’XX’, J = 8.8 Hz, J = 2.0 Hz, 2H), 8.36 (br. s, 1H), 8.69 (br. s, 1H).  HRMS (EI, 70 
eV):  calcd for C24H30N2O2 (M)+·:  378.2307; found:  378.2299. 
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4,4'-(1-Nonyl-4-propyl-1H-pyrazole-3,5-diyl)diphenol (9h):  Pyrazole 9h was prepared using 
the general procedure for demethylation using pyridine hydrochloride from 5h (65 mg, 0.15 
mmol) and 9g was isolated as a clear oil (16 mg, 25%) using flash column chromatography (1:1 
hexanes:EtOAc).  1H-NMR (acetone-d6; 500 MHz)  0.72 (t, J  = 7.3 Hz, 3H), 0.85 (t, J = 7.1 
Hz, 3H), 1.10-1.30 (m, 12H), 1.35 (m, J = 7.7 Hz, 2H), 1.71 (t, J = 6.4 Hz, 2H), 2.46 (t, J = 7.8 
Hz, 2H), 3.92 (t, J = 7.2 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 6.98 (d, J = 8.6 Hz, 2H), 7.21 (d, J = 
8.6 Hz, 2H), 7.55 (d, J = 8.8 Hz, 2H), 8.38 (br. s, 1H), 8.72 (br. s, 1H).   13C-NMR (acetone-d6; 
125 MHz)  14.9, 23.9, 25.3, 27.4, 27.7, 30.0, 30.2, 30.5, 31.5, 33.1, 50.2, 116.5, 116.9, 117.3, 
130.0, 132.8, 173.7.  HRMS (EI, 70 eV):  calcd for C27H36N2O2 (M)+·:  420.2763; found:  
420.2777. 
 
4,4'-(4-Propyl-1-tetradecyl-1H-pyrazole-3,5-diyl)diphenol (9i):  Pyrazole 9i was prepared 
using the general procedure for demethylation using pyridine hydrochloride from 5i (89 mg, 0.17 
mmol) and 9g was isolated as a clear oil (37 mg, 44%) using flash column chromatography (1:1 
hexanes:EtOAc).  1H-NMR (acetone-d6; 500 MHz)  0.73 (t, J = 7.3 Hz, 3H), 0.87 (t, J = 6.8 Hz, 
3H), 1.12-1.31 (m, 20H), 1.36 (m, J = 7.6 Hz, 2H), 1.71 (t, J = 6.4 Hz, 2H), 2.47 (t, J = 7.2 Hz, 
2H), 3.93 (t, J = 7.2 Hz, 2H), 6.89 (d, J = 8.3 Hz, 2H), 6.99 (d, J = 8.6 Hz, 2H), 7.21 (d, J = 8.1 
Hz, 2H), 7.56 (d, J = 8.3 Hz, 2H), 8.42 (br. s, 1H), 8.76 (br. s, 1H).  13C-NMR (acetone-d6; 125 
MHz)  23.9, 25.3, 27.4, 27.7, 30.3, 30.6, 30.8, 30.9, 30.9, 31.5, 33.2, 50.2, 116.5, 117.0, 117.4, 
130.0, 132.8, 143.5, 149.5, 158.0, 159.1, 173.7.  HRMS (EI, 70 eV):  calcd for C32H46N2O2 
(M)+·:  490.3559; found:  490.3545. 
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4,4'-(1-(Adamantan-2-yl)-4-propyl-1H-pyrazole-3,5-diyl)diphenol (9j):  Methylene chloride 
(1.5 mL) was added to pyrazole 9j (154 mg, 0.34 mmol) and cooled to -78 ºC while under N2 
atmosphere.  BF3.SMe2 (0. 28 mL, 2.7 mmol) was syringed into the reaction over 5 min.  The 
reaction warmed slowly to 25°C for 12 h.  The solvent was removed under reduced pressure and 
the reaction was quenched by stirring for 30 min with 4 M NaOH (1 mL).  The mixture was 
acidified using 4 M HCl (2 mL) extracted with ethyl acetate and washed with brine.  Solvent was 
removed under reduced pressure, and the crude solid was purified using flash column 
chromatography (2:1 hexanes:EtOAc) The deprotected pyrazole 9j (67 mg, 46%) was isolated as 
a yellow solid.  1H-NMR (acetone-d6; 500 MHz)  0.70 (t, J = 7.5 Hz, 3H), 1.33 (m, J = 7.5 Hz, 
2H), 1.51 (d, J = 12.2 Hz, 2H), 1.61 (d, J = 11.7 Hz, 2H), 1.72 (br. s, 2H), 1.77 (m, 2H), 1.81 (br. 
s, 1H), 1.88 (br. s, 1H), 2.01 (t, J = 2.4 Hz, 2H), 2.42 (t, J = 7.8 Hz, 2H), 2.86 (d, J = 13.4 Hz, 
2H), 3.00 (s, 1H), 4.30 (br. s, 1H), 6.87 (d, J = 8.3 Hz, 2H), 6.95 (d, J = 8.3 Hz, 2H), 7.15 (d, J = 
8.6 Hz, 2H), 7.57 (d, J = 8.8 Hz, 2H), 8.34 (br. s, 1H), 8.68 (br. s, 1H).  13C-NMR (acetone-d6; 
125 MHz)  14.9, 25.2, 27.4, 28.9, 32.8, 35.0, 39.2, 39.8, 39.8, 63.1, 116.4, 116.8, 117.2, 124.1, 
128.6, 129.8, 132.6, 143.6, 148.3, 157.8, 158.9.  HRMS (EI, 70 eV):  calcd for C28H32N2O2 
(M)+·:  428.2464; found:  428.2448. 
 
DHB:  1,2-Bis(4-hydroxyphenyl)ethane-1,2-dione (10):  DHB was prepared using the general 
procedure for demethylation using pyridine hydrochloride starting with commercially available 
4,4’-dimethoxybenzil (5.0 g, 18.5 mmol) except the reaction stirred for 4 h and no column 
chromatography was necessary, since no starting material remained according to NMR.  DHB 10 
was isolated as a pale yellow solid (4.21 g, 94%).  1H-NMR (CDCl3, 500 MHz)  6.78 (AA’ of 
XX’, J = 9.7 Hz, J = 2.4 Hz, 4H), 7.69 (XX’ of AA’XX’, J = 9.7 Hz, J = 2.8 Hz, 4H), 9.6-10.1 
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(br. s, 2H).   13C-NMR (CDCl3, 120 MHz)  115.7, 124.7, 132.2, 163.5, 193.8. HRMS (EI, 70 
eV):  calcd for C14H10O4 (M)+·:  242.0579; found:  242.0573. 
 
Oxalylbis(4,1-phenylene) bis(2-methylbutanoate) (11a):  DHB 10 (242 mg, 1.0 mmol) was 
dissolved in dry pyridine (3 mL) and cooled to 0 °C while under a N2 atmosphere.  Racemic 2-
methylbutanoyl chloride (603 mg, 5.0 mmol) was slowly syringed into the reaction over 10 min.  
After 1 h, the reaction was allowed to warm to room temperature 12 h.  Solvent was removed 
under reduced pressure, 4.0 M HCl (10 mL) was added, then washed with EtOAc (3x25 mL).  
The combined organic layers were washed with water, then brine, dried over Na2SO4, and the 
solvent was removed under reduced pressure.  No starting material was remaining by TLC and 
verified by NMR, so no further purification was necessary.  The protected DHB ligand 11a was 
isolated as a yellow solid (375 mg, 91%).  1H-NMR (CDCl3, 500 MHz)  1.02 (t, J = 7.5 Hz, 
3H), 1.30 (d, J = 6.8 Hz, 3H), 1.64 (m, J = 7.1 Hz, 1H), 1.83 (m, J = 7.1 Hz, 1H), 2.65 (m, J = 6.9 
Hz, 1H), 7.24 (d, J = 8.8 Hz, 4H), 8.01 (d, J = 8.3 Hz, 4H).  13C-NMR (CDCl3, 120 MHz)  11.5, 
11.6, 16.4, 26.6, 26.7, 41.1, 122.0, 122.6, 130.2, 131.4, 131.8, 156.0, 174.3, 156.0, 174.3, 192.8.  
HRMS (ESI) m/z calcd for C24H26O6 433.1627, found 433.1631. 
 
Oxalylbis(4,1-phenylene) bis(2-(2-(2-methoxyethoxy)ethoxy)acetate) (11b):  Commercially 
available 2-[2-(2-Methoxyethoxy)ethoxy]acetic acid (890 mg, 5.0 mmol) was dissolved in 
methylene chloride (10 mL) under a N2 atmosphere.  Oxalyl chloride (762 mg, 6.0 mmol) was 
syringed into the reaction, and a catalytic amount of anhydrous DMF (1 drop) was added.  The 
reaction stirred at 25 °C for 1 h long after CO2 and HCl evolution ceased.  The solvent was 
removed under reduced pressure.  A cold solution of DHB 10 (484 mg, 2.0 mmol) dissolved in 
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anhydrous pyridine (5 mL) was added to the crude acid chloride at 0 °C.  After 1 h the reaction 
was allowed to warm to room temperature for 12 h.  Solvent was removed under reduced 
pressure, 4.0 M HCl (10 mL) was added, then washed with EtOAc (3x25 mL).  The combined 
organic layers were washed with water, then brine, dried over Na2SO4, and the solvent was 
removed under reduced pressure.  No starting material was remaining by TLC and verified by 
NMR, so no further purification was necessary.  The protected DHB ligand 11b was isolated as a 
yellow viscous oil (1.07 g, 95%).  1H-NMR (CDCl3, 400 MHz)  3.33 (s, 3H), 3.51 (m, J = 3.7 
Hz, J = 2.7 Hz, 2H), 3.62 (m, J = 4.4 Hz, J = 2.2 Hz, 2H), 3.69 (m, J = 4.4 Hz, J = 2.9 Hz, 2H), 
3.79 (m, J = 5.6 Hz, J = 2.2 Hz, 2H), 4.41 Hz (s, 2H), 7.23 (AA’ of AA’XX’, J = 9.8 Hz, J = 2.3 
Hz, 4H), 7.97 (AA’ of AA’XX’, J = 9.3 Hz, J = 2.4 Hz, 4H).  13C-NMR (CDCl3, 100 MHz)  
58.9, 68.6, 70.6, 70.7, 71.1, 71.9, 122.1, 130.5, 131.7, 155.3, 168.2, 192.5. 
 
1,2-Bis(3-bromo-4-methoxyphenyl)-2-hydroxyethanone (12a):  3-Bromo, 4-methoxy 
benzaldehyde (430 mg, 2.0 mmol) and potassium cyanide (65 mg, 1.0 mmol) were dissolved in 
ethanol (2 mL) and water (0.5 mL) and heated to 80 °C with a condenser while under N2 for 3 h.  
The reaction was cooled and the solvents removed under reduced pressure.  The crude reaction 
was diluted with EtOAc and washed with 1M NaOH solution, brine, then dried over Na2SO4.  
Removal of the solvent under reduced pressure and flash column chromatography (1:1 
hexanes:EtOAc) afforded the benzoin product, 10a, as a yellow wax (125 mg, 29%).  1H-NMR 
(CDCl3, 500 MHz)  3.85 (s, 3H), 3.92 (s, 3H), 5.79 (s, 1H), 6.84 (d, J = 8.5 Hz, 1H), 6.86 (d, J 
= 8.8 Hz, 1H), 7.21 (dd, J = 8.8 Hz, 2.2 Hz, 1H), 7.50 (d, J = 2.2 Hz, 1H), 7.81 (dd, J = 8.7 Hz, 
2.1 Hz, 1H), 8.16 (d, J = 2.0 Hz, 1H).  13C-NMR (CDCl3, 125 MHz) 56.2, 56.5, 74.7, 111.1, 
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112.2, 112.3, 127.0, 127.9, 130.5, 132.6, 132.6, 134.5, 160.3, 195.9.  HRMS (ESI) m/z calcd for 
C16H14O4Br2Na 450.9157, found 450.9161. 
 
1,2-Bis(3-chloro-4-methoxyphenyl)-2-hydroxyethanone (12b):  3-Chloro-4-methoxy 
benzaldehyde (682 mg, 4.0 mmol) and potassium cyanide (130 mg, 2.0 mmol) were dissolved in 
ethanol (4 mL) and water (0.5 mL) and heated to 80 °C with a condenser while under N2 for 3 h.  
The reaction was cooled and the solvents removed under reduced pressure.  The crude reaction 
was diluted with EtOAc and washed with 1M NaOH solution, brine, then dried over Na2SO4.  
Removal of the solvent under reduced pressure and flash column chromatography (1:1 
hexanes:EtOAc) afforded the benzoin product, 10b, as a pale yellow oil that solidified upon 
standing into a wax (105 mg, 15%).  1H-NMR (CDCl3, 500 MHz) 3.86 (s, 3H), 3.93 (s, 3H), 
5.79 (s, 1H), 6.90 (d, J = 8.8 Hz, 1H), 6.87 (d, J = 8.6 Hz, 1H), 7.18 (dd, J = 8.3 Hz, 2.2 Hz, 1H), 
7.33 (d, J = 2.2 Hz, 1H), 7.78 (dd, J = 8.7 Hz, 2.2 Hz, 1H).  13C-NMR (CDCl3, 125 MHz) 56.1, 
56.4, 74.8, 111.3, 112.4, 123.3, 127.2, 128.5, 129.8, 131.3, 132.2, 159.4.  HRMS (ESI) m/z calcd 
for C16H14O4Cl2Na 363.0167, found 363.0165. 
 
General Procedure for Benzoin Oxidation:  Benzoin (1.0 eqiv.) was placed in a flask and 
dissolved in HOAc (1 mL) and water (0.1 mL).  Ammonium nitrate (1.3 equiv.) and Cu(OAc)2 
(0.1 eqiv.) were added.  The reaction fitted with a reflux condenser and was heated to 110 °C for 
3 h.  The reaction was cooled, extracted with EtOAc, washed sequentially with sat’d NaHCO3, 
water, and finally brine.  The solvent was dried over Na2SO4, then the solvent was removed 
under reduced pressure.  Purification was done by column chromatography or by 
recrystallization to purify the product. 
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1,2-Bis(3-bromo-4-methoxyphenyl)ethane-1,2-dione (13a):  Anisil 13a was prepared using the 
general procedure for benzoin oxidation from 12a (120 mg, 0.28 mmol) and 13a was isolated as 
a yellow solid by recrystallization from EtOAc and hexanes as a yellow solid (69 mg, 77%).  1H-
NMR (THF-d8, 500 MHz) 3.98 (s, 6H), 7.16 (d, J = 8.6 Hz, 2H), 7.92 (d, J = 1.9 Hz, 2H), 8.17 
(d, J = 1.9 Hz, 2H).  13C-NMR (THF-d8, 125 MHz) 57.1, 112.8, 132.8, 135.4, 162.2, 191.7.  
HRMS (ESI) m/z calcd for C16H12O4NaBr2 448.9000, found 448.9004. 
 
 
1,2-Bis(3-chloro-4-methoxyphenyl)ethane-1,2-dione (13b):  Anisil 13b was prepared using the 
general procedure for benzoin oxidation from 12b (100 mg, 0.29 mmol) and 13a was isolated as 
a yellow solid by recrystallization from EtOAc and hexanes as a yellow solid (70 mg, 70%). 
1H-NMR (THF-d8, 500 MHz) 4.00 (s, 6H), 7.22 (d, J = 8.8 Hz, 2H), 7.88 (dd, J = 8.6 Hz, 2.1 
Hz, 2H), 8.17 (d, J = 2.1 Hz, 2H).  13C-NMR (THF-d8, 125 MHz) 57.1, 113.1, 131.83, 132.1, 
161.4, 191.9.  HRMS (ESI) m/z calcd for C16H12O4Cl2Na 361.0010, found 361.0012. 
 
General Procedure for Stilbene Oxidation to a 1,2-Dione:  The appropriate stilbene (1.0 eqiv.) 
was dissolved in Ac2O (5 mL/mmol stilbene) and cooled to 0 °C.  KMnO4 (4.0 eqiv.) was added 
and stirred at 0 °C for 2 h.  The solvent was removed under reduced pressure, water (10 mL) and 
5 M HCl (5 mL) were added and cooled to 0 °C.  A sat’d solution of NaHSO3 (10 mL) as added 
drop-wise to reduce excess KMnO4.  The product was extracted with EtOAc (3 x 25 mL), 
washed with water (2 x 25 mL), then brine (2 x 25 mL), and dried over Na2SO4.  The solvent 
was removed under reduced pressure.  The crude reaction mixture was dissolved in MeOH (5 
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mL) and water (5 mL) then K2CO3 (1 eqiv.) was added and the reaction stirred at r. t. for 4 h.  
Solvent was removed under reduced pressure, extracted using EtOAc (3 x 25 mL), then washed 
with water (2 x 25 mL) and brind (2 x 25 mL), dried over Na2SO4, and solvent removed under 
reduced pressure.  The crude reaction mixture dissolved in AcOH (5 mL) and water (0.5 mL), 
then NH4NO3 (1 eqiv.) and Cu(II)OAc (0.1 eqiv.) were added and the reaction was heated to 110 
°C for 3 h.  The reaction was cooled and solvent was removed under reduced pressure, water (10 
mL) was added and product was extracted with EtOAc (2 x 25 mL), washed with sat’d NaHCO3 
(2 x 25 mL), water (2 x 25 mL), and brine (2 x 25 mL).  Solvent was removed under reduced 
pressure and the product was isolated by flash column chromatography (2:1 hexanes:EtOAc). 
 
1-(3-Bromo-4-methoxyphenyl)-2-(4-methoxyphenyl)ethane-1,2-dione (13c):  The anisoin 
product 13c was prepared from 15a (260 mg, 0.81 mmol) using the general procedure for 
stilbene oxidation to a 1,2-dione starting with  and was isolated as a yellow solid (98 mg, 35%).  
1H-NMR (CDCl3, 500 MHz) 3.85 (s, 3H), 3.96 (s, 3H), 6.89 (m, J = 8.4 Hz, J = 7.3 Hz, 4H), 
7.77 (dd, J = 8.6 Hz, J = 2.0 Hz, 1H), 7.81 (XX’ of AA’XX’, J = 8.8 Hz, 2H), 8.13 (d, J = 2.0 
Hz, 1H).  13C-NMR (CDCl3, 125 MHz) 55.2, 56.1, 1000.8, 112.1, 113.8, 131.2, 131.9, 134.4, 
164.7, 166.4, 190.6, 192.9  HRMS (ESI) m/z calcd for C16H13O4NaBr 370.9895, found 370.9897.  
    
1-(3-Chloro-4-methoxyphenyl)-2-(4-methoxyphenyl)ethane-1,2-dione (13d):  The anisoin 
product 13d was prepared from 15b (200 mg, 0.73 mmol) using the general procedure for 
stilbene oxidation to a 1,2-dione starting with  and was isolated as a yellow solid (66 mg, 30%).  
1H-NMR (CDCl3, 500 MHz) 3.88 (s, 3H), 3.98 (s, 3H), 6.98 (m, J = 8.4 Hz, J = 7.3 Hz, 4H), 
7.86 (dd, J = 8.6 Hz, J = 1.9 Hz, 1H), 7.93 (XX’ of AA’XX’, J = 8.8 Hz, 2H), 8.03 (d, J = 1.9 
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Hz, 1H).   13C-NMR (Acetone-d6, 125 MHz) 55.6, 56.5, 99.8, 111.6, 114.4, 130.8, 131.7, 
132.4, 160.1, 165.1, 192.2, 192.5.  HRMS (ESI) m/z calcd for C16H12O4ClNa 326.7068, found 
328.7070. 
 
1-(3-Fluoro-4-methoxyphenyl)-2-(4-methoxyphenyl)ethane-1,2-dione (13e):  The anisoin 
product 13e was prepared from 15c (230  mg, 0.89 mmol) using the general procedure for 
stilbene oxidation to a 1,2-dione starting with  and was isolated as a yellow solid (35 mg, 14%).  
1H-NMR (THF-d8, 500 MHz) 3.87 (s, 3H), 3.95 (s, 3H), 7.04 (AA’ of AA’XX’, J = 9.0 Hz, J = 
2.7 Hz, 2H), 7.20 (t, J = 8.3 Hz, 1H), 7.70 Hz (t, J = 1.7 Hz, 1H), 7.72 (m, J = 2.0 Hz, 1H), 7.91 
(XX’ of AA’XX’, J = 8.8 Hz, J = 2.0 Hz, 2H).   13C-NMR (THF-d8, 125 MHz) 56.1, 56.8, 
113.9, 115.2, 117.0, 127.2, 128.8, 133.0, 154.4, 166.1, 193.0, 193.0.   HRMS (ESI) m/z calcd for 
C16H13O4FNa 311.0696, found 311.0696. 
 
 
1-(2-Fluoro-4-methoxyphenyl)-2-(4-methoxyphenyl)ethane-1,2-dione (13f):  The anisoin 
product 13f was prepared from 15d (240 mg, 0.93 mmol) using the general procedure for 
stilbene oxidation to a 1,2-dione starting with  and was isolated as a yellow solid (86 mg, 32%).  
1H-NMR (Acetone-d6, 500 MHz) 3.85 (s, 3H), 3.87 (s, 3H), 6.76 (dd, J = 13.0 Hz, J = 2.3 Hz, 
1H), 6.93 (m, J = 8.8 Hz, 2.4 Hz, 1H), 7.04 Hz (AA’ of AA’XX’, J = 8.8 Hz, 1.7 Hz, 2H), 7.84 
(XX’ of AA’XX’, J = 8.8 Hz, J = 2.0 Hz, 2H), 7.93 (t, J = 8.7 Hz, 1H).   13C-NMR (Acetone-d6, 
125 MHz) 56.3, 57.0, 102.6, 113.0, 115.0, 115.5, 131.5, 132.8, 164.5, 165.9, 166.5, 168.3, 
191.9, 193.2.  HRMS (ESI) m/z calcd for C16H13O4FNa 311.0696, found 311.0697. 
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1,2-Bis(3-fluoro-4-methoxyphenyl)ethane-1,2-dione (13g):  The anisoin product 13g was 
prepared from 15f (168 mg, 0.61 mmol) using the general procedure for stilbene oxidation to a 
1,2-dione starting with  and was isolated as a yellow solid (85 mg, 50%).  1H-NMR (THF-d8, 500 
MHz) 3.96 (s, 6H), 7.22 (t, J = 8.3 Hz, 2H), 7.72 (t, J = 8.3 Hz, 2H), 7.74 (d, J = 2.4 Hz, 2H).  
13C-NMR (THF-d8, 125 MHz) 57.0, 114.1, 117.2, 127.4, 129.1, 152.3, 154.7, 192.3.  HRMS 
(ESI) m/z calcd for C16H12O4F2Na 329.0601, found 329.0597. 
 
 
1,2-Bis(2-fluoro-4-methoxyphenyl)ethane-1,2-dione (13h):  The anisoin product 13h was 
prepared from 15g (131 mg, 0.47 mmol) using the general procedure for stilbene oxidation to a 
1,2-dione starting with  and was isolated as a yellow solid (59 mg, 45%).  1H-NMR (THF-d8, 500 
MHz) 3.93 (s, 6H), 6.84 (dd, J = 13.2 Hz, J = 2.4 Hz, 1H), 6.99 (dd, J = 8.8 Hz, 2.4 Hz, 2H), 
7.96 (t, J = 8.6 Hz, 2H).  13C-NMR (THF-d8, 125 MHz) 57.4, 102.8, 113.6, 133.3, 165.0, 
167.0, 168.5, 190.9.  HRMS (ESI) m/z calcd for C16H12O4F2Na 329.0601, found 329.0604. 
 
 
(4-Methoxybenzyl)triphenylphosphonium chloride (14):  The phosphonium salt was prepared 
according to a literature procedure.25   
 
General Procedure for the Wittig Reaction:  Phosphonium salt 14 (419 mg, 1.0 mmol)  was 
placed into a dry flask, and THF (5mL) was syringed into the reaction, which was cooled to -78 
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°C and stirred for 15 min under a N2 atmosphere.  n-butyl lithium (1.6 M in hexanes, 0.625 mL, 
1.0 mmol) was syringed into the reaction where it was stirred for 30 min at -78 °C, then 30 min 
at 25 °C.  The respective aldehyde (1.0 mmol) was added.  After stirring at 25 °C for 12 h, 
solvent was removed under reduced pressure; the crude reaction was diluted with EtOAc, 
washed with water, then brine, and dried over Na2SO2.  Solvent was removed under reduced 
pressure, and the product was isolated from the crude reaction mixture by flash column 
chromatography (3:1 hexanes:EtOAc). 
 
2-Bromo-1-methoxy-4-(4-methoxystyryl)benzene (15a):  The styrene product 15a was 
prepared using the general procedure for the Wittig reaction and was isolated as an off-white 
solid (270 mg, 85%).  1H-NMR (CDCl3, 500 MHz) 3.79 (s, 3H), 3.83 (s, 3H), 3.87 (s, 3H), 
3.91 (s, 3H), 6.39 (d, 1H, J = 11.7 Hz), 6.47 (d, 1H, J = 11.7 Hz), 6.76 (m, 3H, J = 8.6 Hz, 7.8 
Hz), 6.89 (m, H, J = 11.0 Hz, 8.8 Hz, 6.1 Hz), 7.18 (m, 3H), 7.42 (d, 2H, J = 9.0 Hz), 7.47 (d, J = 
2.0 Hz), 7.71 (d, 1H, J = 2.2 Hz).  13C-NMR (CDCl3, 125 MHz) 55.2, 55.3, 56.2, 56.3, 109.7, 
111.2, 111.5, 111.9, 113.7, 114.1, 124.6, 126.5, 126.8, 127.5, 127.6, 128.9, 129.6, 130.0, 130.7, 
131.5, 131.9, 133.6.  HRMS (ESI) m/z calcd for C16H15O2BrNa 341.0153, found 341.0168. 
 
2-Chloro-1-methoxy-4-(4-methoxystyryl)benzene (15b):  The styrene produce 15b was 
prepared using the general procedure for the Wittig reaction and was isolated as a clear oil that 
solidified to a waxy solid upon standing (234 mg, 85%).  1H-NMR (CDCl3, 500 MHz) 3.79 (s, 
3H), 3.84 (s, 3H), 3.88 (s, 3H), 3.91 (s, 3H), 6.37 (d, 1H, J = 12.2 Hz), 6.48 (d, 1H, J = 12.1 Hz), 
6.79 (m, 3H, J = 8.8 Hz, 3.9 Hz), 6.90 (m, 4H, J = 6.8 Hz, 15.3 Hz), 7.13 (dd, 1H, J = 8.6 Hz, 2.2 
Hz), 7.20 (d, 2H, J = 8.8 Hz), 7.31 (m, 2H, J = 9.8 Hz, 2.2 Hz), 7.43 (d, 2H, J = 9.0 Hz), 7.54 (d, 
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1H, J = 2.2 Hz).  13C-NMR (CDCl3, 125 MHz)  55.1, 55.3, 56.0, 56.2, 111.6, 112.0, 113.6, 
114.1, 122.0, 122.7, 124.7, 125.8, 126.9, 127.4, 127.5, 128.2, 129.3, 129.6, 130.0, 130.5, 130.9, 
131.4, 153.7, 154.1, 158.7, 159.2.  HRMS (ESI) m/z calcd for C16H16O2Cl 275.0839, found 
278.0836. 
 
2-Fluoro-1-methoxy-4-(4-methoxystyryl)benzene (15c):  The styrene product 15c was 
prepared using the general procedure for the Wittig reaction and was isolated as a clear oil that 
solidified to a waxy solid upon standing (241 mg, 93%).  1H-NMR (CDCl3, 500 MHz)  3.80 (s, 
3H), 3.83 (s, 3H), 3.87 (s, 3H), 3.90 (s, 3H), 6.39 (d, 1H, J  = 12.0 Hz), 6.49 (d, 1H, J = 12.0 Hz), 
6.77-6.84 (m, 3H), 6.88 (m, 1H), 6.92 (s, 1H), 6.94 (d, 1H, J = 2.6 Hz), 6.97 (s, 1H), 6.98 (s, 
1H), 7.01 (d, 1H, J = 2.57 Hz) 7.19 (m, 2H, J = 8.6 Hz), 7.24-7.27 (m, 1H), 7.42 (d, 1H, J = 8.6 
Hz). 13C-NMR (CDCl3, 125 MHz)  55.2, 55.3, 56.2, 60.3, 99.8, 99.9, 113.1, 113.7, 114.2, 
116.2, 116.4, 122.5, 124.9, 125.2, 127.3, 127.6, 129.6, 130.0.  HRMS (ESI) m/z calcd for 
C16H16O2F 259.1134, found 259.1134. 
 
2-Fluoro-4-methoxy-1-(4-methoxystyryl)benzene (15d):  The styrene produce 15d was 
prepared using the general procedure for the Wittig reaction and was isolated as a clear oil (230 
mg, 89%).  1H-NMR (CDCl3, 500 MHz)  3.79 (s, 6H), 3.81 (s, 3H), 3.83 (s, 3H), 6.46 (d, 1H, J 
= 13.1 Hz), 6.53-6.66 (m, 3H, J = 12.0 Hz, 10.9 Hz), 6.72 (d, 1H, J = 9.86 Hz), 6.78 (d, 1H, J = 
8.4 Hz), 6.91 (d, 1H, J = 8.4 Hz), 7.05 (dd, 1H, J = 18.9 Hz, 16.5 Hz), 7.19 (m, 2H, J = 7.5 Hz).  
13C-NMR (CDCl3, 125 MHz)  55.1, 55.2, 55.4, 101.3, 101.5, 101.7, 109.7, 110.4, 110.4, 113.6, 
114.1, 118.6, 127.3, 127.5, 128.2, 129.6, 129.9, 130.4, 130.7, 158.7, 159.9, 161.9.  HRMS (ESI) 
m/z calcd for C16H16O2F 259.1134, found 259.1143. 
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1,2-Bis(3-fluoro-4-methoxyphenyl)ethene (15e):  3-fluoro anisaldehyde (308 mg, 2.0 mmol) 
was dissolved in THF (30 mL) and cooled to 0 °C.  (TiCl4)(THF)2 complex (1.00 g, 3.0 mmol) 
was slowly added to the reaction over 5 minutes.  Once the complex dissolved, zinc dust (392 
mg, 6.0 mmol) was added and stirred for 1 h at 0 °C.  The reaction was then heated at 68 °C 
under N2 for 12 h.  The reaction cooled to r.t., solids were filtered, the filtrate was removed under 
reduced pressure, water was added, and extracted with EtOAc (3x25 mL).  The organic layers 
were combined and washed with water (2x25 mL), then brine (2x25 mL), the solvent was dried 
with Na2SO4, and solvent was removed under reduced pressure.  The product was purified using 
flash column chromatography (5:1 hexanes:EtOAc) to produce a clear oil that solidified to a 
waxy solid upon standing (200 mg, 73%).  1H-NMR (CDCl3, 500 MHz) 3.91 (s, 6H), 6.85 (s, 
2H), 6.93 (t, 2H, J = 8.6 Hz), 7.15 (dt, 2H, J = 8.6 Hz, J = 1.7 Hz), 7.25 (dd, 2H, J = 12.7 Hz, J = 
2.0 Hz)  13C-NMR (CDCl3, 125 MHz)  55.6, 101.4, 101.6, 110.4, 118.0, 120.5, 127.3, 127.4.  
HRMS (ESI) m/z calcd for C16H15O2F2 277.1040, found 277.1038. 
 
1,2-Bis(2-fluoro-4-methoxyphenyl)ethene (15f):  2-fluoro anisaldehyde (308 mg, 2.0 mmol) 
was dissolved in THF (30 mL) and cooled to 0 °C.  (TiCl4)(THF)2 complex (1.00 g, 3.0 mmol) 
was slowly added to the reaction over 5 minutes.  Once the complex dissolved, zinc dust (392 
mg, 6.0 mmol) was added and stirred for 1 h at 0 °C.  The reaction was then heated at 68 °C 
under N2 for 12 h.  The reaction cooled to r.t., solids were filtered, the filtrate was removed under 
reduced pressure, water was added, and extracted with EtOAc (3x25 mL).  The organic layers 
were combined and washed with water (2x25 mL), then brine (2x25 mL), the solvent was dried 
with Na2SO4, and solvent was removed under reduced pressure.  The product was purified using 
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flash column chromatography (3:1 hexanes:EtOAc) to produce a clear oil that solidified to a 
waxy solid up standing (168 mg, 61%).  1H-NMR (CDCl3, 500 MHz) 3.81 (s, 6H), 6.63 (dd, 
2H, J = 12.5 Hz, J = 2.4 Hz), 6.71 (tt, 2H, J = 8.7 Hz, J = 2.6 Hz), 7.13 (s, 2H), 7.52 (t, 2H, J = 
8.7 Hz).  13C-NMR (CDCl3, 125 MHz)  56.3, 113.1, 113.3, 122.8, 123.5, 126.5.  HRMS (ESI) 
m/z calcd for C16H15O2F2 277.1040, found 277.1036. 
 
1,2-bis(3-Bromo-4-hydroxyphenyl)ethane-1,2-dione (16a):  Benzoin 16a was prepared using 
the general procedure for demethylation using pyridine hydrochloride from 13a (60 mg, 0.14 
mmol) and 16a was isolated as a yellow solid (39 mg, 70%) using flash column chromatography 
(1:1 hexanes:EtOAc).  1H-NMR (Acetone-d6, 500 MHz)  7.17 (d, 2H, J = 8.6 Hz), 7.82 (m, 2H, 
J = 8.6 Hz, J = 2.0 Hz), 8.14 (d, 2H, J = 8.6 Hz), 10.23 (br. s, 2H).  13C-NMR (Acetone-d6, 125 
MHz)  119.3, 117.5, 127.4, 132.4, 135.9, 161.0, 192.5.  HRMS (ESI) m/z calcd for 
C14H8O4NaBr2 420.8687, found 420.8691. 
 
1,2-bis(3-Chloro-4-hydroxyphenyl)ethane-1,2-dione (16b):  Benzoin 16b was prepared using 
the general procedure for demethylation using pyridine hydrochloride from 13b (64 mg, 0.19 
mmol) and 16b was isolated as a yellow solid (34 mg, 58%) using flash column chromatography 
(1:1 hexanes:EtOAc).  1H-NMR (Acetone-d6, 500 MHz)  7.19 (d, 2H, J = 8.6 Hz), 7.78 (m, 2H, 
J = 8.6 Hz, J = 2.2 Hz), 7.98 (d, 2H, J = 2.0 Hz), 10.19 (br. s, 2H).  13C-NMR (Acetone-d6, 125 
MHz)  117.9, 122.3, 127.1, 131.8, 132.6, 160.0, 192.6.  HRMS (ESI) m/z calcd for 
C14H8O4NaCl2 332.9697, found 332.9697. 
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1-(3-bromo-4-hydroxyphenyl)-2-(4-hydroxyphenyl)ethane-1,2-dione (16c):  Benzoin 16c was 
prepared using the general procedure for demethylation using pyridine hydrochloride from 13c 
(70 mg, 0.20 mmol) and 16c was isolated as a yellow solid (48 mg, 75%) using flash column 
chromatography (1:1 hexanes:EtOAc).  1H-NMR (Acetone-d6, 500 MHz)  7.01 (m, 2H, J = 9.5 
Hz, J = 2.0 Hz), 7.17 (d, 1H, J = 8.6 Hz), 7.79 ( m, 1H, J = 8.6 Hz, J = 2.2 Hz), 7.86 (m, 2H, J = 
8.8 Hz, J = 2.0 Hz), 8.11 (d, 1H, J = 1.95 Hz).  13C-NMR (Acetone-d6, 125 MHz)  111.3, 116.9, 
116.9, 117.5, 126.1, 132.2, 133.4, 135.7, 160.8, 164.6, 193.4, 193.7.  HRMS (ESI) m/z calcd for 
C14H9O4NaBr 342.9582, found 342.9590. 
 
1-(3-chloro-4-hydroxyphenyl)-2-(4-hydroxyphenyl)ethane-1,2-dione (16d):  Benzoin 16d 
was prepared using the general procedure for demethylation using pyridine hydrochloride from 
13d (55 mg, 0.18 mmol) and 16d was isolated as a yellow solid (45 mg, 90%) using flash 
column chromatography (1:1 hexanes:EtOAc).  1H-NMR (Acetone-d6, 500 MHz)  7.01 (m, 2H, 
J = 9.0 Hz, J = 2.2 Hz), 7.18 (d, 1H, J = 8.6 Hz), 7.75 (m, 1H,  J = 8.6 Hz, J = 2.2 Hz), 7.86 (m, 
2H, J = 9.0 Hz, J = 2.9 Hz), 9.88 (br. s, 2H).  13C-NMR (Acetone-d6, 125 MHz)  116.9, 117.9, 
122.3, 131.6, 132.4, 133.4, 159.8, 164.2, 193.5, 193.7.  HRMS (ESI) m/z calcd for C14H9O4NaCl 
299.0087, found 299.0100. 
 
1-(3-Fluoro-4-hydroxyphenyl)-2-(4-hydroxyphenyl)ethane-1,2-dione (16e):  Benzoin 16e 
was prepared using the general procedure for demethylation using pyridine hydrochloride from 
13e (30 mg, 0.10 mmol) and 16e was isolated as a yellow solid (21 mg, 90%) using flash column 
chromatography (1:1 hexanes:EtOAc).  1H-NMR (Acetone-d6, 500 MHz)  7.01 (AA’ of 
AA’XX’, 2H, J = 9.7 Hz, J = 2.8 Hz), 7.16 (t, 1H, J = 8.36 Hz), 7.62 (m, 1H, J = 8.5 Hz, J = 2.0 
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Hz, J = 0.9 Hz), 7.71 (m, 1H, J = 11.4 Hz, J = 2.1 Hz), 7.85 (XX’ of AA’XX’, 2H, J = 9.4 Hz, J 
= 2.6 Hz), 9.78 (br. s, 2H).  13C-NMR (Acetone-d6, 125 MHz)  116.9, 117.4, 117.5, 118.9, 
119.0, 126.2, 129.0, 129.0, 133.4, 151.4, 152.4, 153.3, 164.6, 193.8.  HRMS (ESI) m/z calcd for 
C14H9O4FNa 283.0383, found 283.0388. 
 
1-(2-Fluoro-4-hydroxyphenyl)-2-(4-hydroxyphenyl)ethane-1,2-dione (16f):  Benzoin 16f was 
prepared using the general procedure for demethylation using pyridine hydrochloride from 13f 
(45 mg, 0.16 mmol) and 16f was isolated as a pale yellow solid (33 mg, 79%) using flash column 
chromatography (1:1 hexanes:EtOAc).   1H-NMR (Acetone-d6, 500 MHz)  6.66 (dd, 1H, J = 
12.8 Hz, J = 2.3 Hz), 6.91 (m, 1H, J = 8.8 Hz, J = 2.1 Hz), 7.01 (AA’ of AA’XX’, 2H, J = 9.4 
Hz, J = 2.1 Hz), 7.83 (XX’ of AA’XX’, 2H, J = 8.8 Hz, J = 1.9 Hz), 7.92 (t, 1H, J = 8.6 Hz), 9.79 
(br. s, 2H).  13C-NMR (Acetone-d6, 125 MHz)  104.1, 104.3, 114.2, 114.2, 117.1, 133.3, 133.4, 
133.5, 133.5, 164.4, 164.8, 166.6, 166.7, 192.2, 193.5.  HRMS (ESI) m/z calcd for C14H9O4FNa 
283.0383, found 283.0391. 
 
1,2-Bis(3-fluoro-4-hydroxyphenyl)ethane-1,2-dione (16g):  Benzoin 16g was prepared using 
the general procedure for demethylation using pyridine hydrochloride from 13g (70 mg, 0.25 
mmol) and 16g was isolated as a yellow solid (29 mg, 42%) using flash column chromatography 
(1:1 hexanes:EtOAc).  1H-NMR (Acetone-d6, 500 MHz)  7.17 (t, 2H, J = 8.4 Hz), 7.64 (m, 2H, 
J = 8.6 Hz, J = 0.86 Hz), 7.74 (m, 2H, J = 11.4 Hz, J = 1.9 Hz), 9.95 (br. s, 2H).  13C-NMR 
(Acetone-d6, 125 MHz)  117.8, 119.2, 119.2, 126.8, 129.4, 129.5, 151.6, 152.7, 152.8, 153.6, 
193.3.  HRMS (ESI) m/z calcd for C14H8O4NaF2 301.0288, found 301.0291. 
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1,2-Bis(2-fluoro-4-hydroxyphenyl)ethane-1,2-dione (16h):  Benzoin 16h was prepared using 
the general procedure for demethylation using pyridine hydrochloride from 13h (70 mg, 0.23 
mmol) and 16h was isolated as a pale yellow solid (50 mg, 78%) using flash column 
chromatography (1:1 hexanes:EtOAc).  1H-NMR (Acetone-d6, 500 MHz)  6.69 (dd, 2H, J = 
12.9 Hz, J = 2.1 Hz), 6.92 (dd, 2H, J = 8.8 Hz, J = 2.4 Hz), 7.93 (t, 2H, J = 8.5 Hz), 10.02 (br. s, 
2H).  13C-NMR (Acetone-d6, 125 MHz)  104.1, 104.3, 114.4, 114.4, 133.5, 133.5, 164.9, 166.6, 
166.7, 166.9, 190.8, 197.4.  HRMS (ESI) m/z calcd for C14H8O4F2Na 301.0288, found 301.0285. 
 
Ligand Screening and Dose Response Assay 
The yeast libraries were a kind gift from Mike Mclaughin and were used in the initial DHB 
report.21 
 
Yeast Two-Hybrid Screening:  Ninety-five mutants from the transformation library were 
individually picked using a sterile toothpick and transferred to a round-bottom 96-well plate 
(Evergreen Scientific, Los Angeles) containing 50 l of SC-Leu-Trp minimal media in each 
well.  A control using yeast cells containing the wt hERLBD construct was also added to the 
first well.  The plates incubated for 12-14 h at 30 °C in a container containing a wet towel to 
limit evaporation of water.  After incubation, all wells were diluted with 200 L SC-Leu-Trp-His 
media and the cells were re-suspended.  5 L from each well of yeast culture was transferred to a 
sterile 96-well microtiter plates (Rainin Instruments) for each ligand concentration screened.  
Finally, 200 L of ligand solution (a 1000-fold dilution of stock synthetic ligand or estradiol in 
ethanol with SC-Leu-Trp-His) was added to each well one of the individual ligand plate.  The 
microtiter plates were incubated at 30 °C for 24 h or stopped when the wt hERLBD-estradiol 
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plate showed significant growth when incubated with 1 nM estradiol.   Each synthetic ligand 
plate was visually inspected for wells containing a mutant showing significant growth in the 
presence of synthetic ligand compared to the wells in the plate containing estradiol.  Positive-
growth mutants were streaked on a SC-Leu-Trp agar plates and incubated for 48 h at 30 °C.  The 
mutants were then titrated using the yeast dose response assay. 
 
Yeast Ligand-Dependant Dose Response Assay:  Yeast cells were grown in SC-Leu-Trp 
media (3 mL) for 12 hours in a 30 °C shaker at 250 rpm.  Cultures were re-suspended in solution 
and stock cell culture (4.67 L) was diluted in SC-Leu-Trp-His media (7 mL).  Stock ligand at 
various concentrations in ethanol (2 L) were added to SC-Leu-Trp-His media (98 L) for a 50-
fold dilution and the diluted ligand (10 L) were added to the corresponding wells of a sterile 
flat-bottomed 96-well microtiter plate.  The diluted culture (190 L) was carefully added over 
each corresponding well as to not contaminate the multi-channel pipette tip with the ligand 
solution to achieve an overall 1000-fold dilution of the ligand ethanol stock solution.  The plates 
were incubated for 24 h at 30 °C in a container containing a wet towel to limit evaporation of 
water.  The cells were re-suspended using a multichannel pipette and the OD600 readings were 
taken using a Spectramax-340PCM plate reader (Molecular Devices). 
 
E. Coli (DH5) Transformation:  After thawing DH5 competent cells on ice, 50 L of cells 
and 250-350 ng of plasmid were added to conical tubes.  Cells and DNA were incubated on ice 
for 15 minutes and then heat shocked at 42 °C for 45 seconds.  After heat shock, 1 mL of LB 
media was added to the cells and incubated in a 37 °C shaker at 250 rpm.  Transformed cells 
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were spun down and re-suspended.  They were plated on agar media containing 25 g/mL of 
chloramphenicol.  Plates were grown for 18 h at 37 °C in an incubator. 
 
Plasmid Isolation:  A yeast plasmid miniprep kit (Zymoprep, Orange, CA) as used to isolate the 
plasmid.  QIAprep Spin miniprep kit (Qiagen, Almeda, CA) was used to isolate E. Coli plasmid. 
 
Plasmid Sequencing:  Sequencing was performed by the Core DNA Sequencing Facility at the 
University of Illinois.  Sequences were obtained using an Applied Biosystems 3739XL high-
throughput DNA capillary sequencer. 
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